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Abstract 
 
 
One of the most common HIV-associated opportunistic infections is candidiasis, caused by 
Candida albicans or other Candida species. In immune suppressed subjects, this commensal 
organism can cause an increase in patient morbidity and mortality due to oropharyngeal or 
systemic dissemination. Limited information exists on the prevalence and antifungal 
susceptibility of Candida species in the African continent, the most HIV-affected region globally 
and home to new and emerging drug resistant Candida species. The mechanisms of Candida 
drug resistance in the African continent have also not been described. 
 
In this study, 255 Candida species isolated from the oral mucosa of HIV-positive South African 
and Cameroonian patients were identified using differential and chromogenic media and their 
drug susceptibility profiles tested using the disk diffusion method and the TREK Sensititre 
system, an automated broth microdilution method. Candida cell wall fractions were run on SDS-
PAGE and HPLC-MS with the aim of identifying peptides specifically expressed by antifungal 
drug resistant isolates. 
 
Comparisons between the two groups of isolates revealed differences in Candida species 
prevalence and drug susceptibility with interesting associations observed between specific drug 
resistance and duration of ARV therapy. This study showed that fluconazole, the drug of choice 
for the treatment of candidiasis in the African continent, is not an effective therapy for most 
cases of Candida infection, and suggests that regional surveillance be implemented in the 
continent. A multiple-drug resistant Candida strain was identified in this study, a finding that has 
not previously been documented. 
The use of proteomics tools allowed for the identification of peptides involved in drug resistance 
and the elucidation of Candida colonization mechanisms in HIV-infected African patients. 
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Chapter 1: Review of the Literature 
 
1.1 Candida in HIV infection 
 
Human Immunodeficiency Virus (HIV) is a retrovirus that infects cells bearing the CD4 cell 
surface antigen, which include Th cells, monocytes, dendritic cells and microglia (Mims et al, 
2004). This results in an impaired host immune response and consequent predisposition to 
opportunistic infections (Cury et al, 2003). 
 
HIV infection was responsible for approximately 1.7 million deaths worldwide in 2011, with 
an estimated 2.8 million people being newly infected in 2010 (WHO, 2013). An estimated 
35.3 million people are infected with the HI virus globally, with most of these (22.9 million) 
living in Africa (WHO, 2013). 
The prevalence of HIV in Africa is not uniform: while South Africa has an estimated 17.3% 
of its adult population living with HIV, the overall infection rate in the Cameroon is thought 
to be approximately 4.6% (WHO, 2013). Statistics for 2007 show that the HIV prevalence 
rate is much higher in Southern Africa than in other African regions: More than a quarter 
(26.1%) of the adult population of Swaziland was reported to be infected with HIV, followed 
by Botswana (23.9%) and Lesotho (23.2%). In West Africa the rates were found to be lower: 
Nigeria had 3.1% of its adult population infected by HIV, followed by Equatorial Guinea 
(3.4%), Chad and Congo (both with 3.5%), Gabon (5.9%) and the Central African Republic 
(6.3%) (WHO African Health Observatory, 2010). 
In South Africa and Cameroon HIV is the leading cause of disease burden (40.7% in South 
Africa and 14.4% in Cameroon) accounting for 46% and 5% of the infant mortality rate in 
South Africa and Cameroon respectively (WHO African Health Observatory, 2010). 
 
Human immunodeficiency virus – type 1 (HIV-1) is the predominant HIV type in most 
regions, with HIV-type 2 infections being found in about 1 to 2 million people in West Africa 
(Gottlieb et al, 2008). Although AIDS-related symptoms such as tuberculosis and pneumonia 
appear to be similar in late HIV-1 and -2 infections, the two HIV subtypes are known to have 
different disease progression patterns (Popper et al, 1999, MacNeil et al, 2007), which could 
possibly influence the development of opportunistic infections. 
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One of the most common HIV-associated opportunistic infections is candidiasis, caused 
mainly by Candida albicans or Candida dubliniensis (a novel species first discovered in 
1995). Other Candida species that can become invasive include C. tropicalis, C. krusei and 
C. glabrata. These can cause an increase in patient morbidity and mortality due to 
oropharyngeal or systemic dissemination. HIV-related Candida infections were found to be 
associated with a higher patient mortality in developing countries than in developed countries 
(Clark and Hajjeh, 2002). 
 
Candida infection can present as pseudomembranous candidiasis (thrush), characterized by 
white pseudomembranes in the oral mucosa and/or upper digestive tract; acute atrophic 
candidiasis, characterized by pain and inflammation of the mouth or tongue; chronic 
hyperplastic candidiasis, characterized by homogenous white lesions on the oral mucosa or 
tongue and angular cheilitis, characterised by lesions in the corners of the mouth, usually 
accompanying intra-oral candidiasis (Akpan and Morgan, 2002). In HIV-positive individuals 
linear gingival erythema, a characteristic periodontal lesion, is associated with Candida 
infection (Samaranayake, Keung Leung and Jin, 2009). In severely immunocompromised 
patients, Candida species can spread through the bloodstream and gastrointestinal tract. This 
can lead to systemic candidiasis, which has a mortality rate of up to 57% (Fraser et al, 1992). 
Candida is currently the 4
th
 most commonly isolated microorganism in nosocomial 
bloodstream infections (Budhavari, 2009). 
 
Candida species are pseudohyphae-forming yeasts, which grow as ovoid single cells and 
multiply by budding and division. It has been shown by proteomic analysis that Candida 
species undergo dimorphic transitions from yeast to hyphae, with this factor being related to a 
shift between colonization and actual infection. Different proteins were identified as being 
involved in factors such as metabolism and protein synthesis, creating a possible link between 
protein expression and Candida invasion (Hernandez et al, 2004). 
 
The Candida cell wall, known to change over time, plays a crucial role in its pathogenicity 
(Chaffin et al, 1998). It is composed of 80-90% carbohydrate, forming a complex 
extracellular matrix of β-glucans, chitin, mannan and manno-proteins. The latter accounts for 
around 40% of the total carbohydrate content (Cihlar and Calderone, 2009). 
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Innate immune defenses against Candida are based on the antifungal efficacy of cytokine-
mediated tissue macrophages and circulating neutrophils (polymorphonuclear leukocytes). 
These cytokines include granulocyte colony stimulating factor (G-CSF), granulocyte-
macrophage colony stimulating factor (GM-CSF) and macrophage colony stimulating factor 
(M-CSF). T-helper cell 1 (Th1) cytokines interferon γ (IFNγ), interleukin (IL)-12, IL-15 and 
tumour necrosis factor α (TNFα) have also been implicated in the cytokine-mediated immune 
response against Candida species. T-helper cell 2 (Th2) mediated cytokines IL-4 and IL-10, 
however, have been shown to suppress the antifungal action of phagocytes against Candida 
species (Ernst and Rogers, 2005). 
 
Candida species can survive and multiply inside macrophages and neutrophils. Because 
neutrophils are partly responsible for controlling the establishment of invading fungi, 
immunosuppression may cause an overgrowth of Candida to occur (Mims et al, 2004). C. 
dubliniensis was shown to be more vulnerable to the fungicidal activity of leukocytes than C. 
albicans (Vilela et al, 2002). 
 
Another study showed that pre-exposure of insect larvae to Candida albicans or 
glucan/laminarin resulted in a protection mechanism against a subsequent Candida lethal 
dose. This was shown to be due to an increased expression of antimicrobial peptides by the 
larvae, demonstrating that there can also be peptide changes in the host that can lead to 
different outcomes in Candida infection and colonization (Bergin, 2006, Nett et al, 2006). 
 
It has been demonstrated by DNA subtyping that C. albicans has a minimum of 70 different 
subtypes, and that patients with multiple Candida subtype infections had lower CD4 counts 
than those with single infections (Redding et al, 1997). Another study identified around 85 
immunoreactive serum protein species in patients infected by C. albicans and allowed for the 
characterization of 42 enzymes identified as C. albicans antigens (Pitarch et al, 2004). Cell 
wall surface proteins of C. albicans are known to cause immune responses in the host, and 
have been used with some success in trials for the development of drugs and vaccines against 
Candida species (Thomas et al, 2006b). 
 
The complete genome of Candida is known and is available in different databases (Rossignol 
et al, 2008). However, there are challenges that cannot be solved by using a purely genomic 
approach, and some of these are the mechanisms of drug resistance in fungal species. Proteins 
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perform essential roles in cellular processes, making their study the next logical step after 
detailed mapping of genes. Proteomic studies are generally more complex than genomic 
studies, as in the proteome there is a dynamic response to genetic and environmental factors 
(leading to changes in protein expression) and the specific proteins being analysed are often 
present in a very small amount of sample with many other non-relevant proteins being 
present. Sample processing in proteomics studies can also be more complex, due to protein 
degradation and other factors (Reinders and Sickmann, 2009). The use of proteomic analysis 
in drug resistance studies is able to provide important information on the biological 
complexities and pathogenic behaviour of Candida species, and can lead to new approaches 
in the management of fungal infections (Thomas et al, 2006a). 
 
 
1.2 Susceptibility and resistance to treatment 
 
Various antifungal drugs with different modes of action have been developed over the years. 
These include polyene antifungals (e.g.: nystatin and amphotericin B), which interfere with 
ergosterol synthesis, thereby causing cell membrane leakage; the imidazoles (e.g.: 
miconazole, clotrimazole and ketoconazole), which also interfere with ergosterol and other 
cell membrane sterol synthesis; the echinocandins (e.g.: anidulafungin, micafungin and 
caspofungin), which inhibit β 1-3 glucan synthesis, affecting the fungal cell wall and 5-
Flucytosine, which interferes with fungal RNA and DNA synthesis. The triazoles 
(comprising of fluconazole, posaconazole, voriconazole, itraconazole, isavuconazole, 
pramiconazole and ravuconazole), which interfere with the synthesis of ergosterol, have been 
shown to have fewer side effects than some of the other antifungal drug classes (Khan and 
Jain, 2000). 
 
Fluconazole is responsible for the inhibition of the enzyme cytochrome P450 14α-
demethylase, which converts lanosterol to ergosterol and is required in fungal cell wall 
synthesis (Sweetman, 2004). This antifungal is routinely given as treatment for candidiasis in 
healthcare facilities, as it is less toxic and more effective than imidazole antifungals such as 
ketoconazole or amphotericin B, a polyene antibiotic which binds to ergosterol in the fungal 
cell wall, leading to leakage of cellular contents and subsequent cell death (Kshirsagar et al, 
2005). It is, however, not recommended for pregnant women, as it is a teratogenic drug 
(Pursley et al, 1996, Lopez-Rangel and Allen, 2005). The primary mechanism of fluconazole 
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resistance in C. dubliniensis has been shown to be overexpression of the major facilitator 
efflux pump Mdr1p (Sullivan and Coleman, 1997). A 2002 study identified two proteins in 
Candida glabrata induced by fluconazole exposure, namely a 169-kDa protein which was 
later identified using mass spectrometry as the ATP binding cassette-type drug efflux 
transporter CgCdr1p, and a 61-kDa protein, later identified as lanosterol 14α-demethylase, an 
enzyme targeted by fluconazole (Niimi et al, 2002). 
 
It has also been shown that an increased expression of plasma membrane drug efflux pump 
Cdr1p and Cdr2p causes a decrease in azole susceptibility in C. albicans clinical isolates 
(Holmes et al, 2006). This may explain why patients initially infected with C. albicans and 
treated with fluconazole demonstrate a switch to C. dubliniensis colonization (Martinez et al, 
2002, Sullivan and Coleman, 1997). 
 
Other studies have shown that clinical Candida isolates with high resistance often present 
with multiple resistance mechanisms, including the overexpression of efflux pumps, changes 
in the expression of lanosterol 14α-demethylase enzyme and other mechanisms that lower the 
drug concentration in fungal cells, in such a way that ergosterol synthesis is not interrupted 
(Niimi et al, 2005, White et al, 2002). This is especially true in the case of C. glabrata, which 
seems to have an innate resistance to fluconazole and whose numbers have increased in 
patients presenting with candidiasis in recent years (Vermitsky and Edlind, 2004). 
 
Different studies have shown that resistance to available antifungal therapies is widespread, 
including the case of more recent antifungal drugs such as fluconazole and itraconazole 
(Luque et al, 2009, Manzano-Gayosso et al, 2008). It is thought that this rapid resistance 
occurred due to the widespread and repeated use of these drugs (Jia et al, 2008). Another 
study has also demonstrated that fluconazole has an exposure-response relationship with 
patient mortality, showing that most patients who died from candidiasis had fluconazole 
resistant strains and that patient mortality was associated with low fluconazole therapeutic 
dosages (Baddley et al, 2008). 
 
Different Candida species have varying resistance patterns, which appear to be 
geographically determined. Therefore an early identification facilitates the selection of an 
appropriate antifungal drug. It has been suggested that the use of oral antifungals in 
oropharyngeal candidiasis must be reserved for cases where there is no response to topical 
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antifungal treatment, as resistance to azole antifungal agents is increasing (Powderly, Mayer 
and Perfect, 1999). A 2003 study also stressed the need for fungal species and resistance 
pattern surveillance to avoid an even higher number of improperly treated, and therefore 
resistant, fungal infections (Godoy et al, 2003). This is a cause of concern in the case of 
immunocompromised patients, who are at a much higher risk of developing opportunistic 
complications. 
Limited fluconazole susceptibility data from the African continent is available. A previous 
report of baseline data from South Africa demonstrated 100% susceptibility of C. albicans to 
fluconazole (Blignaut et al, 2002). However, and of importance, is that the study was done 
before the introduction of fluconazole to patients attending HIV-AIDS clinics. Other more 
recent African studies have reported a frequent resistance of C. albicans and non-albicans 
species to azoles (Njunda et al, 2012; Mulu et al, 2013). 
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1.3 Transmission of drug resistant Candida isolates 
 
Studies have shown that oral transmission of C. albicans in HIV-positive couples could 
contribute to the dissemination of fluconazole-resistant isolates (Dromer et al, 1997). DNA 
sampling of oral isolates demonstrated that sexual partners tended to share genetically 
indistinguishable clones. This could also play a role in the increase in fluconazole resistance 
that has been seen in recent years. 
 
A demonstration of genetically indistinguishable strains in different hospitalised patients, 
indicative of person-to-person transmission within the hospital environment, emphasised the 
need for oral sample collection and initiation of treatment in patients who present with 
Candida in the oral mucosa (Fanello et al, 2006). 
 
Earlier studies showed an increased diversity of C. albicans strains in HIV-positive patients 
along a certain period of time, resulting in a change in the Candida species genotype, along 
with changes in fluconazole susceptibility (Lasker et al, 2001) and the ability to spread 
fluconazole-resistant Candida strains to other patients and staff (Makarova et al, 2003). 
 
The differential expression of several proteins that may contribute to fluconazole resistance in 
C. glabrata has been identified (Rogers et al, 2006). These were found to be the up-
regulation of the ATP-binding cassette transporter Cdr1p, the ergosterol biosynthesis enzyme 
Erg11p, proteins involved in glycolysis and glycerol metabolism and proteins involved in the 
response to oxidative stress and cadmium exposure. Other studies have described this 
resistance as a result of point mutations in the gene encoding for lanosterol demethylase
 
(ERG11) and an increased expression of ERG11 or the genes
 
encoding for the multidrug 
efflux pumps CaMDR1, CDR1, and CDR2 (Franz, Ruhnke and Morschhäuser, 1999). It has 
also been found that membrane-associated
 
multidrug transporter proteins Cdr1p, Cdr2p, and 
Mdr1p were not found in fluconazole-resistant isolates (Hooshdaran et al, 2004). However, 
no similar proteomics studies have been done on HIV-positive patients, on the African 
continent or with other Candida species.
 
 
 
 
8 
 
 
1.4 Fluconazole susceptibility testing 
 
The process of determining specific values for fluconazole resistance and susceptibility is not 
straightforward. A recent review addressing this question studied the fluconazole 
susceptibility results of 13.338 isolates obtained from various studies. Specific fluconazole 
concentration values for susceptible, resistant and susceptible-dose dependant isolates were 
determined based on the information collected (Pfaller, Diekema and Sheehan, 2006). 
However, research on antifungal susceptibility testing remains in its infancy. Factors such as 
zone of inhibition, time of incubation and appearance of microcolonies within the 
susceptibility zone when using fluconazole impregnated felt disks are still being used in 
different ways by different groups. This poses a problem, since unlike bacteria, there is no 
standardized method for antifungal susceptibility testing (Pfaller, Diekema and Sheehan, 
2006). The use of fluconazole impregnated felt disks is a simple, rapid and cost-effective 
method (Ernst and Rogers, 2005) that produces clear results (Kustimur et al, 2003) depending 
on which disk diffusion test medium is used. Various agars can be used in antifungal 
susceptibility testing, including Sabouraud Dextrose agar, Yeast Nitrogen Base agar, High 
Resolution Medium and Casitone agar. It has been found that Yeast Nitrogen Base agar 
produces the best results with relation to inhibition zone definition and quality of growth 
when compared with other mycological agars (May, King and Warren, 1997, Yücesoy, 
Guldas and Yuluq, 2001). 
 
Methylene-blue and glucose-enriched Mueller-Hinton (GMB) agar has also been used, 
proving to be a reliable and low-cost medium for Candida susceptibility testing (Lee et al, 
2001) and is the the recommended antifungal disk diffusion medium of the Clinical and 
Laboratory Standards Institute (CLSI, 2009). However, newer drug susceptibility platforms 
which comply with CLSI standards have been developed, leading to more straightforward 
ways of testing Candida isolates against different antifungal drugs. One of these is the TREK 
Sensititre drug susceptibility platform (Cat. No. V2020-SYS, Thermo Scientific, USA), a 
broth microdilution method that provides multiple antifungal drug susceptibility testing. 
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1.5 Antiretroviral (ARV) therapy and antifungal use 
 
By 2013, approximately 7.53 million Africans were on ARV treatment (WHO, 2013). South 
Africa has the world’s largest ARV therapy programme, with various antiretroviral drugs 
being used in combination to combat HIV infection in public hospitals. In 2011, it was 
estimated that 66% of South Africans with advanced HIV infection were on ARV therapy, 
while the figure for Cameroon in the same year was 41% (WHO Data Repository, 2013). 
Azidothymidine (AZT) is a reverse transcriptase inhibitor and the first approved treatment for 
HIV. It is also given to expectant mothers to prevent mother-to-child transmission. Other 
ARVs in common use include Stavudine (d4T), Lamivudine (3TC) Nevirapine (NVP) and 
Efavirenz (EFV). Additional drugs being introduced in the South African Highly Active 
Antiretroviral Therapy (HAART) list (second-line drugs) include Didanosine (ddl) and 
Tenofovir Disoproxil Fumarate (TDF), both reverse transcriptase inhibitors and Lopinavir 
(Kaletra-KLT), a protease inhibitor. A pilot study on resistance to first-line ARV drugs 
showed low levels of resistance to the different antiviral drugs, but stressed that these would 
increase over time, mainly due to high infection levels and patient drop-out rates (Morris et 
al, 2009). 
 
Although not much is known about the interactions between fluconazole and antiretroviral 
drugs, research has shown that the concomitant use of fluconazole and nevirapine resulted in 
an increased plasma level of nevirapine (Wakeham et al, 2010). The use of azoles with 
nevirapine has been shown to decrease the plasma levels of antifungal drugs (Boehringer 
Ingelheim Pharmaceuticals, 2008) and it has been reported that the concurrent use of these 
two medications increases hepatotoxicity (WHO, 2008). Candida infections have continued 
to increase after the introduction of HAART (Traeder, Kowoll and Arasté, 2008). 
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1.6 Techniques used in the study of Candida 
 
Detailed characterization of Candida species is essential to the understanding of resistance to 
antifungals. Recently developed non-culture based techniques to detect Candida species 
include polymerase chain reaction (PCR), Candida albicans germ tube (CAGT) antibody 
detection and 1,3 beta-D (B-D) glucan markers (Budhavari, 2009). However, these 
techniques are used for patient diagnosis before samples are grown in selective media and do 
not replace microbiological examination. Furthermore, these techniques have been associated 
with high numbers of false positive results. Sabouraud’s selective media is still the standard 
in the culturing of fungal isolates, and is widely used for the identification of certain species 
by direct observation of the shape and colour of the colonies. This selective medium has a 
low pH and a high sugar concentration, providing ideal growth conditions for fungal species. 
It is used as a prerequisite growth media for more advanced applications using fungal 
isolates. Confirmation of presumptive clinical Candida albicans or Candida dubliniensis 
isolates is usually done using the germ tube test. This test relies on the ability these two 
species have to form short lateral filaments (germ tubes) when incubated for 2-3 hours in 
bovine serum (Haley and Callaway, 1979). 
Chromogenic media allows for the differentiation of different Candida species based on the 
colour of the colonies. It is very simple to use and produces results that are accurate and 
relatively rapid. The synthetic chromogenic substrates present in this media are cleaved by 
the enzymes hexosaminidase (present in C. albicans, C. dubliniensis and C. tropicalis) and 
alkaline phosphatase (present in C. krusei, C. glabrata, C. kefyr, C. parapsilopsis and C. 
lusitaniae), and result in the production of a specific colour for each species (Rousselle et al, 
1994) corresponding to specific enzymes present in that organism. An accurate result is 
normally obtained after 24-48 hours of incubation. The tomato juice (V8) agar (a mixture of 
tomato juice, CaCO3, dextrose and agar) has been developed to meet the needs of routine 
clinical laboratories that require a low-cost and rapid technique to distinguish between C. 
albicans and C. dubliniensis (Alves et al, 2006), as it can be difficult to distinguish these two 
species in chromogenic agar. In this medium, C. albicans presents as smooth, round colonies, 
while C. dubliniensis presents as rough, irregular colonies. Microscopy of C. dubliniensis 
using this medium reveals the presence of pseudohyphae and chlamydospores. Other 
culturing techniques used in the differentiation of C. albicans and C. dubliniensis include 
growing the organisms in Sabouraud agar plates at 45°C (in which case C. dubliniensis does 
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not grow) (Pinjon et al, 1998, Gales et al, 1999, Us and Cengiz, 2007) and growing the 
organisms in tobacco agar (a mixture of tobacco and agar) at 28°C for 48-72 hours (Khan et 
al, 2004). In this medium C. dubliniensis grows as rough, yellow-brown colonies with 
pseudohyphae and chlamydospores, while C. albicans grows as smooth, white-cream 
colonies without the presence of pseudohyphae or chlamydospores. 
Sabouraud agar, chromogenic and selective agars are used as part of the protocol for the use 
of other techniques, and remain important microbiological tools in isolating and identifying 
microorganisms. However, due to improved technology, cultural studies are being replaced 
by more sophisticated methods of characterization, a few of which are described below. 
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1.7 Techniques used for protein identification 
 
1.7.1 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
SDS-PAGE is a technique widely used in proteomics research to detect protein 
modifications, determine relative protein molecular mass and separate proteins according to 
their electrophoretic ability. Protein separation is done by isolating the organism’s protein 
fractions, standardizing protein concentration, denaturing the protein’s secondary and tertiary 
structures and applying a negative current so that the proteins are separated according to their 
molecular weight (Schägger and Jagow, 1987). 
 
Comparison of the distance traveled by proteins in the sample relative to those in marker 
proteins of known molecular weight allows for the determination of the weight of unknown 
proteins (Abelson, Simon and Deutscher, 1990).  
 
Application of the SDS-PAGE technique to fluconazole-resistant Candida isolates showed 
the expression of proteins Grp2p, Ifd1p, Ifd4p, Ifd5p, Ifd6p Grp2p, and Erg10p, a protein 
involved in the ergosterol biosynthesis pathway (Hooshdaran et al, 2004). Other studies 
employing SDS-PAGE showed an increase in the expression of a 44kDa protein identified as 
exoglucanase after C. albicans strains were subjected to fluconazole (Angiolella et al, 2002), 
the expression of a 40kDa and 60kDa proteins in C. albicans after exposure to fluconazole 
(Kustos et al, 2006), the appearance of a 23.9kDa acid proteinase enzyme in C. tropicalis 
(Okumura, Inoue and Nikai, 2007) and significant differences in the protein band patterns of 
fluconazole-resistant and susceptible Candida strains (Shahid et al, 2006), with 23 proteins 
being more abundant in fluconazole-resistant strains, most of which range from 23kDa to 64 
kDa in molecular weight. Candida glabrata proteins with a molecular weight of 61kDa and 
169kDa have also been implicated in fluconazole resistance, and were identified as 14α-
demethylase, a plasma membrane enzyme induced by fluconazole exposure and the drug 
efflux transporter CgCdr1p, respectively (Niimi et al, 2002).  
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1.7.2 High Performance Liquid Chromatography-Mass Spectrometry (HPLC-MS) 
 
The use of mass spectrometry for the study of proteins has been previously documented 
(Domon and Aebersold, 2006). This analytical technique relies on the ionization of a sample 
and the subsequent measurement of the charge to mass ratios of the samples’ compounds 
(Sparkman, 2000). Proteins are typically characterized by mass spectrometry by means of 
techniques such as time-of-flight MS (TOF-MS) or Fourier transform ion cyclotron 
resonance MS (FT-ICR). Liquid chromatography mass spectrometry (LC-MS) is a very 
sensitive mass spectrometry technique that can also be used in protein identification. This 
technique combines the separation ability of a chromatographic technique and the 
determination of charge to mass ratios of mass spectrometry, to ultimately identify 
components within a sample. 
 
High performance liquid chromatography is a chromatographic technique that can be applied 
in proteomics to separate, identify or quantify different proteins. This method works by 
passing a pressurized liquid and sample mixture through a sorbent-filled column. The 
interaction of the sorbent particles and different sample components result in the separation 
of the latter (Touchstone, 1993). The equipment consists of a sampler, which allows the 
sample mixture to be carried into a column, different pumps used to pass the pressurized 
liquid through the column and a detector, which produces a signal proportional to the amount 
of sample which originates in the column. The detector is connected to a user computer 
interface, thereby allowing for data analysis. 
 
High performance liquid chromatography is an efficient chromatography technique when 
compared with other similar platforms, as higher column pressures and smaller sample sizes 
are used. This ultimately results in better peak resolution. 
Previous studies on Candida species using this technique have relied on the exposure of 
Candida strains to antifungal drugs (Li et al, 2007) and the determination of antifungal drug 
concentration in plasma (Marchetti et al, 2001) or suspension (Amin et al, 2009). The 
approach of exposing a Candida type strain to fluconazole and subsequently reading the 
fluconazole levels in the cultures using HPLC has been reported (Casalinuovo et al, 2008). 
The use of HPLC for Candida species detection has also been documented (Goldenberg et al, 
2005). The large-scale analysis of clinical Candida protein fractions using HPLC is, to the 
best of our knowledge, undocumented. 
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Objectives 
 
The objective of this study was to characterize Candida species isolated from 
immunocompromised patients, by means of microbiological (for species differentiation and 
antimicrobial susceptibility testing) and proteomic (for specific drug-resistance protein 
identification) tools. 
Analysis of oral Candida specimens from different HIV-positive African patients using 
selective and differential media and their exposure to various antifungal drugs (with an 
emphasis on the most widely used drug, fluconazole) is an important approach which will aid 
in our understanding and knowledge of the current Candida prevalence and drug resistance 
patterns in African populations, details of which are at present very limited. This, in turn, will 
have beneficial repercursions in patient treatment. This study could also contribute to the 
management and treatment of Candida based on the Candida species present in HIV-positive 
patients in different regions of the African continent. The use of SDS-PAGE and HPLC-MS 
for characterization would identify specific Candida proteins that are related to fluconazole 
and other antifungal drug resistance, which could be used as the benchmark for new research 
in this area. This presents as a gap in the research that has already been done, as no study has 
compared the expression of specific resistance proteins in Candida with the much more 
detailed results that are obtainable from an HPLC-MS reading in a large number of clinical 
isolates. 
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Chapter 2: Materials and Methods 
 
2.1 Sample collection 
 
Two hundred and twelve (212) samples were collected between 2006 and 2008 from HIV-
positive patients at community hospitals in Khayelitsha (Site B hospital) in and Delft (Delft 
Day Hospital –ARV clinic), both located in the greater Cape Town metropolitan area, in 
South Africa. A further 262 samples were collected in 2011 from HIV-positive patients at the 
Bamenda Regional Hospital in the North West Province of Cameroon, West Africa. This was 
done by scraping the patient’s oral mucosa and tongue using a mouth swab. Only HIV-
positive patients presenting with white pseudomembranous plaque on the tongue or other 
visible oral candidiasis were selected, as these patients had a higher chance of harbouring oral 
Candida. Ethical clearance for this project was given by the Ethics Committee at UWC. 
Approval from the Ministry of Health Regional Hospital Institutional Review Board (IRB) in 
Cameroon was obtained for sample collection in Bamenda. Prior to sample collection, the 
reasons for, and nature of the study were explained to the patients who willingly consented to 
participate. Data from the patient’s hospital folder was collected, where appropriate. The 
participants were required to sign consent forms agreeing to participate in the study 
(Appendix 1) and to submit some personal information in a questionnaire, namely, their 
gender, gender of the sexual partner, age, race, immune status (HIV stage), date diagnosed 
and duration of ARV treatment (Appendix 2). 
 
 
2.2 Isolation of Candida species 
 
The South African samples were examined in the Medical Microbiology laboratories at UWC 
while the Cameroonian samples were examined in a private laboratory in Bamenda. 
Swabs were initially streaked onto Sabouraud’s agar (Cat. no. BO0408T, Oxoid, UK) and 
incubated at 37˚C for 24 hours. Plates showing no growth were re-incubated for a further 24 
hours before being discarded as negative. 
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All isolates were stored at -80°C in Pro-Lab Microbank microbial preservation vials (Cat. no. 
PL.170/M, Pro-Lab, Canada), allowing them to be re-grown as and when needed. 
Cameroonian isolates were transported in these frozen preservation vials to UWC for 
characterisation which included the confirmation of Candida species using chromogenic 
media, Gram staining and the germ tube test. 
 
 
2.3. Characterisation of isolates. 
 
2.3.1. Candida species identification using chromogenic media 
 
Selective agar and chromogenic media included Sabouraud’s agar  modified Fluka 
chromogenic Candida identification agar, (Cat. no. 94382, Sigma-Aldrich, USA) with 
respective selective supplement (Cat. no. 68067, Sigma-Aldrich, USA), Oxoid chromogenic 
Candida agar (Cat. no. CM1002A, Oxoid, UK) with respective selective supplement (Cat. no. 
SR0231E, Oxoid, UK), tomato (V8) agar (Alves et al, 2006) and tobacco agar (Khan et al, 
2004). 
 
Type strains of C. albicans (ATCC 90028 and NCPF 3281), C. tropicalis (ATCC 950), C. 
dubliniensis (NCPF 3949a), C. glabrata (ATCC 26512) and C. krusei (ATCC 2159) served 
as positive controls for the chromogenic species differentiation. 
 
On Fluka chromogenic agar, C. albicans grows as light green colonies, C. dubliniensis as 
dark green colonies, C. glabrata as smooth cream/white colonies and C. tropicalis as metallic 
blue colonies, while C. krusei grows as pink/purple, fuzzy colonies. The identification of C. 
kefyr/parapsilopsis/lusitaneae is not described in the Fluka catalogue. In Oxoid chromogenic 
media, C. albicans grows as light green colonies, C. dubliniensis as dark green colonies, C. 
glabrata as smooth beige/yellow/brown colonies, C. kefyr/parapsilopsis/lusitaneae as 
variable, natural pigment colonies and C. tropicalis as metallic blue colonies, while C. krusei 
grows as pink/brown, fuzzy colonies. 
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2.3.2. Microscopy 
 
The Gram stain was used for the staining of Candida isolates prior to light microscopy 
observation. Pure colonies of the isolates were heat fixed in a glass slide and flooded with 
crystal violet (primary stain), iodine (which acts as a mordant), alcohol (used for 
decolorization) and carbol fuchsin, which acts as a counterstain. 
 
2.3.3. Germ tube test 
 
Presumptive C. albicans and C. dubliniensis cultures were incubated at 37˚C for 2-3 hours in 
fetal bovine serum (Cat. no. A15-101, PAA Laboratories, Austria) for the stimulation of germ 
tube production. Germ tube formation was observed microscopically in a wet mount 
preparation. 
 
Type strains of C. albicans (ATCC 90028 and NCPF 3281) and C. dubliniensis (NCPF 
3949a) served as positive controls for the germ tube test, while C. tropicalis (ATCC 950) 
(which forms pseudohyphae with constriction at the point of attachment when grown in 
serum) served as a negative control. 
 
2.3.4 Candida albicans and C. dubliniensis species differentiation 
 
Presumptive C. albicans and C. dubliniensis cultures were incubated at 37˚C for 48 hours in 
Tomato (V8) agar; at 28˚C for 48-72 hours in Tobacco agar and at 45˚C for 24-48 hours in 
Sabouraud dextrose agar. Differences in growth, colony morphology and 
pseudohyphae/chlamydospore expression allowed for species differentiation. 
 
 
2.4 Antimicrobial susceptibility testing 
 
Fluconazole antimicrobial susceptibility test disks 25µg (Cat. no. X7148, Oxoid, UK) were 
used for the antifungal susceptibility test, and three selective media were used, namely 
Sabouraud’s (Cat. no.CM0041, Oxoid, UK), Difco Yeast Nitrogen Base with glucose 
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(YNBG) (Cat. no. 239210, Beckton, Dickinson and Company, UK) and Methylene-blue and 
glucose-enriched (GMB) Mueller-Hinton (Cat. No. CM0337, Oxoid, UK) agar. 
 
2.4.1. Preparation of agar plates 
 
2.4.1.1. Yeast Nitrogen Base agar with Glucose 
A 10X solution of Yeast Nitrogen Base in powder form (6.7 g/100 mL) and dextrose (5 g/100 
mL) was filtered using a 0.45 µm disposable filter (Ref. no. 25NS, MSI filters, USA) 
attached to a 50mL sterile plastic syringe into a sterile bottle containing Difco granulated 
bacteriological agar (1.3 g/100 mL) (Cat. no. 214530, Difco, USA), according to the 
manufacturer’s instructions. 
 
2.4.1.2 Methylene-blue and glucose-enriched Mueller-Hinton agar 
Methylene-blue and glucose-enriched Mueller-Hinton (GMB) agar was prepared by adding 
2% glucose and 5 µg of methylene blue dye/ml to Mueller-Hinton agar (Cat. no. CM0337, 
Oxoid, UK). 
 
2.4.2. Disk diffusion susceptibility testing 
 
Clinical strains were incubated for 24 hours at 37˚C in Sabouraud’s, yeast nitrogen base agar 
with glucose (YNBG) and Methylene-blue and glucose-enriched Mueller-Hinton (GMB) 
agar. A sweep of colonies was added to sterile plastic Greiner tubes containing 5mL of sterile 
distilled water and the inoculum was adjusted according to McFarland standards, a technique 
using known densities of microorganism suspensions for standardization (McFarland, 1907). 
The dilution ratio used was of approximately 3x10
8
 microorganisms per ml in Sabouraud and 
YNBG. In the case of GMB agar, further dilutions were used to yield a final concentration of 
2x10
4
 to 4x10
4
 microorganisms per ml, as described in the CLSI protocol. Three random 
samples were also analyzed in triplicate using a Bausch&Lomb Spectronic 20 
spectrophotometer (Cat. no. 33-31-72 Bausch&Lomb, USA) at 450nm, and showed an 
absorbance in the range of 0.13 to 0.18. 
 
A sterile cotton swab was dipped in the solution and inoculated on Sabouraud’s, YNBG and 
GMB plates. Fluconazole-impregnated felt disks were then placed on the inoculated plates 
and incubated for 24 hours at 37˚C. The resistance patterns of the samples were seen as 
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inhibition areas around the fluconazole disks, which were then measured, from the edge of 
the disk to the edge of the susceptibility area. The presence of microcolonies within the 
susceptibility zone was also noted and given a score (0= a clear zone with no microcolonies, 
1=a few microcolonies present, 2= moderate growth of microcolonies and 3= many 
microcolonies in the susceptibility area). This was done in duplicate. When differences in 
susceptibility/microcolony growth were seen, the susceptibility test was repeated. In random 
samples, microcolony and outer growth areas were stained and observed microscopically for 
Candida species confirmation. These were subsequently grown in chromogenic media and 
were shown to be the same species. Samples with susceptibility areas less than 7 mm in 
Sabouraud and YNBG (14 mm or less in GMB) and with the presence of microcolonies were 
regarded as resistant, as well as samples with more than a microcolony score of 2, while 
samples with susceptibility areas higher than 12 mm in Sabouraud and YNBG (19 mm or 
more in GMB) and with a microcolony score of 2 or less were regarded as susceptible to 
fluconazole. Strains with a susceptibility area ranging from 7 to 12 mm in Sabouraud and 
YNBG and from 15 to 18 mm in GMB agar were regarded as intermediate (or dose-
dependent) strains, as described in studies employing these media (May, King and Warren, 
1997, Lee et al, 2001). For the purpose of the proteomics section of this study, however, 
intermediate strains were considered resistant, as these would still express drug resistance 
proteins. 
 
2.4.3. TREK Sensititre susceptibility testing 
 
The TREK Sensititre (Cat. No. V2020-SYS, Thermo Scientific, USA) YeastOne 9 (YO9) 
system, a CLSI approved broth microdilution system, consists of microtiter plates embedded 
with nine different drugs (anidulafungin, micafungin, caspofungin, 5-flucytosine, 
posaconazole, voriconazole, itraconazole, fluconazole and amphotericin B) in ascending 
concentrations. The drug concentration ranges on the YO9 wells are 0.008-8 µg/ml for 
micafungin, caspofungin, posaconazole and voriconazole; 0.015-8 µg/ml for anidulafungin; 
0.12-256 µg/ml for fluconazole; 0.015-16 µg/ml for itraconazole; 0.06-64 µg/ml for 5-
flucytosine and 0.12-8 µg/ml for amphotericin B. The wells are also coated with a 
colorimetric agent, allowing for the minimum inhibitory concentration (MIC) of each drug to 
be easily detected both with the naked eye and with the supplied Vizion computer-assisted 
plate reading system. 
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Running of the samples on the TREK Sensititre system was done by diluting second-
generation Candida strains onto sterile phosphate buffered saline tubes to a 0.5 McFarland 
standard, using the supplied TREK nephelometer. This was followed by vortexing the 
suspension according to protocol, dispensing 100 µl of the solution into the YeastOne broth, 
dispensing the inoculated broth onto the YO9 plate wells using an Ovation 25-1250 µl 
automated multichannel pipette (VistaLab, NY, USA, cat. no. 1160-1250), sealing the plates 
with the supplied plate film and incubating for 24 hours at 37°C. 
The plates were then read using the supplied Vizion plate reader and the TREK SWIN 
software. 
 
Newly developed species-specific clinical breakpoints were used for the determination of 
echinocandin drug resistance (anidulafungin, caspofungin and micafungin) for C. albicans, C. 
tropicalis and C. krusei (Pfaller et al, 2012), while CLSI breakpoint categories were used for 
5-flucytosine, itraconazole, fluconazole and amphotericin B (Eraso et al, 2008) and proposed 
breakpoints were used for voriconazole (Pfaller et al, 2006). In the case of posaconazole, for 
which no clinical breakpoints have been established, wild-type MIC values were used (Pfaller 
et al, 2011). MICs were defined as the lowest concentrations that inhibited growth at 100%. 
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2.5 Protein identification using SDS-PAGE 
 
SDS-PAGE protein identification was done on South African samples using a Hoefer 
MightySmall II system (Ref. no. SE 250-10A-.75, Hoefer, USA), a Labnet Enduro 250V 
power supply (Ref. no. E-0203, Labnet, USA) and a Fluka SDS gel preparation kit (which 
includes the separation gel buffer, 30% acrylamide/0.8% bisacrylamide solution, running 
buffer 10x concentrate, Tetramethylene diamine (TEMED) 10% solution, sample incubation 
buffer concentrate and concentrated ammonium persulfate (APS) solution) (Ref. no. 08091, 
Sigma-Aldrich, USA). Type strains of C. albicans (NCPF 3281) and C. dubliniensis (NCPF 
3949a) served as positive controls for the electrophoresis analysis. 
 
Clinical specimens were grown in Sabouraud agar plates for 24 hours, after which individual 
colonies were incubated in 15ml screw cap plastic centrifuge tubes containing 10mL of YPD 
broth (peptone 10 g/L and dextrose 40 g/L distilled water) at 37˚C for 24 hours in a GFL 
agitator (Ref. no. 3015, GFL, Germany). The optical densities of the type strains and six 
random clinical broth cultures were read at 600 nm using a Bausch&Lomb Spectronic 20 
spectrophotometer (Cat. no. 33-31-72 Bausch&Lomb, USA) with the samples having an 
approximate absorbance reading of 5.5. The broth tubes were centrifuged at 3000 g using a 
MSE Super Minor centrifuge (Ref. no. 12-79, MSE, UK). The broth was subsequently 
removed from the tubes using sterile plastic Pasteur pipettes. Two milliliters (2 mL) of sterile 
distilled water was then added to the fungal cells, followed by centrifugation at 3000 g for 10 
minutes using a MSE Super Minor centrifuge (Ref. no. 12-79, MSE, UK) to wash the cells. 
The isolated pellet was then suspended in 2 mL homogenizing buffer (50 mM Tris-HCl, pH 
7.5, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride), using a protein isolation method 
first described by Niimi et al (2002). One gram (1 g) of borosilicate 1 mm solid glass beads 
(Cat. no. Z273619, Sigma-Aldrich, USA) was added to the centrifuge tubes containing the 
fungal pellets and homogenizing buffer. The fungal cells were then disrupted by placing the 
tubes in a vortex for 6 minutes. This was followed by transferring the solution to 2 mL plastic 
microcentrifuge tubes and centrifugation at 5000 g at 4˚C for 10 minutes to remove cell 
debris and unbroken cells, using an Eppendorf benchtop centrifuge (Ref. no. 5415C, 
Eppendorf, Germany). The obtained lysate solutions (now containing only fungal cell 
membrane components) were then centrifuged at 20 000 g at 4˚C for 60 minutes using an 
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Eppendorf microcentrifuge (Ref. no. 5424, Eppendorf, Germany), resulting in the isolation of 
a crude membrane fraction. 
 
Protein concentration was determined using a Bio-Rad Bovine Serum Albumin (BSA) 
Standard Set (Cat. no. 500-0207, Bio-Rad, USA), a protein assay kit based on the Bradford 
protein assay (Bradford, 1976). Sixteen microliters (16 µL) of a 10 mM Tris-HCl, pH 7.0, 5 
mM EDTA solution were added to the isolated pellets and vortexed. Five microliters (5µL) of 
concentrated BSA solutions (0.125 µg/ml, 0.25 µg/ml, 0.5 µg/ml, 0.75 µg/ml, 1 µg/ml, 1.5 
µg/ml and 2 µg/ml) and 5 µL of each sample were then transferred to 96-well plastic 
microplates in duplicate (two wells per sample) and 250 µL of Bradford dye reagent was 
added to each well with the aid of a Labnet multichannel pipette (Ref. no. P4508-300, 
Labnet, USA). The microplates were then placed in a Thermo Scientific Multiskan 355 EX 
microplate reader with computer-assisted user interface (Ref. no. 5118170, Thermo-
Scientific, USA) for absorbance reading at 620 nm. Sample concentration was standardized 
using a plot of the seven prediluted BSA solutions’ concentrations and absorbance readings. 
Samples which expressed a protein concentration higher than 0.8 mg/ml were diluted in GTE 
buffer (10 mM Tris-HCl, pH 7.0, 5 mM EDTA, 20% v/v glycerol) to an approximate protein 
concentration of 0.65 mg/ml. Four microliters (4 µL) of glycerol and 20 µL of SDS loading 
buffer (incubation buffer) were then added to the samples. This loading solution was then 
vortexed to solubilise the protein samples in the buffers and subsequently incubated at 37˚C 
for 30 minutes. 
 
A Bio-Rad Precision Plus Dual Colour Protein marker (Cat. no. 161-0374, Bio-Rad, USA) 
was used for protein weight determination. Protein samples were separated in a 15% SDS 
polyacrylamide gel, prepared by adding 7.5 mL PAA stock solution, 5 mL separation gel 
buffer, 2.25 mL distilled water and 0.25 mL TEMED 10% solution to 0,1 mL APS 10% and 
subsequently loaded between glass and alumina plates supplied with the Hoefer SDS-PAGE 
gel caster system. One hundred percent (100%) ethanol was then added to the top of the gel 
to smoothen its surface and the separating gel was subsequently left to dry. A 3% stacking gel 
solution (0.5 ml PAA stock solution/1 ml stacking gel buffer/3.4 ml distilled water/0.1 ml 
TEMED 10% solution and 0.03 mL APS 10% solution) was then added to the top of the 
separating gel. Ten wells were created in the stacking gel by inserting a plastic comb in the 
top section of the stacking gel solution before it solidified. The glass plate-polyacrylamide 
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gel-alumina plate assemblies were then transferred to the Hoefer electrophoresis unit after the 
stacking gel solidified. The unit’s lower chamber and upper buffer chamber were filled with 
the diluted Fluka SDS kit running buffer. Ten microliters (10 µL) of protein marker and 30 
µL of protein samples were added to their respective wells in the gel using a P20 Gilson 
pipette (Ref. no. F123600, Gilson, France). 20 µL of GTE buffer (10 mM Tris-HCl, pH 7.0, 5 
mM EDTA, 20% v/v glycerol) was added. Twenty microliters (20 µL) of incubation buffer 
solution was used as a negative control. 
A 250V/30mA electric current was applied to the gels after which they were stained with 
Coomassie Brilliant Blue R250 (0.05-0.1% brilliant blue R250 in 10% acetic acid, 40% 
distilled water, 50% methanol) overnight in a GFL agitator (Ref. no. 3015, GFL, Germany).  
Protein gels were subsequently soaked in Coomassie de-stain solution (10% methanol, 30% 
acetic acid, 60% distilled water) for approximately 4 hours (until the gels were clear and 
protein bands could be seen) and soaked in gel drying solution (7.5% acetic acid, 10% 
glycerol, 40% methanol, 50% distilled water) for 3-5 minutes. Gels were then dried using a 
Promega gel drying kit (Cat. no. V7120, Promega, USA). Gel drying films were used to dry 
the protein gels, which were moistened in gel drying solution, secured in a gel drying frame 
using the supplied metal clamps and left to dry overnight. 
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2.6 Protein identification using HPLC-MS 
 
High performance liquid chromatography-mass spectrometry analysis was performed on 40 
isolate fractions from both populations (10 fluconazole-susceptible fractions and 10 
fluconazole-resistant fractions from C. albicans isolates and 20 fractions from the non-
albicans isolates found in this study), by using the same Candida cell surface fraction 
isolation protocol used for the SDS-PAGE analysis. The cell fractions were taken from UWC 
to the Central Analytical Facility (CAF) Proteomics laboratory at Tygerberg Medical Campus 
for analysis. 
 
Filter-aided sample preparation (FASP) was used on the cell fractions, in accordance with the 
protocol set by the University of Stellenbosch’s Central Analytical Facility Proteomics 
laboratory: samples were mixed 1:1 with lysis buffer (50 μl sample with 50 μl SDT lysis 
buffer (4% SDS, 100 mM Tris-HCl pH 7.6, 0.1 M DTT that was added freshly just before 
use)). The 100 μl sample was then mixed with 100 μl UA buffer (8 M urea, 100 mM Tris-
HCl, pH 8.5) and placed on an Amicon ultra 0.5 centrifugal 10 kDa filter (EMD Millipore, 
USA) and subsequently centrifuged for 40 minutes at 14000 g. This was followed by the 
addition of 200 μl UA buffer and centrifugation at 14000 g for 40 minutes. The proteins were 
then alkylated by the addition of 100 μl of 0.05 M iodoacetamide in UA buffer. This was then 
mixed and incubated for 5 minutes before centrifugation at 14 000 g for 30 minutes, followed 
by the addition of 100 μl of UB buffer (8 M urea, 0.1 M Tris-HCl pH 8.0), centrifuged for 30 
minutes at 14 000 g and repeated once more. After centrifugation, 100 μl of a 50 mM 
ammonium bicarbonate solution was added, centrifuged at 14 000 g for 30 minutes and 
repeated once more. This was followed by the addition of 40μl trypsin and incubation at 37°C 
for 17 hours in a wet chamber. The following morning the filter was placed in a clean 
Eppendorf tube and centrifuged for 40 minutes at 14 000 g, followed by the addition of 40 μl 
of a 0.5 M sodium chloride solution and centrifuged for 20 minutes at 14 000 g. Finally, the 
solution was acidified by the addition of 2.4 μl FA solution. The filtrate was then desalted 
using C18 StageTips (Thermo-Fisher Scientific, USA) according to the manufacturer’s 
instructions. The desalted solution was dried in vacuo and stored at -20⁰C. Dried peptides 
were dissolved in 5% acetonitrile in 0.1% formic acid and 10 μl injections were made for 
nano-LC chromatography. 
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All mass spectrometry experiments were performed on a Thermo Scientific EASY-nLC II 
connected to a LTQ Orbitrap Velos mass spectrometer (Thermo Scientific, Bremen, 
Germany) equipped with a nano-electropsray source. For liquid chromatography, separation 
was performed on an EASY-Column (2 cm, ID 100 μm, 5 μm, C18) pre-column followed by 
XBridge BEH130 NanoEase column (15 cm, ID 75 μm, 3.5 μm, C18) column with a flow 
rate of 300 nl/min. The gradient used was from 5-17 % B in 5 min, 17-25% B in 90 min, 25-
60% B in 10 min, 60-80% B in 5 min and kept at 80% B for 10 min. Solvent A was 100% 
water in 0.1 % formic acid, and solvent B was 100 % acetonitrile in 0.1% formic acid. 
 
The mass spectrometer was operated in data-dependent mode to automatically switch 
between Orbitrap-MS and LTQ-MS/MS acquisition. Data were acquired using the Xcaliber 
software package. The precursor ion scan MS spectra (m/z 400 – 2000) were acquired in the 
Orbitrap with resolution R = 60000 with the number of accumulated ions being 1 x 10
6
. The 
20 most intense ions were isolated and fragmented in linear ion trap (number of accumulated 
ions 1.5 x 10
4
) using collision induced dissociation. The lock mass option 
(polydimethylcyclosiloxane; m/z 445.120025) enabled accurate mass measurement in both 
the MS and MS/MS modes. In data-dependent LC-MS/MS experiments, dynamic exclusion 
was used with 60s exclusion duration. Mass spectrometry conditions were 1.8 kV, capillary 
temperature of 250°C, with no sheath and auxiliary gas flow. The ion selection threshold was 
500 counts for MS/MS and an activation Q-value of 0.25 and activation time of 10 ms were 
also applied for MS/MS. 
 
 
2.7 Statistical analysis 
 
Statistical analysis was done using the SPSS 21.0 statistical software. Descriptive statistics 
and chi-square tests were used for the comparison of different Candida colonization patterns 
and patient data. Analysis of fluconazole and other antifungal drug susceptibility results was 
also done by means of chi-square tests (p<0.05).  
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Chapter 3: Results 
 
3.1 Candida species growth patterns 
 
Table 1 shows the colony growth patterns of Candida species isolates 24 hours after sample 
collection and incubation and the respective percentage of isolates for each species (more 
detailed information can be seen in appendix 3). Growth was defined as scanty when ≤ 5 
colonies were seen after the first sample incubation, while a higher number (> 6 colonies) and 
a more uniform appearance of colonies was categorized as light growth. In the South African 
samples, Candida albicans was the most prevalent species, followed by C. glabrata and C. 
dubliniensis. 
 
Table 1: Growth pattern results of the first inoculation of all South African Candida isolates. 
Candida spp/Growth Scanty (%) Light (%) Moderate (%) Heavy (%) 
C. albicans 52 (49%) 40 (38%) 12 (11%) 2 (1.9%) 
C. dubliniensis 4 (40%) 5 (50%) 1 (10%) 0 (0%) 
C. glabrata 4 (33%) 7 (58%) 1 (8.3% 0 (0%) 
 
 
C. albicans was also the predominant isolate from the Cameroonian samples, followed by C. 
glabrata and other Candida species (Table 2). 
 
Table 2: Growth pattern results of the first inoculation of all Cameroonian Candida isolates. 
Candida spp/Growth Scanty (%) Light (%) Moderate (%) Heavy (%) 
C. albicans 61 (66.3%) 21 (22.8%) 9 (9.8%) 1 (1.1%) 
C. dubliniensis 0 (0%) 1 (100%) 0 (0%) 0 (0%) 
C. glabrata 24 (100%) 0 (0%) 0 (0%) 0 (0%) 
C. krusei 4 (100%) 0 (0%) 0 (0%) 0 (0%) 
C. tropicalis 2 (50%) 1 (25%) 0 (0%) 1 (25%) 
C. kefyr/ 
parapsilopsis/lusitaneae 2 (100%) 0 (0%) 0 (0%) 0 (0%) 
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3.2 Colonial morphology on selective/differential media 
 
Isolates were inoculated onto chromogenic agar and incubated at 30˚C for 24-48 hours. The 
different colours and textures that distinguish the various species are clearly demonstrated in 
Figures 1 and 2 using Fluka and Oxoid chromogenic media, respectively. The Candida 
species differentiation results are shown in accordance with the colours/textures expressed by 
the Candida type strains when grown on both chromogenic media, as no individual 
chromogenic medium is able to accurately distinguish between all Candida species found in 
this study (C. glabrata, for example, shows a slight pink coloration when grown on Fluka 
chromogenic agar, instead of the cream white colour described in the product catalogue). A 
mixed culture of different species on Fluka chromogenic medium can be observed in Figure 
1(g). 
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a     b 
 
c     d 
 
e     f 
 
g 
Fig. 1: Growth of Candida species on Fluka chromogenic media: 
a: C. albicans 
b: C. dubliniensis 
c: C. glabrata 
d: C. tropicalis 
e: C. krusei 
f: C. kefyr/C. parapsilopsis/C. lusitaneae 
g: Mixed growth 
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a      b 
 
c      d 
 
e      f 
Fig. 2: Growth of Candida species on Oxoid chromogenic media: 
a: C. albicans 
b: C. dubliniensis 
c: C. glabrata 
d: C. tropicalis 
e: C. krusei 
f: C. kefyr/C. parapsilopsis/C. lusitaneae 
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Tomato juice agar was used for the further differentiation between C. albicans and C. 
dubliniensis. Figure 3(a) shows a C. albicans culture after inoculation onto tomato juice agar 
and subsequent incubation at 37˚C for 48 hours (detailed results on chromogenic and tomato 
juice agars can be seen in appendix 4). Figure 3(b) represents a C. dubliniensis culture on 
tomato juice agar under the same growth conditions. C. albicans grew as a smooth, shiny 
colony, while C. dubliniensis yielded a characteristic rough, dry colony. Similar results were 
observed for growth on Tobacco agar incubated at 28˚C for 48 hours (Figure 4). 
 
  
a      b 
Fig. 3: Growth of Candida species on tomato juice agar: 
a: C. albicans 
b: C. dubliniensis 
 
 
  
a             b 
Fig. 4: Growth of Candida species on tobacco agar: 
a: C. albicans 
b: C. dubliniensis 
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3.3 Candida species microscopical morphology 
 
Figure 5 shows the different Candida type strains stained with carbol fuschin and examined 
by oil immersion microscopy using an Optikam B3 camera (Optika Microscopes, Italy) 
attached to an optical microscope. Figure 6 shows some of the different Candida cell 
morphologies isolated from clinical samples in this study. 
 
Microscopy played an important role in the initial identification of Candida species. Candida 
krusei was the only Candida species that could be presumptively identified by microscopy, 
due to its noticeably larger cells.  
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a      b 
  
c      d 
 
e 
Fig. 5: Candida type strain cell morphologies (1000X). 
a: C. albicans ATCC 90028 
b: C. dubliniensis NCPF 3949a 
c: C. glabrata ATCC 26512 
d: C. tropicalis ATCC 950 
e: C. krusei ATCC 2159 
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a      b 
  
c      d 
 
Fig. 6: Candida clinical strain cell morphologies (1000X). 
a: C. albicans/C. dubliniensis/C. kefyr/C. parapsilopsis/C. lusitaneae 
b: C. glabrata 
c: C. tropicalis 
d: C. krusei 
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3.4 Frequency distribution of Candida species identified from clinical isolates 
 
One hundred and twenty six (126) of the swabs collected from the South African population 
resulted in positive Candida growth, with two patients harbouring two Candida species. This 
equates to 59.4% of the total number of patients testing positive for the presence of Candida 
in their oral mucosa. Eighty three percent (83%) of the patient’s isolates were identified as C. 
albicans (106 isolates), 9.4% as C. glabrata (12 isolates) and 7.8% as C. dubliniensis (10 
isolates). 
 
In the case of the Cameroonian population, 127 (48.5%) of the swabs collected resulted in 
positive Candida growth. Seventy one point three percent (71.3%) of the patient’s isolates 
were identified as C. albicans (92 isolates), 18.9% as C. glabrata (24 isolates), 3.1% as C. 
krusei (4 isolates), 3.1% as C. tropicalis (4 isolates), 0.77% as C. dubliniensis (1 isolate) and 
1.55% as either either C. kefyr, C. parapsilopsis or C. lusitaneae (2 isolates) (Figure 7). 
 
 
 
 
Fig. 7: Distribution of Candida species found in the oral mucosa of HIV+ patients (number of isolates 
represented on the y-axis). 
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3.5 Antifungal susceptibility testing 
 
3.5.1 Fluconazole disc diffusion susceptibility testing 
 
Fluconazole susceptibility testing was optimized by inoculating three random clinical strains 
in triplicate following the same methodology as previously described for clinical isolates 
(subheading 2.4), with a McFarland standard of 1, 2 and 3. The same susceptibility patterns 
were observed for all dilutions (Table 3). This was done for the case of a possible dilution 
mistake while visually adjusting the clinical fungal cell dilutions, to confirm if the 
susceptibility results would remain the same in a more concentrated Candida dilution. 
 
Table 3: McFarland dilution optimization test, showing inhibition areas and microcolony formation 
after fluconazole susceptibility testing of three different samples. 
No. McFarland dilution Inhibition area (mm) Microcolonies 
1 
McFarland1 4 0 
McFarland2 4 0 
McFarland3 4 0 
2 
McFarland1 2 1 
McFarland2 2 1 
McFarland3 2 1 
3 
McFarland1 resistant resistant 
McFarland2 resistant resistant 
McFarland3 resistant resistant 
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Figure 8 demonstrates susceptibility or resistance to fluconazole. Susceptibility is 
demonstrated by a zone of inhibition around the fluconazole-impregnated disc (Fig. 7a), 
intermediate resistance is indicated by the growth of fungal microcolonies in the 
susceptibility area (Fig.7b) and resistance is indicated where the fungal growth grew over the 
impregnated disc (Fig. 7c), when cultures were incubated in YNBG at 37˚C for 24 hours. 
 
  
a      b 
 
c 
Fig. 8: Inhibition of Candida growth in YNBG media in the presence of a fluconazole disk (a clear inhibition 
area can be seen around the disk) (a), presence of microcolonies in the susceptibility area (b) and resistance to 
fluconazole (no inhibition area can be seen on the plate) (c). 
 
 
 
 
 
37 
 
 
Susceptibility and resistance were also clearly demonstrated when cultures were incubated in 
GMB at 37˚C for 24 hours. 
 
  
a      b 
 
Fig. 9: Inhibition of Candida growth in GMB media in the presence of a fluconazole disk (a clear inhibition area 
can be seen around the disks) (a) and resistance to fluconazole (there is no distinct inhibition area around the 
disks) (b). 
 
 
Figures 10 and 11 show the susceptibility results obtained after growing the South African 
and Cameroonian Candida strains in the presence of fluconazole impregnated disks in YNBG 
agar. More than half of the isolates showed resistance in both the South African and 
Cameroonian populations, with the Cameroonian group showing higher numbers of 
intermediate, or dose-dependent, isolates. 
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Fig. 10: South African fluconazole susceptibility results in Yeast Nitrogen Base agar. 
 
35.00%
13.00%
52.00%
Susceptible Intermediate Resistant
 
Fig. 11: Cameroonian fluconazole susceptibility results in Yeast Nitrogen Base agar. 
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Fifty four point seven percent (54.7%) of the South African Candida samples demonstrated 
some degree of resistance to fluconazole in YNBG agar (resistant and intermediate samples). 
The value for the Cameroonian group was higher, at 65%. All YNBG resistant South African 
samples showed resistance on Sabouraud’s and GMB, apart from two C. glabrata samples 
which showed intermediate resistance in GMB. In the case of intermediate resistance samples 
grown on YNBG, all these showed up as resistant in the other two media. Tables 4 and 5 
show the fluconazole susceptibility values on YNBG agar for the South African and 
Cameroonian populations, respectively. 
 
Table 4: Fluconazole susceptibility results of South African Candida species grown on YNBG agar. 
SA Candida spp/Fca 
susceptibility n=128 Susceptible (%) 
 
Intermediate (%) Resistant (%) 
C. albicans 106 (83%) 46 (43.4%) 0 (0%) 60 (56.6%) 
C. dubliniensis 10 (7.8%) 9 (90%) 0 (0%) 1 (10%) 
C.glabrata 12 (9.4%) 3 (25%) 1 (8.3%) 8 (66.7%) 
 
 
Table 5: Fluconazole susceptibility results of Cameroonian Candida species grown on YNBG agar. 
Cam Candida spp/ 
Fca susceptibility n=127 Susceptible (%) Intermediate (%) Resistant (%) 
C. albicans 92 (72.4%) 44 (47.8%) 9 (9.8%) 39 (42.4%) 
C. glabrata 24 (18.9%) 1 (4.2%) 7 (29.2%) 18 (75%) 
C. krusei 4 (3.1%) 0 (0%) 0 (0%) 4 (100%) 
C. tropicalis 4 (3.1%) 0 (0%) 0 (0%) 4 (100%) 
C. dubliniensis 1 (0.8%) 0 (0%) 1 (100%) 0 (0%) 
Other 2 (1.6%) 0 (0%) 1 (50%) 1 (50%) 
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Tables 6 and 7 show the chi-square results of the susceptibility test done on Candida species 
grown on YNBG agar. The significance values demonstrate the statistical association 
between different Candida species and their susceptibility to fluconazole on YNBG and 
confirm the reliability of this medium in fluconazole susceptibility testing. No statistically 
significant associations were seen in the other agars used in this study. The note in (a.) is 
generated by the SPSS statistics programme and shows which p-value should be read based 
on the percentage value obtained. 
 
 
Table 6: Chi-square susceptibility results of South African Candida spp. grown on YNBG agar. 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 27.564
a
 2 p=0.000 
Likelihood Ratio 19.640 2 p=0.000 
Linear-by-Linear Association 21.454 1 p=0.000 
N of Valid Cases 128   
a. 2 cells (33.3%) have expected count less than 5. The minimum expected 
count is 1.65. 
 
 
Table 7: Chi-square susceptibility results of Cameroonian Candida spp. grown on YNBG agar. 
Chi-Square Tests 
  Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 26.856
a
 5 p= 0.000 
Likelihood Ratio 38.207 5 p= 0.000 
N of Valid Cases 127 
    
        
a. 8 cells (66.7%) have expected count less than 5. The minimum expected 
count is .34. 
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3.5.2. Susceptibility testing using the TREK system 
 
Figure 9 shows the TREK Sensititre YO9 drug panel and the different results seen on the 
TREK Sensititre plates. The different drugs and their concentrations are demonstrated in 
Fig.12(a), susceptible strains are indicated by the absence of growth on wells without a red 
ring around them (b), azole drug resistance showing growth within the wells (c), while 
multiple drug resistance is indicated by growth in most of the wells (d). 
 
  
a      b 
  
c      d 
Fig. 12: Drug panel and different results seen on the TREK Sensititre plates. 
a: Different drugs and concentrations of the TREK panel 
b: Susceptible strain (growth only in red circled wells) 
c: Azole drug resistance 
d: Multiple drug resistance (only 5-Flucytosine >2µg/ml inhibits the growth of the organism) 
 
 
As described by Eraso et al (2008) and Pfaller et al (2006, 2012), Table 8 demonstrates the 
different antifungal drug susceptibility breakpoints used for the different Candida species 
using the TREK system. A blank cell indicates that to our knowledge, no break points have 
been established for this drug. 
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Table 8: Different drug susceptibility clinical breakpoints used in this study. 
  C. albicans C. glabrata 
  Susceptible Intermediate Resistant Susceptible Intermediate Resistant 
Anidulafungin ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL ≤0.12 μg/mL  0.25 μg/mL ≥0.5 μg/mL 
Caspofungin ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL ≤0.12 μg/mL  0.25 μg/mL ≥0.5 μg/mL 
Micafungin ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL ≤0.06 μg/mL 0.12 μg/mL ≥0.25 μg/mL 
5-Flucytosine ≤4 µg/mL 8-16 μg/mL ≥32 µg/mL ≤4 µg/mL 8-16 μg/mL ≥32 µg/mL 
Itraconazole ≤0.12 µg/mL 0.25-0.5 µg/mL ≥1 µg/mL ≤0.12 µg/mL 0.25-0.5 µg/mL ≥1 µg/mL 
Fluconazole ≤8 µg/mL 16-32 μg/mL ≥64 µg/mL ≤8 µg/mL 16-32 μg/mL ≥64 µg/mL 
Amphotericin B <1 µg/mL _ ≥1 μg/mL <1 µg/mL _ ≥1 μg/mL 
Posaconazole <0.016µg/mL _ ≥0.016µg/mL <0.5µg/mL _ ≥0.5µg/mL 
Voriconazole ≤1 µg/mL 2µg/mL ≥4 μg/mL ≤1 µg/mL 2µg/mL ≥4 μg/mL 
 
  C. tropicalis C. krusei 
  Susceptible Intermediate Resistant Susceptible Intermediate Resistant 
Anidulafungin ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL 
Caspofungin ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL 
Micafungin ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL 
5-Flucytosine ≤4 µg/mL 8-16 μg/mL ≥32 µg/mL ≤4 µg/mL 8-16 μg/mL ≥32 µg/mL 
Itraconazole ≤0.12 µg/mL 0.25-0.5 µg/mL ≥1 µg/mL ≤0.12 µg/mL 0.25-0.5 µg/mL ≥1 µg/mL 
Fluconazole ≤8 µg/mL 16-32 μg/mL ≥64 µg/mL ≤8 µg/mL 16-32 μg/mL ≥64 µg/mL 
Amphotericin B <1 µg/mL _ ≥1 μg/mL <1 µg/mL _ ≥1 μg/mL 
Posaconazole <0.03µg/mL _ ≥0.03µg/mL <0.25µg/mL _ ≥0.25µg/mL 
Voriconazole ≤1 µg/mL 2µg/mL ≥4 μg/mL ≤1 µg/mL 2µg/mL ≥4 μg/mL 
 
  C. dubliniensis C. kefyr/para/lusi 
  Susceptible Intermediate Resistant Susceptible Intermediate Resistant 
Anidulafungin _ _ _ _ _ _ 
Caspofungin _ _ _ _ _ _ 
Micafungin _ _ _ _ _ _ 
5-Flucytosine ≤4 µg/mL 8-16 μg/mL ≥32 µg/mL ≤4 µg/mL 8-16 μg/mL ≥32 µg/mL 
Itraconazole ≤0.12 µg/mL 0.25-0.5 µg/mL ≥1 µg/mL ≤0.12 µg/mL 0.25-0.5 µg/mL ≥1 µg/mL 
Fluconazole ≤8 µg/mL 16-32 μg/mL ≥64 µg/mL ≤8 µg/mL 16-32 μg/mL ≥64 µg/mL 
Amphotericin B <1 µg/mL _ ≥1 μg/mL <1 µg/mL _ ≥1 μg/mL 
Posaconazole _ _ _ _ _ _ 
Voriconazole ≤1 µg/mL 2µg/mL ≥4 μg/mL ≤1 µg/mL 2µg/mL ≥4 μg/mL 
( - : no breakpoint available for the organism/drug) 
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The TREK drug susceptibilities of Candida species isolated from the South African 
population are summarised in Table 9. These results demonstrate the differences in 
susceptibility patterns of different Candida species when exposed to the different drugs 
present on the YO9 panel. The significance values show the statistical associations between 
different Candida species and their susceptibility to the various antifungal drugs. Statistical 
associations were seen for all drugs with the exception of 5-Flucytosine. 
 
Table 9: TREK susceptibility results of Candida species obtained from the South African population.  
 
C. albicans 
n=106 
C. glabrata 
n=12 
C. dubliniensis 
n=10 
Spp/resistance 
associations 
Amphotericin B 
 
Susceptible 97 7 9 
 
p=0.01 
Intermediate 0 0 0 
Resistant 9 5 1 
5-Flucytosine 
 
Susceptible 101 11 10 
 
 
Intermediate 0 0 0 
Resistant 5 1 0 
Anidulafungin 
 
Susceptible 101 11 _ 
 
p=0.000 
Intermediate 3 0 _ 
Resistant 2 1 _ 
Caspofungin 
 
Susceptible 98 9 _ 
 
p=0.000 
Intermediate 8 3 _ 
Resistant 0 0 _ 
Micafungin 
 
Susceptible 106 12 _ 
 
p=0.000 
Intermediate 0 0 _ 
Resistant 0 0 _ 
Fluconazole 
 
Susceptible 53 8 9 
 
p=0.032 
Intermediate 1 4 0 
Resistant 52 0 1 
Itraconazole 
 
Susceptible 43 4 9 
 
p=0.008 
Intermediate 1 6 0 
Resistant 62 2 1 
Voriconazole 
 
Susceptible 49 12 9 
 
p=0.000 
Intermediate 0 0 0 
Resistant 57 0 1 
( - : no breakpoint available for the organism/drug). 
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Isolates from the Cameroonian population yielded the susceptibility patterns shown in Table 
10. Cameroonian sample 174 did not grow in the TREK broth and was therefore not included 
in this section. These results demonstrate the differences in susceptibility patterns of different 
Candida species when exposed to the different drugs present on the YO9 panel. The 
significance values show the statistical associations between different Candida species and 
their susceptibility to the various antifungal drugs. Statistical associations were seen for all 
drugs with the exception of 5-Flucytosine. 
 
Table 10: TREK drug susceptibility results of Candida species obtained from the Cameroonian 
population. 
 
C. albicans 
n=92 
C. glabrata 
n=24 
C. tropicalis 
n=4 
C. krusei 
n=3 
C. 
para/lusi/kefyr 
n=2 
C. 
dubliniensis 
n=1 
Spp/ 
resistance 
associations 
Amphotericin B 
 
Susceptible 88 23 2 1 1 0 
p=0.001 
 
Intermediate 0 0 0 0 0 0 
Resistant 4 1 2 2 1 1 
5-Flucytosine 
 
Susceptible 86 24 4 2 1 1 
 
Intermediate 0 0 0 1 0 0 
Resistant 6 0 0 0 0 0 
Anidulafungin 
 
Susceptible 92 16 4 3 - - 
p=0.000 
 
Intermediate 0 5 0 0 - - 
Resistant 0 3 0 0 - - 
Caspofungin 
 
Susceptible 92 16 4 3 - - 
p=0.000 
 
Intermediate 0 7 0 0 - - 
Resistant 0 1 0 0 - - 
Micafungin 
 
Susceptible 92 3 4 3 - - 
p=0.000 
 
Intermediate 0 5 0 0 - - 
Resistant 0 16 0 0 - - 
Fluconazole 
 
Susceptible 45 16 4 1 2 1 
p=0.041 
 
Intermediate 1 7 0 0 0 0 
Resistant 46 1 0 2 0 0 
Itraconazole 
 
Susceptible 44 5 1 1 2 1 
p=0.044 
 
Intermediate 1 15 3 2 0 0 
Resistant 47 4 0 0 0 0 
Voriconazole 
 
Susceptible 46 23 4 2 2 1 
p=0.000 
 
Intermediate 0 0 0 0 0 0 
Resistant 46 1 0 1 0 0 
( - : no breakpoint available for the organism/drug) 
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Isolates from South Africa and Cameroon tested with posaconazole (for which there are no 
established breakpoints) showed high resistance to this drug across all tested Candida 
species. The results for this drug are shown in Table 11. 
 
Table 11: Posaconazole susceptibility results. 
 C. albicans C. glabrata C. tropicalis C. krusei 
Susceptible (%) Resistant (%) Susceptible (%) Resistant (%) Susceptible (%) Resistant (%) Susceptible (%) Resistant (%) 
South Africa 17 (16%) 89(83.9%) 7 (58.3%) 5 (41.7%) _ _ _ _ 
Cameroon 18 (19.6%) 74 (80.4%) 9 (37.5%) 15 (62.5%) 0 (0%) 4 (100%) 1 (33.3%) 2 (66.6%) 
( - : no breakpoint available for the organism/drug) 
 
 
Tables 12 and 13 show the chi-square statistical association results and symmetric measures 
of the susceptibility test done on South African and Cameroonian Candida species run on the 
TREK Sensititre system. The significance values are seen for the individual drugs on the 
YO9 panel and elucidate the statistical associations between different Candida species and 
their drug susceptibility results. In both populations, 5-Flucytosine was the only drug on the 
YO9 panel for which no statistically significant association was seen when comparing the 
prevalence of Candida species and drug susceptibility. The symmetric measures show how 
strong the different associations were. Detailed results of these statistical associations can be 
seen in appendix 8. 
 
Table 12: Chi-square and symmetric measure results of South African species vs drug susceptibility. 
South Africa Chi-square test results Symmetric measures 
Amphotericin B p=0.01 Strong association 
5-Flucytosine p=0.685 Weak association 
Anidulafungin p=0.000 Strong association 
Caspofungin p=0.000 Strong association 
Micafungin p=0.000 Strong association 
Fluconazole p=0.032 Moderate association 
Itraconazole p=0.008 Moderate association 
Voriconazole p=0.000 Strong association 
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Table 13: Chi-square and symmetric measure results of Cameroonian species vs drug susceptibility. 
Cameroon Chi-square test results Symmetric measures 
Amphotericin 
B 
p=0.001 Strong association 
5-Flucytosine p=0.265 Moderate association 
Anidulafungin p=0.000 Strong association 
Caspofungin p=0.000 Strong association 
Micafungin p=0.000 Strong association 
Fluconazole p=0.041 Moderate association 
Itraconazole p=0.044 Moderate association 
Voriconazole p=0.000 Strong association 
 
 
Antifungal drug susceptibility testing was done on all type strains (Table 14) for comparative 
reasons, using the fluconazole disk diffusion method and the three media used in the clinical 
strains, namely Sabourauds, GMB and YNBG, and the TREK Sensititre micro dilution broth 
method. 
 
Table 14: Comparison of fluconazole drug susceptibility results using disk diffusion and the TREK 
system. 
  Sab GMB YNBG TREK 
Type strain mm Mc Interpretation mm Mc Interpretation mm Mc Interpretation Result Interpretation 
C. albicans 
NCPF3281 
0 Res. Resistant 22 0 Susceptible 0 Res. Resistant >256 Resistant 
C. 
dubliniensis 
NCPF3949a 
5 1 Resistant 20 0 Susceptible >20 0 Susceptible =0.5 Susceptible 
C. albicans 
ATCC90028 
17 2 Susceptible 15 0 Intermediate 0 Res. Resistant >256 Resistant 
C. tropicalis 
ATCC950 
12 0 Intermediate 10 0 Resistant 16 0 Susceptible =2 Susceptible 
C. krusei 
ATCC2159 
3 0 Resistant 4 0 Resistant 0 Res. Resistant =64 Resistant 
C. glabrata 
ATCC26512 
3 0 Resistant 10 0 Resistant 0 Res. Resistant =32 Intermediate 
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3.5.3. Distribution and susceptibility patterns of Candida species by gender 
 
The distribution and susceptibility patterns of Candida species with relation to factors such as 
gender, ethnicity and HIV status did not originally form part of the objectives of this study. 
However, the analysis of the data deemed these comparisons worth mentioning. 
 
Candida species prevalence according to patient gender is summarised in Table 15. 
Differences in Candida species colonization between the two genders can be seen, with 
females harbouring more species than males. Out of the total 196 Candida strains isolated 
from the oral mucosa of 194 HIV-positive women, 152 were identified as C. albicans, 27 as 
C. glabrata, 8 as C. dubliniensis, 4 as C. krusei, 3 as C. tropicalis and 2 as either C. 
parapsilopsis, C. lusitaneae or C. kefyr. Two women were colonized by both C. albicans and 
C. glabrata. The number of isolates may differ from the number of patients, as multiple 
species were isolated in two South African patients. Table 15 examines the prevalence of 
Candida according to gender within population groups. 
 
Table 15: Candida species prevalence according to patient gender.  
 
 
Tables 16 and 17 show the associations between Candida species and fluconazole 
susceptibility in relation to gender distribution for both populations, using the YNBG disk 
diffusion method and the TREK Sensititre system. As with the previous table and for future 
tables, the number of cases may differ from the number of patients, as multiple species were 
isolated in two South African patients. 
Spp. According to 
gender 
South African 
n=128 
Cameroonian 
n=127 
Males (%) Females (%) Males (%) Females (%) 
C. albicans 31 (88.6%) 75 (81.5%) 15 (65.2%) 77 (74%) 
C. dubliniensis 3 (8.6%) 7 (9.3%) 0 (0%) 1 (0.96%) 
C. glabrata 2 (5.7%) 10 (10.9%) 7 (30.4%) 17 (16.3%) 
C. tropicalis 0 (0%) 0 (0%) 1 (4.3%) 3 (2.9%) 
C. krusei 0 (0%) 0 (0%) 0 (0%) 4 (3.8%) 
C. kefyr/ parapsilopsis/ 
lusitaneae 
0 (0%) 0 (0%) 0 (0%) 2 (1.9%) 
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Table 16: South African and Cameroonian Candida species prevalence and fluconazole susceptibility 
according to patient gender using the YNGB disk diffusion method (percentages are per gender/per 
species). 
Spp. and susceptibility 
according to gender 
 
Susceptible (%) 
 
Intermediate (%) 
 
Resistant (%) 
 SA (%) Cam (%) SA (%) Cam (%) SA (%) Cam (%) 
C. albicans Females 35 (46.7%) 37 (46.8%) 0 (0%) 8 (10.4%) 40 
(53.3%) 
32 
(41.6%) 
Males 11 (35.5%) 7 (46.7%) 0 (0%) 1 (66.7%) 20 
(64.5%) 
7 (46.7%) 
C. dubliniensis Females 6 (85.7%) 0 (0%) 0 (0%) 1 (100%) 1 
(14.3%) 
0 (0%) 
Males 3 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
C. glabrata Females 3 (30%) 1 (5.9%) 1 
(10%) 
4 (23.5%) 6 (60%) 12 
(70.6%) 
Males 0 (0%) 0 (0%) 0 (0%) 2 (28.6%) 2 
(100%) 
5 (71.4%) 
C. tropicalis Females - 0 (0%) - 0 (0%) - 4 (100%) 
Males - 0 (0%) - 0 (0%) - 0 (0%) 
C. krusei Females - 0 (0%) - 0 (0%) - 4 (100%) 
Males - 0 (0%) - 0 (0%) - 0 (0%) 
C. kefyr/ 
parapsilopsis/ 
lusitaneae 
Females - 0 (0%) - 1 (50%) - 1 (50%) 
Males - 0 (0%) - 0 (0%) - 0 (0%) 
 
 
Table 17: South African and Cameroonian Candida species prevalence and fluconazole susceptibility 
according to patient gender using the TREK Sensititre system (percentages are per gender/per 
species). 
Spp. and susceptibility 
according to gender 
 
Susceptible (%) 
 
Intermediate (%) 
 
Resistant (%) 
 SA (%) Cam (%) SA (%) Cam (%) SA (%) Cam (%) 
C. albicans Females 
40 (53.3%) 41 (53.2%)  
1 
(1.3%)  
0 (0%)  
34 
(45.3%)  
36 
(46.8%)  
Males 
13 (41.9%) 4 (26.7%)  0 (0%)  1 (6.7%)  
18 
(58.1%)  
10 
(66.7%)  
C. dubliniensis Females 
6 (85.7%) 1 (100%)  0 (0%)  0 (0%)  
1 
(14.3%)  
0 (0%)  
Males 3 (100%) 0 (0%)  0 (0%)  0 (0%)  0 (0%)  0 (0%)  
C. glabrata Females 
7 (70% ) 11 (64.7%)  
3 
(30%)  
5 
(29.4%)  
0 (0%)  1 (5.9%)  
Males 
1 (50% ) 5 (71.4%)  
1 
(50%)  
2 
(28.6%)  
0 (0%)  0 (0%)  
C. tropicalis Females - 3 (100%)  - 0 (0%)  - 0 (0%)  
Males - 1 (100%)  - 0 (0%)  - 0 (0%)  
C. krusei Females - 1 (25%)  - 0 (0%)  - 3 (75%)  
Males - 0 (0%)  - 0 (0%)  - 0 (0%)  
C. kefyr/ 
parapsilopsis/ 
lusitaneae 
Females - 2 (100%)  - 0 (0%)  - 0 (0%)  
Males - 
0 (0%)  
- 
0 (0%)  
- 
0 (0%)  
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3.5.4 Distribution, associations and susceptibility patterns of Candida species in women 
 
Since women are known to be more predisposed to Candida than their male counterparts, the 
colonization patterns, antifungal drug susceptibility results and different parameters that are 
unique to women, including their pregnancy status, were investigated. For this section, 
antifungal drugs were grouped into the azoles and echinocandins, as these are drug classes 
which would most probably be dispensed for treating these patients and both are well 
represented on the TREK panel. In the combined female population, resistance to azole drugs 
was very high in the case of C. albicans (54%) and C. krusei (100%). The echinocandin 
drugs showed high levels of resistance the case of C. glabrata (40.7%) (Table 18). 
No associations were seen between Candida species prevalence and age, health status or 
presence of tuberculosis. It was noted that C. albicans was the only species isolated from the 
oral mucosa of patients who were either pregnant or had recently given birth (Table 18). 
 
Table 18 shows the Candida species associations and drug susceptibility results in females, 
when combining the female patient results from both populations. For the susceptibility 
testing results an isolate was considered to be resistant if it fell within the established 
“resistant” breakpoint category for one or more of the tested drugs in that class, as detailed in 
the breakpoint studies described in Table 8. 
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Table 18: Candida species associations and drug susceptibility in females. 
  C. albicans 
  
C. dubliniensis 
  
C. glabrata 
  
C. tropicalis 
  
C. krusei * 
  
C. kefyr/para/lusi 
  
p-
values 
  (n=152) 
  
(n=8) 
  
(n=27) 
  
(n=3) 
  
(n=4) 
  
(n=2) 
  
  
Age distribution 
10-20yrs (n=3) 3(100%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
  
21-50yrs (n=163) 127(77.9%) 
  
8(4.9%) 
  
21(12.9%) 
  
2(1.2%) 
  
4(2.4%) 
  
1(0.6%) 
  
  
>50yrs (n=30) 22(73.3%) 
  
0(0%) 
  
6(20%) 
  
1(3.3%) 
  
0(0%) 
  
1(3.3%) 
  
  
Health status 
AIDS - (n=147) 112(76.2%) 
  
8(5.4%) 
  
20(13.6%) 
  
2(1.4%) 
  
3(2%) 
  
2(1.4%) 
  
  
AIDS + (n=49) 40(81.6%) 
  
0(0%) 
  
7(14.3%) 
  
1(2%) 
  
1(2%) 
  
0(0%) 
  
  
Pregnancy 
Not pregnant 
(n=182) 
138(75.8%) 
  
8(4.4%) 
  
27(14.8%) 
  
3(1.6%) 
  
4(2.2%) 
  
2(1.1%) 
  
  
Pregnant/recent 
birth (n=14) 
14(100%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
  
Patients on TB treatment 
No (n=172) 133(77.3%) 
  
8(4.7%) 
  
24(14%) 
  
2(1.2%) 
  
3(1.7%) 
  
2(1.2%) 
  
  
Yes (n=24) 19(79.2%) 
  
0(0%) 
  
3(12.5%) 
  
1(8.3%) 
  
1(8.3%) 
  
0(0%) 
  
  
ARV therapy 
No ARV therapy 
(n=35) 
30(85.7%) 
  
2(5.7%) 
  
2(5.7%) 
  
1(2.9%) 
  
0(0%) 
  
0(0%) 
  
  
AZT/NVP/ 3TC 
(n=73) 
57(78.1%) 
  
0(0%) 
  
13(17.9%) 
  
0(0%) 
  
3(4.1%) 
  
0(0%) 
  
  
d4T/NVP/ 3TC 
(n=31) 
21(67.7%) 
  
3(9.7%) 
  
5(16.1%) 
  
0(0%) 
  
1(3.2%) 
  
1(3.2%) 
  
  
d4T/EFV/ 3TC 
(n=24) 
22(91.7%) 
  
1(4.2%) 
  
1(4.2%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
  
AZT/EFV/ 3TC 
(n=17) 
13(76.5%) 
  
0(0%) 
  
3(17.6%) 
  
1(5.9%) 
  
0(0%) 
  
0(0%) 
  
  
LPV/r 
combinations 
(n=5) 
3(60%) 
  
1(20%) 
  
1(20%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
  
AZT/DDI/ KLT 
(n=3) 
1(33.3%) 
  
1(33.3%) 
  
1(33.3) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
  
TDF/3TC (n=2) 2(100%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
  
AZT/3TC/ 
lopinavir/ritonavir 
(n=1) 
0(0%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
1(100%) 
  
  
AZT/3TC/ KLT 
(n=1) 
1(100%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
  
Not known (n=4) 2(50%) 
  
0(0%) 
  
1(25%) 
  
1(25%) 
  
0(0%) 
  
0(0%) 
  
  
Duration of ARV therapy 
No ARV therapy 
(n=35) 
30(85.7%) 
  
2(5.7%) 
  
2(5.7%) 
  
1(2.9%) 
  
0(0%) 
  
0(0%) 
  
p=0.008 
<1yr (n=50) 43(86%) 
  
1(2%) 
  
6(12%) 
  
0(0%) 
  
0(0%) 
  
0(0%) 
  
  
≥1-<3yrs (n=49) 35(71.4%) 
  
5(10.2%) 
  
7(14%) 
  
1(2%) 
  
1(2%) 
  
0(0%) 
  
  
≥3yrs (n=60) 44(73.3%) 
  
0(0%) 
  
11(18.3%) 
  
0(0%) 
  
3(5%) 
  
2(3.3%) 
  
  
Unknown (n=2) 0(0%)   0(0%)   1(50%)   1(50%)   0(0%)   0(0%)     
Susceptibility 
patterns 
Susceptible Resistant Susceptible Resistant Susceptible Resistant Susceptible Resistant Susceptible Resistant Susceptible Resistant   
Azoles 70(46%) 82(54%) 7(87.5%) 1(12.5%) 22(81.5%) 5(18.5%) 3(100% 0(0%) 0(0%) 3(100%) 2(100%) 0(0%) p=0.000 
Echinocandins 150(98.7%) 2(1.3%) - - 16(59.3%) 11(40.7%) 3(100%) 0(0%) 3(100%) 0(0%) - - p=0.000 
*One of the C. krusei isolates did not grow on the TREK plate, and was therefore not included in the susceptibility section of this table. 
“-” = no established breakpoint for the organism/drug. 
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3.6 Distribution of Candida species related to age and ethnicity. 
 
Age and race were examined for frequency of species distribution. Frequency was calculated 
for each age group as a percentage of each individual species isolated. In the South African 
population, C.albicans was most prevalent in the 31-40 year age group as was the case for the 
Cameroonian group (Table 19). C. glabrata and C.dubliniensis were also detected in this age 
group more than in any of the other age groups in South Africa. As female patients 
approached or passed menopause, C. glabrata became the dominant species in the 
Cameroonian population. 
 
The effect of ethnicity or race was also examined within the South African population, which 
was composed of patients from different racial groups (Table 20). Species distribution and 
prevalence was markedly increased in the black population, compared to the other race 
groups. 
 
Table 19: Candida species associated with age. 
Age C. albicans C. dubliniensis C. glabrata 
  SA (%) Cam (%) SA (%) Cam (%) SA (%) Cam (%) 
≤20 years 3 (2.80%) 0 (0%)  0 (0%)  0 (0%)  0 (0%)  0 (0%)  
21-30 years 33 (31%) 14 (15.2%)  2 (20%) 0 (0%)  3 (25%) 0 (0%)  
31-40 years 44 (41.5%) 34 (37%)  4 (40%) 0 (0%)  9 (75%) 8 (33.3%)  
41-50 years 19 (18%) 22 (23.9%) 2 (20%) 1 (100%)  0 (0%)  6 (25%)  
51-60 years 5 (4.7%) 16 (17.4%)  2 (20%) 0 (0%)  0 (0%)  9 (37.5%)  
≥61 years 2 (1.9%) 3 (3.3%)  0 (0%)  0 (0%)  0 (0%)  1 (4.2%)  
 
Age C. tropicalis C. krusei C. kefyr/para/lusi 
  SA (%) Cam (%) SA (%) Cam (%) SA (%) Cam (%) 
≤20 years _ 0 (0%)  _ 0 (0%)  _ 0 (0%)  
21-30 years _ 1 (25%)  _ 2 (50%)  _ 0 (0%)  
31-40 years _ 1 (25%)  _ 2 (50%)  _ 1 (50%)  
41-50 years _ 1 (25%)  _ 0 (0%)  _ 0 (0%)  
51-60 years _ 1 (25%)  _ 0 (0%)  _ 1 (50%)  
≥61 years _ 0 (0%)  _ 0 (0%)  _ 0 (0%)  
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Table 20: South African Candida species associated with race. 
 
 
 
 
 
 
3.7 Distribution of Candida species related to HIV status 
 
HIV infection is associated with opportunistic co-infections such as Candida. This study 
examined the prevalence of Candida in HIV-positive subjects (Table 21, where AIDS refers 
to individuals with late-stage HIV-related opportunistic infections) and attempted to associate 
the findings with the treatment (Tables 22 and 23) and duration of ARV therapy (Table 24). 
Detailed information on these tables can be found in appendices 5, 6 and 7. Species 
prevalence appeared to decrease in AIDS patients possibly because most of them were on 
ARVs (only patients with lower CD4 counts are routinely enrolled for ART in both countries’ 
state hospitals). This is confirmed in Table 21 where patients not on ARV showed a higher 
prevalence of Candida than those being treated with ARVs even though the prevalence 
altered with different treatment regimes in the South African group. In the Cameroonian 
group, species prevalence seemed to increase in those being treated with the AZT, NVP, 3TC 
cocktail (Table 23). 
 
Table 21: Candida species associated with HIV status. 
HIV Status C. albicans C. dubliniensis C. glabrata 
  SA (%) Cam (%) SA (%) Cam (%) SA (%) Cam (%) 
HIV+ 65 (61%) 68 (73.9%) 10 (100%) 1 (100%) 9 (75%) 17 (70.8%)  
AIDS 41 (39%) 24 (26.1%) 0 (0%)  0 (0%) 3 (25%) 7 (29.2%) 
 
HIV Status C. tropicalis C. krusei C. kefyr/para/lusi 
  SA (%) Cam (%) SA (%) Cam (%) SA (%) Cam (%) 
HIV+ - 3 (75%)  - 3 (75%)  - 2 (100%)  
AIDS - 1 (25%) __- 1 (25%) - 0 (0%)  
 
Candida species 
and race Black (%) Coloured (%) Indian (%) White (%) 
C. albicans 98 (83%) 6 (75%) 1 (100%) 1 (100%) 
C. dubliniensis 9 (7.6%) 1 (12.5%) 0 (0%) 0 (0%) 
C. glabrata 11 (9.3%) 1 (12.5%) 0 (0%) 0 (0%) 
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Table 22: Candida species associated with antiretroviral therapy in the South African group. 
Candida 
species and 
ARV therapy  No ARVs d4T, EFV, 3TC d4T, NVP, 3TC AZT, NVP, 3TC 
C. albicans 40 (38%) 33 (31%) 24 (23%) 7 (6.6%) 
C. dubliniensis 2 (20%) 3 (30%) 4 (40%) 0 (0%) 
C. glabrata 2 (17%) 2 (17%) 5 (42%) 1 (8.3%) 
 AZT, EFV, T3C AZT, DDI, KLT AZT, 3TC, KLT TDF, EFV, 3TC 
C. albicans 0 (0%) 1 (0.9%) 1 (0.9%) 1 (0.9%) 
C. dubliniensis 0 (0%) 1 (10%) 0 (0%) 0 (0%) 
C. glabrata 1 (8.3%) 1 (8.3%) 0 (0%) 0 (0%) 
AZT: Azidothymidine (zidovudine), DDI: Didanosine, D4T: Stavudine, EFV: Efavirenz, KLT: Kaletra (lopinavir), NVP: 
Nevirapine, TDF: Tenofovir disoproxil fumarate (tenofovir), 3TC: Lamivudine. 
 
 
Table 23: Candida species associated with antiretroviral therapy in the Cameroonian group. 
Candida species 
and ARV therapy  No ARVs (%) d4T, 3TC (%) d4T, NVP, 3TC (%) AZT, NVP, 3TC (%) 
C. albicans 4 (4.3%) 1 (1.1%)  3 (3.3%)  57 (62%)  
C. dubliniensis 0 (0%) 0 (0%)  0 (0%)  0 (0%)  
C. glabrata  (0%) 0 (0%)  2 (8.3%)  14 (58.3%)  
C. tropicalis 1 (25%) 0 (0%)  0 (0%)  0 (0%)  
C. krusei 0 (0%) 0 (0%)  1 (25%)  3 (75%)  
C. kefyr/ 
parapsilopsis/ 
lusitaneae 0 (0%) 0 (0%)  1 (50%)  0 (0%)  
  
AZT, EFV, T3C 
(%) TDF, T3C (%) AZT, 3TC, KLT (%) LPV/r + (%) 
C. albicans 19 (20.7%) 1 (1.1%)  0 (0%)  4 (4.3%)  
C. dubliniensis 0 (0%) 0 (0%)  0 (0%)  1 (100%)  
C. glabrata 5 (20.1%) 1 (4.2%)  0 (0%)  1 (4.2%)  
C. tropicalis 2 (50%) 0 (0%)  0 (0%)  0 (0%)  
C. krusei 0 (0%) 0 (0%)  0 (0%)  0 (0%)  
C. kefyr/ 
parapsilopsis/ 
lusitaneae 0 (0%) 0 (0%)  1 (50%)  0 (0%)  
AZT: Azidothymidine (zidovudine), DDI: Didanosine, D4T: Stavudine, EFV: Efavirenz, KLT: Kaletra (lopinavir), LPV/r: 
Alluvia, NVP: Nevirapine, TDF: Tenofovir disoproxil fumarate (tenofovir), 3TC: Lamivudine. 
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Patients on ARVs for less than 1 year showed a greater prevalence of Candida than those 
who had not received treatment. The longer the duration above one year, the lower the 
prevalence in both groups (Table 24). 
 
Table 24: Candida species associated with duration of antiretroviral therapy. 
ARV Duration C. albicans C. dubliniensis C. glabrata 
  SA (%) Cam (%) SA (%) Cam (%) SA (%) Cam (%) 
No ARVs 39 (36.8%) 5 (5.2%) 2 (20%) 0 (0%)  2 (16.7%) 0 (0%)  
<1year  41 (38.7%) 17 (17.7% ) 2 (20%) 0 (0%)  7 (58.3%) 0 (0%)  
1-2years  13 (12.3%) 12 (12.5%) 5 (50%) 0 (0%) 1 (8.3%) 5 (20.8%) 
2-3years  9 (8.5%) 9 (9.4%) 1 (10%) 0 (0%) 1 (8.3%) 2 (8.3%) 
≥3years  4 (3.8%) 53 (55.2%) 0 (0%)  1 (100%) 1 (8.3%) 17 (70.8%) 
 
ARV Duration C. tropicalis C. krusei C. kefyr/para/lusi 
  SA (%) Cam (%) SA (%) Cam (%) SA (%) Cam (%) 
No ARVs - 1 (25%) - 0 (0%)  - 0 (0%)  
<1year  - 0 (0%)  - 0 (0%)  - 0 (0%)  
1-2years  - 1 (25%) - 1 (25%) - 0 (0%)  
2-3years  - 1 (25%) - 0 (0%) - 0 (0%) 
≥3years  _- 1 (25%) - 3 (75%) - 2 (100%) 
Antiretroviral therapy duration and Candida species prevalence statistical association for Cameroonian results: p=0.034. 
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3.8 Protein Identification 
 
3.8.1 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
 
 
Table 25 places together the molecular mass and function of fluconazole-resistance 
associated proteins identified in the different studies explained in chapter 1. 
 
Table 25: Candida proteins expressed in the presence of fluconazole, their approximate molecular 
mass and function. 
Protein Molecular Mass Function 
Pdc11p 5.4kDa Carbohydrate metabolism 
Ifd5p 5.4kDa 
Alcohol dehydrogenase-
oxidoreductase 
Ifd1p 5.6kDa 
Alcohol dehydrogenase-
oxidoreductase 
Ifd6p 5.9kDa 
Alcohol dehydrogenase-
oxidoreductase 
Ifd4p 6kDa 
Alcohol dehydrogenase-
oxidoreductase 
Cdc19p 6.5kDa Carbohydrate metabolism 
Gap1p 6.6kDa Carbohydrate metabolism 
Tropiase 23.9kDa Acid proteinase 
Grp2p 37.62kDa Reductase 
Unknown 40kDa Unknown 
Erg10p 41.7kDa Ergosterol biosynthesis pathway 
Exoglucanase 44kDa  
Unknown 60kDa Unknown 
14a-
demethylase 61kDa Ergosterol biosynthesis 
Cdr2p 96kDa Membrane multidrug transporter 
Mdr1p 109.258kDa Membrane multidrug transporter 
CgCdr1p 169kDa Membrane multidrug transporter 
23 others 23-64kDa Unknown 
 
Figure 13 shows a Coomassie blue stained protein gel obtained using SDS-PAGE, already 
dried and sandwiched between two drying films. The second protein row corresponds to the 
Bio-Rad broad range protein marker used to determine the approximate molecular weights of 
the sample proteins. Figures 14 to 17 reveal the individual protein gel bands for the Candida 
species identified as C. albicans (susceptible and resistant strains are shown, based on TREK 
results), C. dubliniensis and C. glabrata, respectively, with the patient’s number shown 
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below and the colours denoting resistance patterns. A protein marker band is shown on the 
left, as well as a type strain for each species, where available. 
 
 
 
Fig. 13: A Coomassie-stained protein gel with nine sample protein lanes and a protein marker lane with specific 
and easily identifiable protein standards (values shown in kiloDaltons). 
 
 
 
           
PM      Ca     42     57      93       102     103    135   141    195   198 
Figure 14: Fluconazole-susceptible C. albicans SDS-PAGE protein gel results. 
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PM        Ca    14   40  44       46  47      48       60       95      100     101    112 
Figure 15: Fluconazole-resistant C. albicans SDS-PAGE protein gel results. 
 
 
 
           
PM          Cd        7         51        59        82        105      136    138    154      184  
Figure 16: C. dubliniensis SDS-PAGE protein gel results. 
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PM            11        36b        72        77         81         92        107      118    144      147 
Figure 17: C. glabrata SDS-PAGE protein gel results. 
 
 
Table 26 shows the molecular weights of the unique bands identified by SDS-PAGE in this 
study and the fluconazole susceptibility of the respective isolates. Proteins with a molecular 
weight of 24kDa were only seen in intermediate (dose-dependent) or drug-resistant cell 
fractions. 
 
Table 26: Molecular weight and fluconazole susceptibility of proteins of interest identified by SDS-
PAGE. 
Molecular weight Fluconazole susceptibility 
24kDa I,R 
23-27kDa S 
36kDa S 
37kDa S 
44kDa S,R 
49kDa S 
50kDa S,I 
S=susceptible; I=intermediate; R=resistant. 
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3.8.2 High Performance Liquid Chromatography-Mass Spectrometry 
 
Thermo Proteome Discoverer 1.3 software (Thermo Scientific, Bremen, Germany) was used 
to identify proteins via automated database searching (Mascot, Matrix Science, London, UK, 
and Sequest) of all tandem mass spectra against the Uniprot Candida database. 
Carbamidomethyl cysteine was set as fixed modification, and oxidized methionine, N-
acetylation and deamidation (NQ) was used as variable modifications. The precursor mass 
tolerance was set to 10 ppm, and fragment mass tolerance set to 0.8 Da. Two missed tryptic 
cleavages were allowed. Proteins were considered positively identified when they were 
identified with at least 1 tryptic peptides per proteins, a Mascot score threshold of 20 and 
Sequest score threshold of 1.5. Percolator was used for peptide validation with a maximum 
delta Cn of 0.5, and decoy database searches with a FDR of 0.02 and 0.05 with validation 
based on the q-value. 
 
The individual peptides’ information was then further searched on the Uniprot Candida 
database (Uniprot, 2013) to identify specific peptide functions related to antifungal drug 
resistance. 
 
 
Tables 27 and 28 show the detailed information of drug-resistance related proteins identified 
using HPLC-MS for C. albicans fluconazole-susceptible and intermediate/resistant isolate 
fractions, respectively, and their function as described on the UniProt database. Tables 29 and 
30 show the HPLC-MS results for the non-albicans species which were found to be 
susceptible and intermediate/resistant to fluconazole, respectively. Only proteins above a 
mascot score of 24 were considered significant, and with a protein sequence coverage above 
5%. 
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Table 27: Fluconazole-susceptible C. albicans cell fraction HPLC-MS results. 
Isolate 
number 
Accession Description Score Coverage 
# 
Proteins 
# 
Unique 
Peptides 
# 
Peptides 
# 
PSMs 
# 
AAs 
MW 
[kDa] 
calc. pI Function 
C50 P41797 Heat shock 
protein SSA1 
OS=Candida 
albicans (strain 
SC5314 / ATCC 
MYA-2876) 
GN=SSA1 PE=1 
SV=2 - 
[HSP71_CANAL] 
2130.39 33.69 3 10 19 66 656 70.3 5.17 
Binds human 
HTN3/histatin-
5, a peptide 
from saliva, and 
mediates its 
fungicidal 
activity. 
C80 2342.92 46.19 2 11 24 84 656 70.3 5.17 
C88 2868.32 44.05 4 11 26 129 656 70.3 5.17 
C132 1956.02 44.66 3 11 26 110 656 70.3 5.17 
C182 1858.36 47.56 4 21 28 122 656 70.3 5.17 
SA3 704.61 24.85 4 6 14 42 656 70.3 5.17 
SA70 111.74 17.38 4 2 10 18 656 70.3 5.17 
SA126 910.50 26.52 5 4 17 50 656 70.3 5.17 
SA163 1756.18 45.43 3 10 27 97 656 70.3 5.17 
SA201 692.88 22.87 4 5 13 27 656 70.3 5.17 
 
C50 P46587 Heat shock 
protein SSA2 
OS=Candida 
albicans (strain 
SC5314 / ATCC 
MYA-2876) 
GN=SSA2 PE=1 
SV=3 - 
[HSP72_CANAL] 
1334.50 22.79 1 3 11 50 645 70.0 5.06 
Binds 
HTN3/histatin-
5, a peptide 
from human 
saliva, and 
mediates its 
fungicidal 
activity 
C80 1565.69 29.61 1 2 14 61 645 70.0 5.06 
C88 1816.01 27.44 2 1 17 86 645 70.0 5.06 
C132 1415.21 28.53 1 2 14 75 645 70.0 5.06 
SA3 455.98 14.73 1 1 8 29 645 70.0 5.06 
SA70 86.30 13.80 1 1 8 13 645 70.0 5.06 
SA126 573.48 19.53 2 1 12 30 645 70.0 5.06 
SA163 1233.05 39.07 1 5 22 71 645 70.0 5.06 
SA201 488.06 19.53 1 2 10 19 645 70.0 5.06 
 
C88 P46598 Heat shock 
protein 90 
homolog 
OS=Candida 
albicans (strain 
SC5314 / ATCC 
MYA-2876) 
GN=HSP90 PE=1 
SV=1 - 
[HSP90_CANAL] 
620.44 27.02 1 11 19 35 707 80.8 4.88 
Binds 
HTN3/histatin-
5, a peptide 
from human 
saliva, and 
mediates its 
fungicidal 
activity. 
C132 377.90 14.14 1 3 9 21 707 80.8 4.88 
C182 424.47 20.08 1 7 11 16 707 80.8 4.88 
 
C80 P43084 Probable 
NADPH 
dehydrogenase 
OS=Candida 
albicans 
GN=EBP1 PE=1 
SV=2 - 
[EBP1_CANAX] 
280.05 32.43 1 9 9 20 407 46.0 6.39 
Oxidoreductase 
that binds 
mammalian 
estrogens with 
high affinity. 
SA163 52.80 9.83 1 1 4 4 407 46.0 6.39 
SA201 37.74 8.11 1 3 3 4 407 46.0 6.39 
 
C80 O13318 pH-responsive 
protein 2 
OS=Candida 
albicans (strain 
SC5314 / ATCC 
MYA-2876) 
GN=PHR2 PE=2 
SV=2 - 
390.41 11.58 2 5 5 18 544 58.7 4.64 
Required for 
apical cell 
growth and 
plays an 
essential role in 
morphogenesis. 
May be integral 
to the 
C88 335.93 13.42 2 5 5 20 544 58.7 4.64 
C132 422.77 10.85 2 4 5 22 544 58.7 4.64 
C182 328.88 4.96 1 2 2 12 544 58.7 4.64 
SA3 53.31 4.96 1 1 2 2 544 58.7 4.64 
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SA70 [PHR2_CANAL] 67.03 7.54 1 3 3 4 544 58.7 4.64 pathogenic 
ability of the 
organism  
SA126 370.51 6.80 1 3 3 10 544 58.7 4.64 
SA163 192.31 10.48 1 3 4 5 544 58.7 4.64 
SA201 369.62 6.80 2 3 3 12 544 58.7 4.64 
 
C80 Q06099 S-
(hydroxymethyl) 
glutathione 
dehydrogenase 
OS=Candida 
maltosa 
GN=FDH1 PE=3 
SV=1 - 
[FADH_CANMA] 
192.83 5.77 1 2 2 13 381 40.0 6.70 
Confers 
resistance to 
formaldehyde. 
C88 61.62 5.77 1 2 2 4 381 40.0 6.70 
C132 170.76 5.77 1 2 2 10 381 40.0 6.70 
C182 130.24 9.71 1 1 4 11 381 40.0 6.70 
SA3 122.16 7.87 1 3 3 12 381 40.0 6.70 
SA70 46.10 6.82 1 2 3 8 381 40.0 6.70 
SA126 229.23 7.87 1 3 3 18 381 40.0 6.70 
SA201 208.85 5.77 1 2 2 9 381 40.0 6.70 
 
C50 P43071 Multidrug 
resistance 
protein CDR1 
OS=Candida 
albicans 
GN=CDR1 PE=3 
SV=1 - 
[CDR1_CANAX] 
148.36 6.46 2 5 6 8 1501 169.8 6.98 Transporter, 
whose 
physiological 
function is not 
yet established. 
Confers 
resistance to 
the chemical 
cycloheximide. 
SA163 34.99 2.66 2 2 4 4 1501 169.8 6.98 
Legend: Accession: UniProt database query number; Score: mascot score; Coverage: the % sequence coverage of the protein as detected by 
the MS; # of proteins: total nr of proteins detected; # unique peptides: total nr of peptides detected for the protein that is unique to the 
protein; #PSM: peptides spectrum matches, estimation of the false positive protein identifications using decoy database containing reversed 
sequences. The PSM shown are all within the parameters due to the use of percolater that calculates statistically meaningful q-values. #AA: 
nr of amino acids present within the protein as given in the database. MW: molecular weight of the protein as given in database; pI: pI of 
protein as given in database. 
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Table 28: Fluconazole-intermediate and -resistant C. albicans cell fraction HPLC-MS results. 
Isolate 
number 
Accession Description Score Coverage # 
Proteins 
# Unique 
Peptides 
# 
Peptides 
# 
PSMs 
# AAs MW 
[kDa] 
calc. 
pI 
Function 
C35 P41797 Heat shock protein 
SSA1 OS=Candida 
albicans (strain 
SC5314 / ATCC 
MYA-2876) 
GN=SSA1 PE=1 
SV=2 - 
[HSP71_CANAL] 
1246.81 38.57 3 10 21 55 656 70.3 5.17 Binds human 
HTN3/histatin-
5, a peptide 
from saliva, 
and mediates 
its fungicidal 
activity. 
C42 1626.76 37.35 3 11 21 107 656 70.3 5.17 
C73 1905.13 44.66 2 22 24 101 656 70.3 5.17 
C76 331.14 17.07 2 2 10 26 656 70.3 5.17 
C199 3521.43 48.32 1 12 30 174 656 70.3 5.17 
C255 521.37 24.70 4 11 16 59 656 70.3 5.17 
SA28 1369.57 31.71 3 6 19 73 656 70.3 5.17 
SA40 320.86 10.52 3 1 7 38 656 70.3 5.17 
SA50 1121.96 25.30 5 10 15 90 656 70.3 5.17 
SA78 316.91 20.73 5 8 13 56 656 70.3 5.17 
SA100 704.10 26.83 4 5 16 47 656 70.3 5.17 
 
C35 P46587 Heat shock protein 
SSA2 OS=Candida 
albicans (strain 
SC5314 / ATCC 
MYA-2876) 
GN=SSA2 PE=1 
SV=3 - 
[HSP72_CANAL] 
916.33 28.22 1 4 14 39 645 70.0 5.06 Binds 
HTN3/histatin-
5, a peptide 
from human 
saliva, and 
mediates its 
fungicidal 
activity 
C199 1812.37 35.50 1 5 18 104 645 70.0 5.06 
SA28 1019.96 27.91 1 3 15 54 645 70.0 5.06 
SA40 320.62 11.16 3 1 7 36 645 70.0 5.06 
SA100 477.11 22.02 1 1 13 36 645 70.0 5.06 
 
C42 P46598 Heat shock protein 
90 homolog 
OS=Candida 
albicans (strain 
SC5314 / ATCC 
MYA-2876) 
GN=HSP90 PE=1 
SV=1 - 
[HSP90_CANAL] 
372.85 16.12 1 7 11 24 707 80.8 4.88 
Binds 
HTN3/histatin-
5, a peptide 
from human 
saliva, and 
mediates its 
fungicidal 
activity. 
C76 154.89 10.18 1 3 10 17 707 80.8 4.88 
C199 960.76 24.33 1 12 14 32 707 80.8 4.88 
SA50 207.22 16.27 1 7 12 19 707 80.8 4.88 
SA78 283.68 9.90 1 4 7 15 707 80.8 4.88 
 
C42 P10591 Heat shock protein 
SSA1 
OS=Saccharomyces 
cerevisiae (strain 
ATCC 204508 / 
S288c) GN=SSA1 
PE=1 SV=4 - 
[HSP71_YEAST] 
651.81 19.16 1 1 12 45 642 69.6 5.11 
Binds human 
HTN3/histatin-
5, a peptide 
from saliva, 
and mediates 
its fungicidal 
activity. 
C76 479.69 26.32 1 2 15 43 642 69.6 5.11 
C199 1098.03 23.36 1 3 15 61 642 69.6 5.11 
 
C76 P10592 Heat shock protein 
SSA2 
OS=Saccharomyces 
cerevisiae (strain 
ATCC 204508 / 
S288c) GN=SSA2 
PE=1 SV=3 - 
[HSP72_YEAST] 
518.71 28.01 1 2 16 50 639 69.4 5.06 
Binds human 
HTN3/histatin-
5, a peptide 
from saliva, 
and mediates 
its fungicidal 
activity. 
 
C35 O13318 pH-responsive 188.95 9.38 2 4 4 8 544 58.7 4.64  May be 
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C42 protein 2 
OS=Candida 
albicans (strain 
SC5314 / ATCC 
MYA-2876) 
GN=PHR2 PE=2 
SV=2 - 
[PHR2_CANAL] 
703.02 11.40 2 4 5 28 544 58.7 4.64 integral to the 
pathogenic 
ability of the 
organism 
C73 1074.28 9.56 2 5 5 38 544 58.7 4.64 
C199 178.31 9.56 1 4 4 11 544 58.7 4.64 
SA28 57.02 7.54 1 3 3 4 544 58.7 4.64 
SA40 118.12 6.99 1 2 4 7 544 58.7 4.64 
SA50 76.33 9.38 1 3 4 6 544 58.7 4.64 
SA78 205.11 6.80 2 3 3 8 544 58.7 4.64 
SA100 140.40 12.68 1 3 5 9 544 58.7 4.64 
 
C35 P43084 Probable NADPH 
dehydrogenase 
OS=Candida 
albicans GN=EBP1 
PE=1 SV=2 - 
[EBP1_CANAX] 
154.00 17.20 1 5 5 10 407 46.0 6.39 Oxidoreductase 
that binds 
mammalian 
estrogens with 
high affinity. 
C50 243.37 32.92 1 10 10 13 407 46.0 6.39 
C73 166.13 19.90 1 5 7 15 407 46.0 6.39 
C199 66.64 12.53 1 4 6 6 407 46.0 6.39 
 
C42 Q06099 S-(hydroxymethyl) 
glutathione 
dehydrogenase 
OS=Candida 
maltosa GN=FDH1 
PE=3 SV=1 - 
[FADH_CANMA] 
152.77 5.25 1 2 2 8 381 40.0 6.70 Confers 
resistance to 
formaldehyde. 
C73 244.05 9.97 1 3 4 20 381 40.0 6.70 
C199 39.40 3.15 1 1 1 1 381 40.0 6.70 
C255 147.09 7.87 1 2 3 13 381 40.0 6.70 
SA28 97.46 9.71 1 1 4 9 381 40.0 6.70 
SA40 88.42 7.87 1 2 3 7 381 40.0 6.70 
SA50 121.47 9.97 1 3 4 8 381 40.0 6.70 
SA78 67.40 7.35 1 2 3 8 381 40.0 6.70 
SA100 75.32 8.14 1 1 3 5 381 40.0 6.70 
 
C73 P78595 Multidrug 
resistance protein 
CDR2 OS=Candida 
albicans (strain 
SC5314 / ATCC 
MYA-2876) 
GN=CDR2 PE=3 
SV=2 - 
[CDR2_CANAL] 
152.73 2.87 2 1 4 6 1499 168.9 6.98 Multidrug 
efflux 
transporter. 
Confers 
resistance to 
azole 
antifungal 
agents, to 
other 
antifungals 
(terbinafine, 
amorolfine) 
and to a variety 
of metabolic 
inhibitors. 
             
C42 P43071 Multidrug 34.79 2.40 2 1 5 9 1501 169.8 6.98 Transporter, 
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C199 resistance protein 
CDR1 OS=Candida 
albicans GN=CDR1 
PE=3 SV=1 - 
[CDR1_CANAX] 
37.92 4.06 2 1 5 5 1501 169.8 6.98 whose 
physiological 
function is not 
yet established. 
Confers 
resistance to 
the chemical 
cycloheximide. 
Legend: Accession: UniProt database query number; Score: mascot score; Coverage: the % sequence coverage of the protein as detected by 
the MS; # of proteins: total nr of proteins detected; # unique peptides: total nr of peptides detected for the protein that is unique to the 
protein; #PSM: peptides spectrum matches, estimation of the false positive protein identifications using decoy database containing reversed 
sequences. The PSM shown are all within the parameters due to the use of percolator that calculates statistically meaningful q-values. #AA: 
nr of amino acids present within the protein as given in the database. MW: molecular weight of the protein as given in database; pI: pI of 
protein as given in database. 
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Table 29: Fluconazole-susceptible non-albicans cell fraction HPLC-MS results. 
Isolate 
number 
Accession Description Score Coverage 
# 
Proteins 
# 
Unique 
Peptides 
# 
Peptides 
# 
PSMs 
# 
AAs 
MW 
[kDa] 
calc. 
pI 
Function 
C. dubliniensis 
SA7 
P41797 Heat shock protein SSA1 
OS=Candida albicans (strain 
SC5314 / ATCC MYA-2876) 
GN=SSA1 PE=1 SV=2 - 
[HSP71_CANAL] 
511.08 24.24 3 4 14 42 656 70.3 5.17 Binds human 
HTN3/histatin-5, a 
peptide from saliva, 
and mediates its 
fungicidal activity. 
SA138 
343.94 20.58 4 3 13 39 656 70.3 5.17 
SA184 
475.62 23.63 5 6 14 43 656 70.3 5.17 
SA7 
P46587 Heat shock protein SSA2 
OS=Candida albicans (strain 
SC5314 / ATCC MYA-2876) 
GN=SSA2 PE=1 SV=3 - 
[HSP72_CANAL] 
403.67 16.43 1 1 9 26 645 70.0 5.06 Binds 
HTN3/histatin-5, a 
peptide from 
human saliva, and 
mediates its 
fungicidal activity SA138 
296.68 21.55 1 1 12 30 645 70.0 5.06 
SA7 
Q06099 S-
(hydroxymethyl)glutathione 
dehydrogenase 
OS=Candida maltosa 
GN=FDH1 PE=3 SV=1 - 
[FADH_CANMA] 
135.77 9.97 1 4 4 12 381 40.0 6.70 
Confers resistance 
to formaldehyde. 
SA138 
45.23 12.60 1 2 5 9 381 40.0 6.70 
SA184 
90.61 7.87 1 2 3 8 381 40.0 6.70 
SA138 
O13318 pH-responsive protein 2 
OS=Candida albicans (strain 
SC5314 / ATCC MYA-2876) 
GN=PHR2 PE=2 SV=2 - 
[PHR2_CANAL] 
55.96 2.21 1 1 1 2 544 58.7 4.64 
May be integral to 
the pathogenic 
ability of the 
organism SA184 
46.28 4.96 1 1 2 2 544 58.7 4.64 
C. glabrata 
SA72 
P46587 Heat shock protein SSA2 
OS=Candida albicans (strain 
SC5314 / ATCC MYA-2876) 
GN=SSA2 PE=1 SV=3 - 
[HSP72_CANAL] 
99.87 13.80 4 3 8 19 645 70.0 5.06 Binds 
HTN3/histatin-5, a 
peptide from 
human saliva, and 
mediates its 
fungicidal activity C219 
212.42 14.73 2 1 10 39 645 70.0 5.06 
SA107 
P41797 Heat shock protein SSA1 
OS=Candida albicans (strain 
SC5314 / ATCC MYA-2876) 
GN=SSA1 PE=1 SV=2 - 
[HSP71_CANAL] 
309.00 16.92 4 5 9 20 656 70.3 5.17 Binds human 
HTN3/histatin-5, a 
peptide from saliva, 
and mediates its 
fungicidal activity. 
C219 
P46598 Heat shock protein 90 
homolog OS=Candida 
albicans (strain SC5314 / 
ATCC MYA-2876) 
GN=HSP90 PE=1 SV=1 - 
[HSP90_CANAL] 
440.46 18.25 1 7 13 38 707 80.8 4.88 Binds 
HTN3/histatin-5, a 
peptide from 
human saliva, and 
mediates its 
fungicidal activity. 
C219 
P10591 Heat shock protein SSA1 
OS=Saccharomyces 
cerevisiae (strain ATCC 
204508 / S288c) GN=SSA1 
PE=1 SV=4 - [HSP71_YEAST] 
385.11 22.27 1 2 13 36 642 69.6 5.11 Binds human 
HTN3/histatin-5, a 
peptide from saliva, 
and mediates its 
fungicidal activity. 
C219 
P10592 Heat shock protein SSA2 
OS=Saccharomyces 
cerevisiae (strain ATCC 
204508 / S288c) GN=SSA2 
PE=1 SV=3 - [HSP72_YEAST] 
265.40 23.94 1 1 14 47 639 69.4 5.06 Binds human 
HTN3/histatin-5, a 
peptide from saliva, 
and mediates its 
fungicidal activity. 
SA107 
Q06099 S-(hydroxymethyl) 
glutathione dehydrogenase 
OS=Candida maltosa 
GN=FDH1 PE=3 SV=1 - 
[FADH_CANMA] 
55.84 6.82 1 1 3 7 381 40.0 6.70 
Confers resistance 
to formaldehyde. 
SA107 
O13318 pH-responsive protein 2 
OS=Candida albicans (strain 
SC5314 / ATCC MYA-2876) 
GN=PHR2 PE=2 SV=2 - 
[PHR2_CANAL] 
76.23 7.54 1 3 3 6 544 58.7 4.64 
 May be integral to 
the pathogenic 
ability of the 
organism 
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C. parapsilopsis/lusitaneae/kefyr 
C17 
P46587 Heat shock protein SSA2 
OS=Candida albicans (strain 
SC5314 / ATCC MYA-2876) 
GN=SSA2 PE=1 SV=3 - 
[HSP72_CANAL] 
1214.22 27.60 6 2 18 96 645 70.0 5.06 Binds human 
HTN3/histatin-5, a 
peptide from saliva, 
and mediates its 
fungicidal activity. C21 
1296.94 23.72 2 1 14 101 645 70.0 5.06 
C17 
P46598 Heat shock protein 90 
homolog OS=Candida 
albicans (strain SC5314 / 
ATCC MYA-2876) 
GN=HSP90 PE=1 SV=1 - 
[HSP90_CANAL] 
579.20 19.38 1 7 14 39 707 80.8 4.88 Binds 
HTN3/histatin-5, a 
peptide from 
human saliva, and 
mediates its 
fungicidal activity. C21 
662.48 21.78 1 9 17 56 707 80.8 4.88 
C17 
P10591 Heat shock protein SSA1 
OS=Saccharomyces 
cerevisiae (strain ATCC 
204508 / S288c) GN=SSA1 
PE=1 SV=4 - [HSP71_YEAST] 
627.09 21.50 4 1 17 71 642 69.6 5.11 Binds human 
HTN3/histatin-5, a 
peptide from saliva, 
and mediates its 
fungicidal activity. 
C21 
P41797 Heat shock protein SSA1 
OS=Candida albicans (strain 
SC5314 / ATCC MYA-2876) 
GN=SSA1 PE=1 SV=2 - 
[HSP71_CANAL] 
1299.31 27.90 2 2 17 103 656 70.3 5.17 Binds human 
HTN3/histatin-5, a 
peptide from saliva, 
and mediates its 
fungicidal activity. 
C21 
P10592 Heat shock protein SSA2 
OS=Saccharomyces 
cerevisiae (strain ATCC 
204508 / S288c) GN=SSA2 
PE=1 SV=3 - [HSP72_YEAST] 
694.17 18.15 2 1 11 71 639 69.4 5.06 Binds human 
HTN3/histatin-5, a 
peptide from saliva, 
and mediates its 
fungicidal activity. 
C21 
O13318 pH-responsive protein 2 
OS=Candida albicans (strain 
SC5314 / ATCC MYA-2876) 
GN=PHR2 PE=2 SV=2 - 
[PHR2_CANAL] 
94.18 6.25 1 2 3 5 544 58.7 4.64 
 May be integral to 
the pathogenic 
ability of the 
organism 
 
C. krusei 
C258 
P46598 Heat shock protein 90 
homolog OS=Candida 
albicans (strain SC5314 / 
ATCC MYA-2876) 
GN=HSP90 PE=1 SV=1 - 
[HSP90_CANAL] 
99.76 4.24 1 2 3 8 707 80.8 4.88 Binds 
HTN3/histatin-5, a 
peptide from 
human saliva, and 
mediates its 
fungicidal activity. 
 
C. tropicalis 
C245 
P41797 Heat shock protein SSA1 
OS=Candida albicans 
(strain SC5314 / ATCC 
MYA-2876) GN=SSA1 
PE=1 SV=2 - 
[HSP71_CANAL] 
678.38 30.18 2 3 16 81 656 70.3 5.17 Binds human 
HTN3/histatin-
5, a peptide 
from saliva, 
and mediates 
its fungicidal 
activity. C250 
711.49 28.05 2 2 16 73 656 70.3 5.17 
C245 
P10591 Heat shock protein SSA1 
OS=Saccharomyces 
cerevisiae (strain ATCC 
204508 / S288c) 
GN=SSA1 PE=1 SV=4 - 
[HSP71_YEAST] 
652.16 16.51 1 1 10 57 642 69.6 5.11 Binds human 
HTN3/histatin-
5, a peptide 
from saliva, 
and mediates 
its fungicidal 
activity. C250 
576.74 17.76 1 1 12 58 642 69.6 5.11 
C245 
P46587 Heat shock protein SSA2 
OS=Candida albicans 
(strain SC5314 / ATCC 
MYA-2876) GN=SSA2 
PE=1 SV=3 - 
585.05 31.47 2 2 17 74 645 70.0 5.06 
Binds human 
HTN3/histatin-
5, a peptide C250 
586.43 27.60 2 1 16 68 645 70.0 5.06 
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[HSP72_CANAL] from saliva, 
and mediates 
its fungicidal 
activity. 
C250 
P46598 Heat shock protein 90 
homolog OS=Candida 
albicans (strain SC5314 / 
ATCC MYA-2876) 
GN=HSP90 PE=1 SV=1 - 
[HSP90_CANAL] 
117.31 10.75 1 5 8 12 707 80.8 4.88 Binds human 
HTN3/histatin-
5, a peptide 
from saliva, 
and mediates 
its fungicidal 
activity. 
Legend: Accession: UniProt database query number; Score: mascot score; Coverage: the % sequence coverage of the protein as detected by 
the MS; # of proteins: total nr of proteins detected; # unique peptides: total nr of peptides detected for the protein that is unique to the 
protein; #PSM: peptides spectrum matches, estimation of the false positive protein identifications using decoy database containing reversed 
sequences. The PSM shown are all within the parameters due to the use of percolator that calculates statistically meaningful q-values. #AA: 
nr of amino acids present within the protein as given in the database. MW: molecular weight of the protein as given in database; pI: pI of 
protein as given in database. 
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Table 30: Fluconazole-intermediate and -resistant non-albicans cell fraction HPLC-MS results. 
Isolate 
number 
Accession Description Score Coverage 
# 
Proteins 
# Unique 
Peptides 
# 
Peptides 
# 
PSMs 
# AAs 
MW 
[kDa] 
calc. pI Function 
C. glabrata 
SA11 
P10592 Heat shock protein SSA2 
OS=Saccharomyces 
cerevisiae (strain ATCC 
204508 / S288c) GN=SSA2 
PE=1 SV=3 - [HSP72_YEAST] 
167.98 8.14 4 1 6 15 639 69.4 5.06 Binds human 
HTN3/histatin-
5, a peptide 
from saliva, and 
mediates its 
fungicidal 
activity. C237 
1471.64 49.92 1 5 25 108 639 69.4 5.06 
SA11 
P41797 
  
Heat shock protein SSA1 
OS=Candida albicans (strain 
SC5314 / ATCC MYA-2876) 
GN=SSA1 PE=1 SV=2 - 
[HSP71_CANAL] 
167.95 11.13 3 1 8 12 656 70.3 5.17 Binds human 
HTN3/histatin-
5, a peptide 
from saliva, and 
mediates its 
fungicidal 
activity. 
SA36b 
127.92 17.07 4 5 10 15 656 70.3 5.17 
SA77 
46.84 8.99 4 2 6 9 656 70.3 5.17 
SA92 
71.82 6.10 4 2 4 4 656 70.3 5.17 
C237 P46598 
Heat shock protein 90 
homolog OS=Candida 
albicans (strain SC5314 / 
ATCC MYA-2876) 
GN=HSP90 PE=1 SV=1 - 
[HSP90_CANAL] 
242.16 8.06 1 4 6 17 707 80.8 4.88 Binds 
HTN3/histatin-
5, a peptide 
from human 
saliva, and 
mediates its 
fungicidal 
activity. 
SA11 
Q06099 
  
S-
(hydroxymethyl)glutathione 
dehydrogenase 
OS=Candida maltosa 
GN=FDH1 PE=3 SV=1 - 
[FADH_CANMA] 
  
33.20 2.62 1 1 1 2 381 40.0 6.70 
Confers 
resistance to 
formaldehyde. SA36b 
0.00 5.77 1 2 2 2 381 40.0 6.70 
 
C. dubliniensis 
SA82 
P41797 Heat shock protein SSA1 
OS=Candida albicans (strain 
SC5314 / ATCC MYA-2876) 
GN=SSA1 PE=1 SV=2 - 
[HSP71_CANAL] 
521.81 27.44 3 8 15 49 656 70.3 5.17 Binds human 
HTN3/histatin-
5, a peptide 
from saliva, and 
mediates its 
fungicidal 
activity. 
SA82 
P46598 Heat shock protein 90 
homolog OS=Candida 
albicans (strain SC5314 / 
ATCC MYA-2876) 
GN=HSP90 PE=1 SV=1 - 
[HSP90_CANAL] 
212.78 9.19 1 4 6 10 707 80.8 4.88 Binds 
HTN3/histatin-
5, a peptide 
from human 
saliva, and 
mediates its 
fungicidal 
activity. 
SA82 
P10591 Heat shock protein SSA1 
OS=Saccharomyces 
cerevisiae (strain ATCC 
204508 / S288c) GN=SSA1 
PE=1 SV=4 - [HSP71_YEAST] 
206.84 12.77 1 1 7 28 642 69.6 5.11 Binds human 
HTN3/histatin-
5, a peptide 
from saliva, and 
mediates its 
fungicidal 
activity. 
SA82 
Q06099 S-
(hydroxymethyl)glutathione 
dehydrogenase 
OS=Candida maltosa 
GN=FDH1 PE=3 SV=1 - 
[FADH_CANMA] 
102.72 9.97 1 2 4 12 381 40.0 6.70 
Confers 
resistance to 
formaldehyde. 
SA82 
O13318 pH-responsive protein 2 
OS=Candida albicans (strain 
SC5314 / ATCC MYA-2876) 
89.27 4.78 1 2 2 5 544 58.7 4.64  May be integral 
to the 
pathogenic 
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GN=PHR2 PE=2 SV=2 - 
[PHR2_CANAL] 
ability of the 
organism. 
 
C. krusei 
C144 
P41797 Heat shock protein SSA1 
OS=Candida albicans (strain 
SC5314 / ATCC MYA-2876) 
GN=SSA1 PE=1 SV=2 - 
[HSP71_CANAL] 
117.63 11.74 4 2 8 14 656 70.3 5.17 Binds human 
HTN3/histatin-
5, a peptide 
from saliva, and 
mediates its 
fungicidal 
activity. 
C172 
P10592 Heat shock protein SSA2 
OS=Saccharomyces 
cerevisiae (strain ATCC 
204508 / S288c) GN=SSA2 
PE=1 SV=3 - [HSP72_YEAST] 
38.12 5.48 2 1 4 8 639 69.4 5.06 Binds human 
HTN3/histatin-
5, a peptide 
from saliva, and 
mediates its 
fungicidal 
activity. 
C172 
P46587 Heat shock protein SSA2 
OS=Candida albicans (strain 
SC5314 / ATCC MYA-2876) 
GN=SSA2 PE=1 SV=3 - 
[HSP72_CANAL] 
58.03 5.12 2 1 3 12 645 70.0 5.06 Binds 
HTN3/histatin-
5, a peptide 
from human 
saliva, and 
mediates its 
fungicidal 
activity. 
C172 
P46598 Heat shock protein 90 
homolog OS=Candida 
albicans (strain SC5314 / 
ATCC MYA-2876) 
GN=HSP90 PE=1 SV=1 - 
[HSP90_CANAL] 
171.58 2.97 1 1 2 4 707 80.8 4.88 Binds 
HTN3/histatin-
5, a peptide 
from human 
saliva, and 
mediates its 
fungicidal 
activity. 
Legend: Accession: UniProt database query number; Score: mascot score; Coverage: the % sequence coverage of the protein as detected by 
the MS; # of proteins: total nr of proteins detected; # unique peptides: total nr of peptides detected for the protein that is unique to the 
protein; #PSM: peptides spectrum matches, estimation of the false positive protein identifications using decoy database containing reversed 
sequences. The PSM shown are all within the parameters due to the use of percolator that calculates statistically meaningful q-values. #AA: 
nr of amino acids present within the protein as given in the database. MW: molecular weight of the protein as given in database; pI: pI of 
protein as given in database. 
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Table 31 summarizes the drug resistance-related proteins identified by HPLC-MS, showing 
which Candida species expressed the proteins, their resistance to fluconazole, the protein 
description and function. 
 
Table 31: Summary of drug resistance-related Candida proteins identified by HPLC-MS. 
Candida spp. 
 
Fluconazole 
resistance 
Description of 
protein 
Function 
 
C. albicans, C. dubliniensis, C. 
glabrata, C. 
parapsilopsis/kefyr/lusitaneae, 
C. tropicalis S, R 
Heat shock 
protein SSA1  
Binds human HTN3/histatin-5, a 
peptide from saliva, and mediates its 
fungicidal activity. 
C. albicans, C. dubliniensis, C. 
glabrata, C. 
parapsilopsis/kefyr/lusitaneae, 
C. tropicalis S, R 
Heat shock 
protein SSA2  
Binds human HTN3/histatin-5, a 
peptide from saliva, and mediates its 
fungicidal activity. 
C. albicans, C. glabrata, C. 
parapsilopsis/kefyr/lusitaneae, 
C. krusei, C. tropicalis S,R 
Heat shock 
protein 90  
Binds human HTN3/histatin-5, a 
peptide from saliva, and mediates its 
fungicidal activity. 
C. albicans S, R 
Probable 
NADPH 
dehydrogenase  
Oxidoreductase that binds 
mammalian estrogens with high 
affinity. 
C. albicans, C. dubliniensis, C. 
glabrata, C. 
parapsilopsis/kefyr/lusitaneae S, R 
pH-responsive 
protein 2  
May be integral to the pathogenic 
ability of the organism 
C. albicans, C. dubliniensis, C. 
glabrata S, R 
S-
(hydroxymethyl) 
glutathione 
dehydrogenase  Confers resistance to formaldehyde 
C. albicans S, R 
Multidrug 
resistance 
protein CDR1  
Confers resistance to the chemical 
cycloheximide 
C. albicans R 
Multidrug 
resistance 
protein CDR2  
Multidrug efflux transporter. Confers 
resistance to azole antifungal agents, 
to other antifungals (terbinafine, 
amorolfine) and to a variety of 
metabolic inhibitors. 
S=susceptible; R=resistant. 
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Figures 18 and 19 show the chromatograms obtained after HPLC-MS analysis of the Candida 
cell wall fraction using the FASP method on a C. albicans drug-susceptible isolate and an 
azole-resistant isolate, respectively. Figures 20 and 21 show the HPLC-MS analysis 
chromatograms for a C. glabrata isolate which demonstrated intermediate susceptibility to 
azole drugs and a C. krusei isolate which was found to be resistant to fluconazole. 
 
 
 
Fig. 18: Chromatogram for drug-susceptible C. albicans isolate SA163. 
 
 
 
Fig. 19: Chromatogram for azole-resistant C. albicans isolate C73. 
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Fig. 20: Chromatogram for azole-intermediate C. glabrata isolate SA92. 
 
 
 
 
Fig. 21: Chromatogram for fluconazole-resistant C. krusei isolate C144. 
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Chapter 4: Discussion and Conclusion 
 
Oral candidiasis is a common opportunistic infection in the course of HIV disease 
progression. Changes in the clinical severity of oral candidiasis and type of Candida species 
profile may be a reflection of immunological changes in patients. Although C. albicans is the 
most commonly reported species in HIV literature, there appears to be a gradual trend 
globally toward change in the Candida species prevalence with non-albicans Candida being 
more frequently isolated from patients with HIV/AIDS along with an associated intrinsic or 
acquired antifungal resistance becoming apparent in several Candida species. The emergence 
of resistant non-albicans species might pose a problem in treatment strategies and requires 
further investigation. Studies related to changes in the distribution of Candida species during 
the progression of HIV infection and the development of resistance to antimycotics are rare in 
Africa. 
 
The aim of this study was therefore to isolate and characterize Candida species from two 
different HIV-positive African populations namely South Africa and Cameroon from which 
very high rates of HIV infection have been reported. This is important, as no similar study 
has previously been done. Also, to our knowledge, no study had combined the use of SDS-
PAGE and HPLC-MS for a broad analysis of clinical yeast isolates from HIV-positive 
patients in South Africa and Cameroon. Candida species, as opportunistic organisms, are a 
cause of concern in HIV-positive patients. Of even greater concern is the emergence of 
antifungal drug resistance. Fluconazole is very often the only oral antifungal available to 
HIV-positive patients in African public hospitals, and the emerging resistance renders it 
ineffective against Candida infections. 
 
The characterization of Candida species employed the use of chromogenic/selective media 
for species differentiation and drug susceptibility testing. Other factors, such as patient 
gender, immune status and age were also taken into account. 
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4.1 Species identification 
 
Different microbiological media have been developed in recent years to rapidly identify 
Candida species. The use of different media in this study for species isolation and 
identification produced clear, reproducible results in all species. The only exception was the 
identification of Candida parapsilopsis/lusitaneae/kefyr, for which there was no concrete 
differentiation agar based on chromogenic substrates. 
 
It is important to note that no individual solid culture media can be relied upon for Candida 
species differentiation. The results obtained from the different chromogenic media had to be 
compared to correctly identify the individual species, as in some cases two or three different 
species presented with the same colour in certain media. In the case of C. albicans and C. 
dubliniensis differentiation, although a slight colour difference could be seen in both 
chromogenic agars, no medium was able to give clear results. Therefore, suspected samples 
(which demonstrated a darker tonality) were subsequently inoculated and grown on tomato 
juice agar and tobacco agar and incubated at 45˚C followed by microscopy. The use of these 
techniques greatly aided in the correct differentiation of these two species. 
 
Species differentiation in chromogenic and differential culture media was a crucial step for 
further microbiological and proteomic analysis of the isolates. Correct identification of 
clinical specimens cannot be done exclusively using more detailed techniques such as HPLC-
MS, for example, which is extremely sensitive to protein expression and is only able to 
accurately identify cultured type strains in the computer’s database to species level if a 
database is present. The use of chromogenic and differential agars in the microbiological 
identification of the clinical species eliminated this problem. 
 
Chromogenic culture media also allowed for the identification and isolation of multiple 
species present in swab samples. 
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4.2 Candida species prevalence in South African and Cameroonian patients 
 
One hundred and twenty-eight (128) of the swab samples collected from South African 
patients yielded Candida growth, with 127 Candida isolates from the swabs collected in the 
Cameroon. The results of the first inoculation of the swabs into Sabouraud’s agar showed that 
most specimens showed scanty to light growth after incubation at 37˚C for 24 hours, with no 
significant differences observed for the different Candida species. Candida species were 
identified and differentiated using chromogenic agar. Confirmatory tests were done to 
differentiate between C. albicans and C. dubliniensis. 
 
The prevalence of Candida in the oral mucosa of healthy individuals is approximately 40-
60% (Odds, 1987). However, a study done on healthy and HIV-positive patients (Sánchez-
Vargas et al, 2005) showed that the prevalence of Candida in HIV infection was higher than 
in healthy individuals. The overall Candida prevalence in the present study was found to be 
similar to that of healthy individuals, although in the higher percentage values, especially in 
the case of the South African group. 
 
The prevalence of Candida albicans in South African HIV-positive patients was found to be 
much higher than that of other Candida species with C. glabrata more frequently isolated 
than C. dubliniensis. Another South African study (Blignaut, 2007) also demonstrated C. 
albicans to be the most predominant species, followed by C. dubliniensis. Further studies 
from this region would confirm the shift in species prevalence of C. glabrata. 
 
Species such as C. krusei, C. parapsilopsis and C. tropicalis, which have been described as 
invasive Candida species in other studies (Arredondo-García et al, 2009, Chen et al, 2009, 
Prakoeswa et al, 2009) were not observed in the South African population. However, these 
three species were observed in the Cameroonian samples where the most prevalent species 
was also found to be C. albicans. Other species isolated from the Cameroonian samples were 
a large number of C. glabrata and two other species characterized as C. kefyr, C. lusitaneae 
or C. parapsilopsis. An association between diet and Candida carriage, especially non-
albicans species, has been previously documented (Coleman et al, 1995, Jabra-Rizk et al, 
2001, Kadir, Uygun and Akyüz, 2005, Kwamin et al, 2013). We can speculate that this may 
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well have been the case with the Cameroonian patients from whom non-albicans species were 
isolated. 
 
The frequency of C. albicans as the predominant species, followed by C. glabrata, has been 
reported by Mousavi et al (2012), Badiee et al (2010), Fidel, Vazquez and Sobel (1999) and 
Hamza et al (2008). However, the distribution of non-albicans species differed in each of 
these studies with C. tropicalis, C. parapsilopsis and C. krusei reported by Hamza et al 
(2008) in Tanzania and C. dubliniensis, C. krusei, C. kefyr, C. parapsilopsis and C. tropicalis 
reported from Iran (Badiee et al, 2010, Mousavi et al, 2012). The distribution of Candida 
species appears to vary according to geographic region and sometimes within the same region 
(Mares et al, 2008, Basma et al, 2009). 
 
A study from Venezuela reported distribution in the order of C. albicans, C. tropicalis, C. 
glabrata, C. parapsilopsis and C. krusei (Magaldi et al, 2001). Candida albicans, followed 
by C. tropicalis, has also been reported in a study from Cameroon with C. dubliniensis 
reported less frequently with an absence of C. glabrata (Njunda et al, 2013). A study from 
Ghana reported a distribution of C. albicans, C. tropicalis, C. krusei, C. parapsilopsis, C. 
sake, C. dubliniensis, C. globosa, C. formata, C. glabrata and C. lusitaneae (Kwamin et al, 
2013). 
A study done in Indonesia (Prakoeswa et al, 2009) found that only 35.29% of Candida 
infections in HIV-positive patients were due to C. albicans, with the remainder (64.71%) 
being C. tropicalis, C. dubliniensis, C. glabrata and C. guilliermondi collectively. 
Only one case of C. dubliniensis was seen in the Cameroonian group in the present study. C. 
dubliniensis has previously been reported in the Cameroon but also in very low numbers 
(Njunda 2013). This species has been associated with HIV/AIDS in Caucasian and well-
resourced populations (Blignaut et al, 2003). In the South African group, which represents a 
more genetically mixed population, C. dubliniensis numbers were slightly higher confirming 
this species as a contributor to Candida carriage in HIV-positive South African patients. 
 
C. dubliniensis was first identified in Africa in HIV-positive patients in 2001 (Fisher, Basson 
and van Zyl, 2001) and is considered to have a colonial morphology phenotypically similar to 
C. albicans with a proposed genotypical differentiation using molecular techniques only. This 
study has shown a clear differentiation between C. albicans and C. dubliniensis by growth on 
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tomato juice agar and tobacco agar, a method which may be employed in a resource-poor 
setting where the reagents required for molecular methods may not be affordable. 
 
 
4.3 Antifungal susceptibility testing 
 
The comparison of fluconazole drug susceptibility tests used on the type strains showed 
similar results for YNBG agar and the TREK system, which further confirms the reliability of 
these two techniques. The other media used (Sabouraud and GMB agars) only showed similar 
results as the first two in the case of the C. krusei and C. glabrata type strains and 
individually in the case of the C. albicans (Sabouraud) and C. dubliniensis (GMB) NCPF 
type strains. 
 
Seventy-seven percent (77%) of South African Candida isolates were found to express 
resistance to fluconazole when grown in Sabouraud agar, while 18% of isolates were 
classified as intermediate, or dose-dependent. The number of resistant (78%) C. albicans 
strains in this medium was much higher than the intermediate (19.8%) and susceptible ones 
(1.9%), with 60% of C. dubliniensis and 83% of C. glabrata isolates showing resistance to 
fluconazole on Sabouraud agar. 
 
Although Sabouraud agar is the ideal medium to grow Candida isolates, it performed poorly 
in antimicrobial susceptibility testing. This has been previously reported (May, King and 
Warren, 1997). The GMB quality control organism susceptibility test showed values outside 
the range specified by the CLSI. The clinical strain results and South African population 
results for fluconazole susceptibility using Sabouraud and GMB agars were presented for 
comparative reasons, but because of discrepancies YNBG agar was preferred, as this agar has 
shown the best performance when compared with other media due to its increased sensitivity 
in the susceptibility testing of Candida species (May, King and Warren, 1997, Yücesoy, 
Guldas and Yuluq, 2001). Although this medium was more difficult to prepare, the dilution 
protocols were more straightforward than in the case of GMB, leading to faster processing of 
samples, reduced use of consumables and less chance of dilution errors. 
 
South African antimicrobial susceptibility results in YNBG showed very high resistance 
levels in C. glabrata (66.7%), followed by C. albicans (56.6%) and C. dubliniensis (10%). 
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The intermediate (dose-dependent) result for C. glabrata was 8.3%. In theory, patients 
harbouring these species could be treated with fluconazole if higher doses are used and/or if 
treatment is extended. 
 
In the Cameroonian population, the YNBG results showed the highest resistance levels in C. 
krusei and C. tropicalis (100%), followed by C. glabrata (75%), C. 
kefyr/parapsilopsis/lusitaneae (50%) and C. albicans (42.4%). The only C. dubliniensis 
isolate collected from this population showed intermediate (dose-dependent) resistance. Other 
intermediate (dose-dependent) results were seen in C. kefyr/parapsilopsis/lusitaneae (50%), 
C. glabrata (29.2%) and C. albicans (9.8%). 
 
The present study showed that resistance to fluconazole is present in Candida species isolated 
from clinical samples. This is a cause for concern, as this is one of the few and in some cases 
the only oral antifungal drug available at public hospitals on the continent. The high levels of 
resistance seen in Candida species could contribute to an increase in patient morbidity and 
mortality. Different studies consider C. dubliniensis to be more resistant to fluconazole than 
C. albicans (Fisher, Basson and van Zyl, 2001, Powderly, Mayer and Perfect, 1999). 
However, a high difference in resistance levels was not seen in this study. Studies in other 
parts of the world have shown similar azole-resistant Candida species in HIV-positive 
patients (Fidel, Vazquez and Sobel, 1999, Hamza et al, 2008, Badiee et al, 2010). 
 
The high fluconazole resistance levels seen in the present study are disturbing, but can be 
partly blamed on the prolonged prescription of this drug in clinical candidiasis cases. 
Candida resistance to antifungal drugs in Cameroon, where the sale of medicines is not 
regulated, can also be blamed on the unregulated sale of medications, which leads to the 
distribution of antifungal drugs by untrained persons and/or self-medication by the patients. 
 
Candida albicans isolated from patients who had not previously been treated with fluconazole 
showed resistance to fluconazole (9.8%) and itraconazole (4.9%) and this resistance was 
found to increase to 44.7% and 44.15% after treatment with these drugs (Magaldi et al, 
2001). 
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Prophylactic administration of fluconazole in patients with low CD4 counts may result in 
clinical treatment failure which is significantly correlated with reduced susceptibility to 
fluconazole and other azoles (Müller et al, 2000). 
 
Although C. albicans was the most prevalent species in the present study, drug resistance in 
both populations was much more prominent in non-albicans species. The representation of 
five non-albicans Candida species isolated from the Cameroon could be the cause of the 
higher fluconazole intermediate/resistant results in this population, due to non-albicans 
species being inherently more resistant than C. albicans. 
 
The co-existence of two Candida species (C. albicans and C. glabrata) in patients SA36 and 
SA203, with both species demonstrating the same resistance patterns to fluconazole, could 
signal the exchange of genetic information related to drug resistance and predisposed the host 
to a higher degree of fungal colonization and infection. It is possible that these two species 
formed an important part of a microbial biofilm in the oral mucosa of these patients, which 
might thus have resulted in increased pathogenicity. 
 
Cross-resistance to azoles has been reported for Candida species (Magaldi et al, 2001) with 
all colonies from the same swabs developing the same resistance patterns. Horizontal 
transmission where the same resistance patterns in genetically identical species isolated from 
partners was observed, even when one partner had never received previous treatment 
(Dromer et al, 1997). Cross-resistance to a range of clinically used antifungals may also be 
attributed to the antifungal agents used (Sojakova et al, 2004). 
 
Non-albicans Candida species such as C. glabrata have been implicated as the causative 
agents of 46% of systemic Candida infections (Wingard, 1995). Since very high levels of C. 
glabrata isolates from both populations were found to be either resistant or intermediate to 
fluconazole in immunocompromised patients, this poses a cause for concern, as these species 
are able to cause a very high level of systemic infections even though they occur in much 
lower numbers than C. albicans. Candida glabrata and C. krusei have been reported to be 
less susceptible/intrinsically resistant to fluconazole (Bodey et al, 2002, Badiee et al, 2010) 
and this occurrence in HIV-positive patients is increasing. 
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There is a possibility that different susceptibility results would have been obtained in some of 
the clinical samples tested if a higher fluconazole dosage had been used, even though it has 
been shown that 25 µg fluconazole impregnated felt disks give similar results to 50 µg felt 
disks (Kustimur et al, 2003). In the same line of thought, it is possible and probable that, in 
some cases, clinical Candida strains may demonstrate a higher susceptibility to fluconazole if 
the antifungal therapeutic dose is increased. For the purpose of this study, however, these 
fluconazole dose-dependent strains were still considered resistant, as they showed particular 
molecular patterns related to fluconazole resistance. 
 
Recently developed echinocandins and third generation azole compounds have shown a 
better efficacy in combating certain Candida infections (Pemán and Almirante, 2008) and 
could be considered as second-line drugs to deal with fluconazole-resistant fungal infections. 
 
The results from the TREK Sensititre system showed a 45.3% overall fluconazole resistance 
(including intermediate drug resistance isolates) of Candida species in HIV-infected patients 
in the Western Cape of South Africa. In Cameroon the value was 45.2%. Although the values 
were very similar in these two regions, the numbers of resistant isolates were much higher 
than those previously documented in other studies. 
 
The TREK Sensititre system proved to be a very useful tool in determining the resistance 
patterns of all clinical isolates against various antifungal drugs. This CLSI-approved method 
substituted the GMB agar diffusion technique (the standard CLSI method) in this study, as it 
provided repeatable and consistent results. The fact that it includes newer generation drugs, 
including the echinocandins, was also very valuable. 
 
In the South African population, both C. albicans and C. glabrata showed low resistance 
levels to echinocandin drugs. Very high azole resistance levels were noted in C. albicans and 
high azole resistance in the case of C. glabrata isolates. C. dubliniensis isolates responded 
well to azole drugs, with the exception of one isolate. 
 
Four point seven percent (4.7%) of C. albicans and 8.3% of C. glabrata species were found 
to be resistant to 5-flucytosine. All C. dubliniensis isolates were susceptible to this drug. 
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An extreme drug resistance Candida isolate was identified using the TREK system. Isolate 
SA82, a Candida dubliniensis strain, was found to be resistant to eight drugs on the TREK 
panel. The only exception was 5-flucytosine, which inhibited growth of this isolate in 
concentrations above 2µg/ml. This is, to our knowledge, the first time that such high 
resistance levels have been documented. This could signal the emergence of multiple drug 
resistant Candida species. 
 
In the Cameroonian population, C. albicans, C. tropicalis and C. krusei strains showed no 
resistance to echinocandin drugs, while C. glabrata strains showed high resistance levels 
against micafungin. In the case of the azole drugs, the reverse was seen: C. albicans strains 
were more resistant to azoles (greater than or equal to 50% resistance in all azoles for C. 
albicans), with C. glabrata responding better to this class of drugs. The C. dubliniensis strain 
and two species identified as C. parapsilopsis/lusitaneae/kefyr showed no resistance to azole 
drugs, with C. tropicalis strains showing susceptibility to both fluconazole and voriconazole. 
Most species tested with 5-flucytosine showed very promising results. The exceptions were 
C. krusei, with only one isolate (33.3% of total) showing intermediate resistance, and C. 
albicans, where 5.4% of isolates were totally resistant. 
 
Resistance to amphotericin B was seen with respect to all Candida species, with non-albicans 
species demonstrating especially high resistance levels, particularly C. glabrata obtained 
from the South African population. 
 
There is a possibility that the repeated exposure of Candida species to antifungal drugs, 
particularly in the Cameroon where more non-albicans species are present, might have led to 
changes in the distribution of Candida species. Species-specific azole resistance has been 
documented in Brazil (Colombo et al, 2002) and resistance to a specific antifungal drug has 
been shown to result in cross-resistance to other drugs of the same class (Müller et al, 2000). 
 
 
Statistical tests done between Candida species and resistance patterns showed moderate to 
strong associations between the former, with the exception of 5-flucytosine. These results 
further demonstrate that the resistance patterns of specific antifungal drugs are related to the 
specific Candida species they target. 
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4.4 The role of gender 
 
In South Africa, female patients were found to have a higher incidence of Candida when 
compared to their male counterparts, as 62% of females tested positive for Candida, as 
opposed to 55% of males. In Cameroon, however, these values were 48.4% and 48.9% 
respectively. As in the South African group in the present study, candidiasis was reported to 
be higher in females (76.8%) than males (23.2%) in the study by Njunda et al (2013), which 
associated CD4+ T cell counts <200 cells/µl with frequency of candidiasis. 
 
No significant association was seen to exist between patient’s gender and C. albicans and C. 
dubliniensis colonization. South African female patients had a much higher prevalence of C. 
glabrata in the oral mucosa when compared with the male patients, with double the 
percentage. In the Cameroonian patients, the reverse was observed, as the percentage of 
males with C. glabrata present in their oral mucosa was higher than that of females, with 
females showing a greater diversity of species. 
 
The fact that Candida albicans was the only species isolated from the oral mucosa of patients 
who were either pregnant or had recently given birth could indicate a link between pregnancy 
and Candida species colonization. It would be interesting to increase the sample size and do a 
comparison of the Candida present in other body sites of these patients (Nowakowska, 
Kurnatowska and Wilkzynsky, 2001) especially since Candida species have been implicated 
in pre-term delivery (Hay and Czeizel, 2007). Candida krusei (an intrinsically resistant 
species) and C. parapsilopsis/lusitaneae/kefyr were only seen in the female population, with 
fewer representatives of other Candida species being present in males. These results support 
the literature on the estrogen target of Candida species, which predisposes females to a 
higher burden of Candida colonization. 
 
 
4.5 Effect of age and ethnicity 
 
A higher percentage of Candida species was isolated from South African patients ranging 
between 21 to 30 and 31 to 40 year old age groups. This seemed to shift to older age groups 
in the Cameroonian population. Similar results within the same age group were reported in a 
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recent study of candidiasis in HIV-positive patients in Cameroon (Njunda et al, 2013) and an 
earlier study in Iran (Mousavi et al, 2012). A high percentage (75%) of C. glabrata isolates 
was obtained from South African patients in the 31 to 40 year old age group (Table 19). This 
species was more uniformly distributed in the Cameroonian population. 
 
No association was seen between Candida species and race. The majority of the patients who 
participated in the study were black, with few representatives of other racial groups. A study 
on a larger sample size done on different geographical areas would be needed to ascertain 
whether species prevalence can be related to race. 
 
 
4.6 Effect of HIV stage 
 
Thirty-four percent (34%) of South African patients and 25.6% of Cameroonian patients who 
tested positive for Candida carriage in their oral mucosa had symptoms of late-stage 
immunosuppression and opportunistic infections (AIDS) which included tuberculosis, lymph 
node enlargement and to a lesser degree systemic and localized fungal infections elsewhere in 
the body. Thirty-nine percent (39%) of South African patients with C. albicans and 25% of 
South African patients with C. glabrata were severely immunosuppressed (AIDS patients). 
However, none of the patients from South Africa or Cameroon with C. dubliniensis carriage 
were found to have late stage immunosuppression. In Cameroon the percentages of severely 
immunocompromised patients were more uniform for C. albicans (26.1%), C. glabrata 
(29.2%), C. krusei (25%) and C. tropicalis (25%), with the few C. dubliniensis and C. 
kefyr/parapsilopsis/lusitaneae isolates only being present in HIV-positive patients with no 
symptoms of late-stage disease. 
 
 
4.7 Effect of ARV therapy 
 
Overall, 52.8% of South African patients on ARV medication had Candida in their oral 
mucosa. Thirty-three percent (33%) of South African patients presenting with Candida in the 
oral mucosa were not on antiretroviral therapy at the time of sample collection. The highest 
number of C. albicans isolates was collected from this group (38%). Most patients on ARV 
therapy were either on d4T/Efavirenz/3TC or d4T/Nevirapine/3TC triple therapy, which 
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belong to the first antiretroviral regimen. A reduced number of patients were on Zidovudine 
(AZT), which is used during pregnancy or KLT/DDL/TDF therapies, which at the time was 
being introduced in public hospitals. 
 
Of the Cameroonian patients 46.4% on ARV medication had Candida in their oral mucosa. In 
this group, only 3.9% of patients with Candida in their oral mucosa were not on antiretroviral 
therapy at the time of sample collection. In this group, patients on the AZT/NVP/3TC 
cocktail had the highest C. albicans (62%) and C. glabrata (58.3%) colonization, probably 
because this was the most commonly dispensed ARV drug cocktail at the site. In Cameroon, 
it was noted that AZT was part of most drug combinations, while d4T was the drug of choice 
for the South African group. 
 
A high number of both C. dubliniensis (40%) and C. glabrata (42%) colonization was seen in 
South African patients taking the d4T/Nevirapine/3TC ARV cocktail. A future study with a 
higher sample number of these species would confirm if this drug combination renders the 
patient more susceptible to these non-albicans species. 
 
It can also be postulated that, because this is an ARV combination that has been in use for a 
longer period of time in this part of the continent, HIV might have acquired resistance to this 
cocktail over the years. This has been suggested by another study from Ghana (Kwamin et al, 
2013). Much lower carriage values were found with the more recent ARV combinations such 
as AZT/DDL/Kaletra, AZT/3TC/Kaletra and TDF/Efavirenz/3TC in the present study. No 
similar associations were seen in the Cameroonian group. 
 
The number of C. albicans isolates steadily declined in South African patients on prolonged 
ARV therapy. This makes sense, as the lower viral count caused by the antiretroviral therapy 
over a longer period would confer better immunity. These immune responses would, in turn, 
reduce the burden of opportunistic infections and prevent their spread to other anatomical 
sites. However, the reverse is true for the Cameroonian population, as most Candida isolates 
were obtained from patients on antiretroviral drugs for longer than 3 years. 
The number of C. dubliniensis South African isolates increased in patients who were on ARV 
therapy between 12 and 23 months. This number declined after more than 24 months of 
therapy, while C. glabrata isolates were increased in patients who were on ARV therapy for 
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less than 12 months. A higher prevalence of candidiasis among patients who were not on 
ARV treatment has been previously reported (Njunda et al, 2013). 
The shift from C. albicans to the more drug-resistant non-albicans species seen after 
continued ART is therefore a cause for concern. A future study employing a larger sample 
size and focusing on ARV combinations and CD4 counts, for example, would provide more 
information on the colonization behaviour of these species on immunocompromised patients. 
 
 
4.8 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
 
Limited studies have examined the protein profile in fluconazole-resistant Candida species. 
The generation of protein profiles by SDS-PAGE has been accepted as an effective typing 
method for the characterization of Candida (Rodrigues et al, 2004). 
 
The Fluka SDS gel preparation kit allowed for quicker, easier, safer and less expensive 
preparation of polyacrylamide gels, when compared to conventional SDS-PAGE reagents. 
The Hoefer system allowed for the simultaneous running of two 8X8cm gels in 
approximately 1 hour and proved to be a simple and effective SDS-PAGE system for this 
type of application, while use of the gel drying kit allowed for a quick drying process and 
better gel consistency for handling and storage of cast gels. 
 
The protein assay kit used in this study allowed for protein quantification in all samples that 
were above the desired concentration, as these were simply diluted in buffer solution. 
However, samples with very low cell densities analyzed using SDS-PAGE resulted in blank 
or very faint protein lanes. It was noted that some non-albicans species took longer to grow in 
solid and liquid media and that after surface protein isolation and Bradford protein 
quantification the protein bands in some cases were very faint or could not be seen. In these 
cases the process was repeated with a longer incubation time (48 hours) and a new gel was 
run. It must be noted that even when a sample had a certain cell density, after dilution with 
glycerol and running buffer the sample would be much more diluted. This did not occur in 
the case of C. albicans species, as in most cases C. albicans samples with lower 
concentrations than other Candida species would appear in the SDS-PAGE gel results as very 
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clear protein bands, while the non-albicans species often appeared as blank lanes or as very 
faint protein bands, even though protein concentration was standardized. 
 
Polyacrylamide gel electrophoresis analysis showed well expressed protein bands in both 
susceptible and resistant C. albicans samples. The most defined one was present at 
approximately 46kDa, followed by four protein bands between 30 and 36kDa. These were 
very similar to the protein bands found in the C. albicans NCPF control. 
 
A 24kDa protein related to the tropiase acid proteinase was found to be expressed in C. 
albicans isolates SA90, SA94 and SA109 (all resistant to fluconazole). 
 
In the case of C. dubliniensis a protein band in the region of 49 kDa was found in the C. 
dubliniensis NCPF control (a drug-susceptible type strain), as well as a band in the region of 
36 kDa, consistent with Grp2p reductase, followed by 3 protein bands ranging from 23 kDa, 
consistent with acid proteinase, to 27 kDa. It was interesting to note that isolate fraction 7 
(which was susceptible to all drugs on the TREK panel) had very similar protein patterns to 
those of the C. dubliniensis NCPF type strain. A ~44 kDa protein consistent with 
exoglucanase was found to be expressed in isolate fractions SA82, an extreme drug resistant 
strain, and SA136, a drug-susceptible strain. 
 
In the case of C. glabrata, a protein band in the region of 37 kDa was found in isolate 
fraction SA144, a fluconazole-susceptible sample, consistent with Grp2p reductase. A 24 kDa 
protein consistent with the tropiase acid proteinase was found to be expressed in isolate 
fraction SA92 (a fluconazole-intermediate (dose-dependant) isolate). A 50 kDa protein band 
was also present in isolate fraction SA92 and in fraction SA107 (a fluconazole susceptible 
isolate). 
 
These results show that clinical Candida strains seem to express drug-resistance protein 
patterns in resistant C. albicans isolates. However, the expression of proteins previously 
described as related to fluconazole resistance seemed to be present in both resistant and 
susceptible non-albicans species. 
 
It must be noted that the proteins described above, previously found to be related to 
fluconazole resistance, often expressed resistance patterns to other azoles or different drug 
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classes. Isolate SA144, a fluconazole –susceptible isolate which expressed a 37 kDa protein, 
was resistant to 5-flucytosine, while isolate SA107, also susceptible to fluconazole, 
demonstrated resistance to amphotericin B. The 24 kDa protein found in the fluconazole-
intermediate isolate SA92 was resistant to amphotericin B, itraconazole and posaconazole. 
This molecular weight is consistent with an acid proteinase, an enzyme found in Candida 
which is known to destroy important host immune proteins, destroy host cells and induce 
changes in the organism’s pathogenicity (Staib, 1969). 
 
Previous studies have exposed Candida species to fluconazole, allowing for the 
overexpression of resistance proteins before the cellular components were run on the 
acrylamide gels. This study suggests that while the expression of probable fluconazole-
resistance proteins in fluconazole-susceptible strains could be due to a similar response 
mechanism to other azole drugs (such as in the case of SA92), the appearance of resistance 
proteins in isolates resistant to other groups of antifungals (with different modes of action) 
needs to be further investigated. 
 
A more sensitive stain, such as a silver stain, could have been used in the SDS-PAGE protein 
analysis. However, the use of such a stain would have resulted in the appearance of many 
protein bands in the gels, which would have made it difficult to identify bands of interest. 
Therefore, the stain used in this study remains the best option in reading protein bands, 
especially as cell fractions with a relatively limited array of individual proteins were used. 
This study analysed the South African isolates’ cell fractions by SDS-PAGE, looking for the 
expression of proteins of interest in relation to drug resistance. This provided a different 
perspective into the Candida proteome in vivo, as Candida SDS-PAGE proteomics studies 
usually rely on the analysis of type strains or few clinical strains, often with prior exposure to 
fluconazole and then analysed by gel electrophoresis. 
 
 
4.9 High Performance Liquid Chromatography – Mass Spectrometry 
 
Fluconazole resistance in C. albicans is thought to occur by reduced fluconazole 
accumulation (Sanglard et al, 1995, Venkasteswarlu et al, 1995) as a result of reduced 
cellular uptake or due to increased efflux. Another mechanism of resistance could be via an 
 
 
 
 
88 
 
altered drug target, namely 14α-sterol demethylase, encoded by ERG16 (Casalinuovo et al, 
2004). 
 
With the elucidation of the full proteome of various organisms, the use of modern techniques 
such as high performance liquid chromatography and updated online databases, it is now 
possible to identify proteins accurately and with extreme sensitivity. Overall, this platform 
was by far superior to SDS-PAGE, as the results were very specific and detailed and the 
proteins identified by mass spectrometry could easily be searched using a protein online 
database. 
 
The sample preparation used for the SDS-PAGE and HPLC-MS analysis allowed for the 
selection of proteins present in the Candida cell wall, although some proteins that do not 
form part of the cell wall were identified by liquid chromatography-mass spectrometry. This 
seems to show that the cell wall fraction isolation technique used in this study (originally 
developed for the less sensitive gel electrophoresis analysis), which involves lysing the cells, 
allows for some intracellular components to remain in the final cell fraction, and these can 
still be read by the very sensitive mass spectrometer. This did not interfere with the results, as 
the description and origin of the individual proteins identified by HPLC-MS could be 
determined when matching the results to the UniProt database, allowing for these readings to 
be excluded. 
 
Up to 206 individual proteins were identified per cell fraction analysis using the HPLC FASP 
method. This number was not uniform across different cell fractions: C. 
parapsilopsis/lusitaneae/kefyr yielded fewer proteins than other species, but proteins of 
interest were still detected. 
 
Different proteins, some of which could be involved in mechanisms of drug resistance, were 
identified using HPLC-MS. These included membrane transporter proteins; proteins 
described as being related to cellular response to heat, osmotic stress, oxidative stress, 
starvation, pH changes and toxic substances; molecular chaperones (heat shock proteins) that 
regulate target proteins; proteins that cause allergic reactions in humans and proteins that 
elicit immune responses in patients with malignant haematological disorders. However, due 
to the nature of this study, only proteins that were confirmed as being responsible for/related 
to drug resistance were included. Cell membrane proteins that affected the organism’s 
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pathogenicity and virulence were also considered to be of interest and were included in the 
results. 
 
Due to the limited amount of proteins identified by SDS-PAGE and the fact that only 40 of 
the Candida cell fractions were analysed by HPLC-MS, no meaningful statistical analyses 
could be performed on these sections. 
 
Different colonization tactics used by oral Candida species could be elucidated using HPLC-
MS: C. albicans drug-susceptible isolates seemed to bind to the oral mucosa by expressing 
proteins that bind to HTN3/histatin-5 found in saliva, affecting the fungicidal activity of these 
human antimicrobial proteins. Salivary histatins have a potent antifungal activity and the 
mediation of fungicidal activity by this mechanism was first described in 2003 (Li et al). The 
presence of histatin-binding proteins in all Candida isolates by HPLC-MS demonstrated that 
this is a crucial mechanism in oral colonization across all Candida species. Other 
colonization mechanisms seen in these isolates included the expression of oxidoreductases 
that bind strongly to estrogen (which might explain the higher female Candida colonization 
seen in this study) and the expression of pH responsive proteins, which affect the 
pathogenicity of these Candida isolates. Changes in the expression of pH-regulated genes 
have been shown to induce changes in the virulence of Candida species (Mühlschlegel and 
Fonzi, 1997). 
 
The expression of a multidrug resistance transporter protein CDR1 of unknown physiological 
function found in four isolates in this group, which confers resistance to cycloheximide, 
chloramphenicol and miconazole (Prasad et al, 1995), was a finding that has previously been 
documented in the development of Candida drug resistance. Due to this, two of these 
proteins, which had a protein sequence coverage below 5%, were included in the results, as 
the presence of this protein showed that the same mechanism was visibly present in both 
populations. 
 
It has been demonstrated that CDR1 is present in greater amounts than the CDR2 multidrug 
efflux transporter protein in Candida albicans (thereby explaining the 4-fold presence of this 
protein when compared to CDR2) and that it may play a role in fluconazole drug resistance 
(Holmes et al, 2008). It has been shown that when this protein is overexpressed it leads to 
resistance to different chemicals as well as to azole antifungal drugs (Niimi et al, 2004). It 
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may be speculated that in the presence of specific physiological stimuli, the overexpression of 
CDR1 might confer these isolates with resistance against certain antifungal drugs. 
 
Salivary HTN3/histatin-5 –binding proteins, estrogen-binding oxidoreductases and pH 
responsive proteins were also seen in fluconazole-resistant C. albicans isolates. In this group 
a drug-resistance related protein was identified in a Cameroonian cell fraction: multidrug 
efflux transporter protein CDR2, which is responsible for resistance to azole antifungal 
agents, to other antifungals (terbinafine, amorolfine) and to a variety of metabolic inhibitors 
(Sanglard et al, 1997), were found on isolate C73. Although this multidrug efflux protein has 
also been implicated in echinocandin resistance (Schuetzer-Muehlbauer et al, 2003), this was 
not seen in this isolate, which was susceptible to all drug classes except the azoles. Salivary 
HTN3/histatin-5 –binding proteins were also identified in drug-susceptible and -resistant non-
albicans species. 
 
The comparison of SDS-PAGE gels and HPLC-MS analysis yielded some interesting results: 
isolate SA82, a multi-drug resistant C. dubliniensis strain, presented with five different 
proteins related to its pathogenicity and drug resistance: three heat shock proteins that bind to 
HTN3/histatin, a pH-responsive protein and a protein that confers resistance to formaldehyde 
were found in this isolate’s cell fraction. A protein of approximately 40kDa seen on the SDS-
PAGE gel of this and other isolates was consistent with S-(hydroxymethyl) glutathione 
dehydrogenase, the protein found by HPLC that confers resistance to formaldehyde. The 
same 40kDa identified by HPLC-MS that confers resistance to formaldehyde could have been 
described in 2006 in a study employing SDS-PAGE analysis of Candida species (Kustos et 
al), as an unknown protein expressed in the presence of fluconazole. This protein was found 
across different Candida species, both susceptible and resistant to fluconazole. 
 
A 169kDa drug efflux transporter protein has been reported to be expressed by C. glabrata in 
the presence of fluconazole (Niimi et al, 2002). This was not the case in the present study. 
However, proteins with very similar molecular weights (168.9kDa and 169.8kDa) and with 
the same function (multidrug transporter proteins), which confer resistance to cycloheximide 
and to azoles, other drugs and metabolic inhibitors were seen in three C. albicans 
fluconazole-resistant isolates. 
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These results further demonstrate the specificity of HPLC-MS results in elucidating the drug 
resistance mechanisms of Candida species present in these HIV-infected individuals. It was 
noted, however, that the use of SDS-PAGE allowed for the identification of proteins of low 
molecular weight that were not seen in the HPLC-MS analysis. Gel electrophoresis analysis 
allowed for the identification of proteins between 23 kDa and 36kDa that are suspected of 
being related to drug resistance. The proteins of interest seen by liquid chromatography had a 
molecular weight of 40kDa or more. 
 
 
4.10. Summary and Conclusion 
 
Although a single species of Candida was isolated from the majority of samples cultured, two 
patients in this group were colonized by both C. albicans and C. glabrata. This may signal 
the existence of a symbiotic relationship between these two species, within a Candida biofilm 
in the oral mucosa. The increased pathogenicity of C. glabrata when forming part of a 
biofilm has been previously documented (Sereviratne, 2010). 
 
The prevalence and drug susceptibility of Candida species in HIV-positive patients varied 
across these two regions of the African continent (South Africa and Cameroon). Therefore, 
regional surveillance is recommended in different regions of the continent, as this knowledge 
would ultimately lead to better patient care. 
 
In the South African group, a severely immunocompromised patient was seldomly seen. This 
could be attributed to better access to healthcare facilities and modern medications as well as 
the fact that these patients are tracked by healthcare providers. 
 
In HIV-positive patients, C. albicans infections have the best prognosis compared to 
infections caused by non-albicans species. The resistance to fluconazole of these non-albicans 
species plays a very important role in the management of HIV-positive patients. It can 
therefore be speculated that if the patients had not been receiving treatment (which results in 
a CD4+ increase), a higher number of non-albicans invasive (and potentially more resistant) 
species could have been seen in this study’s results. However, studies looking at the 
interaction between fluconazole and tipranavir/ritonavir combination (Vourvahis and 
Kashuba, 2007) and etravirine (Kakuda, Schöller-Gyüre and Hoetelmans, 2011) and the 
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increased plasma half-life of zidovudine when administered with fluconazole (Sahai et al, 
1994) have indicated that certain ARV drugs may interact with azole compounds, rendering 
them less effective (Boehringer Ingelheim Pharmaceuticals, 2008). Similar studies involving 
ARV regimes used in Africa interacting with fluconazole would contribute greatly to our 
understanding of the emerging drug resistance in Africa. 
 
The Candida isolates used in this study were collected either at baseline or while the patient 
was already on ARV treatment. It is estimated that, by December 2008, only 44% of patients 
in Sub-Saharan Africa in need of ARV therapy were taking antiretroviral drugs (WHO, 
2013). This means that the remaining 66% of immunocompromised patients would be more 
susceptible to HIV opportunistic infections, including Candida. 
 
It was noted that a much higher number of females attended the ARV clinics when compared 
to their male counterparts. This could be because of the higher predisposition that females 
have to HIV when compared to males, and/or the presence of HIV/Sexually transmitted 
infections screening programs available to pregnant women in healthcare facilities, which 
would result in more women finding out about their seropositivity. Another important factor 
to consider is the difference in the ARV regimen compliance of males and females, as social 
and cultural factors present in different geographical regions may influence the decision of 
patients to comply with ARV therapy. 
 
 
The use of traditional disk diffusion antifungal drug susceptibility testing using YNBG agar 
produced very similar results to the TREK Sensititre CLSI-approved modern microdilution 
system, and is therefore the susceptibility testing medium of choice. Both these techniques 
can be used in resource-limited laboratories, with the TREK system being the best system 
due to its simplicity and ability to test organisms against different drugs simultaneously. 
 
Programmes on species prevalence and antifungal use and resistance pattern surveillance 
have been successfully developed and introduced in Europe, Asia-Pacific, Latin America and 
North America (Adriaenssens et al, 2010, Cuenca-Estrella et al, 2008, Pfaller et al, 2011). 
The high HIV prevalence and accompanying immunodeficiency in sub-Saharan Africa and 
the presence of different HIV subtypes in the Continent are strong driving factors 
emphasizing the need for regional Candida surveillance programmes. Changes in drug 
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susceptibility over time serve as a reminder for the need to test clinical Candida isolates for 
sensitivity to antifungal drugs in the effort to improve patient care and reduce patient 
morbidity and mortality. The use of the TREK Sensititre platform for drug susceptibility 
testing can be done rapidly and with minimal training and reagents and is therefore a 
promising method for use in resource-limited laboratories in Africa. This type of technology 
should be widely available in public hospitals, as the emergence of drug-resistant species due 
to incorrect empirical treatment is a cause of concern. 
 
Human immunodeficiency virus-infected groups that were found to be the most vulnerable to 
Candida infections included women, who are the most predisposed to Candida in general, 
and patients who were on antiretroviral treatment for longer periods of time, who were more 
predisposed to non-albicans drug resistant isolates. 
 
When comparing drug resistance patterns of Candida in females, strong associations were 
seen between specific Candida species and their susceptibility to azoles and echinocandins 
(high azole resistance patterns were seen in C. albicans isolates and C. krusei, while C. 
glabrata was the most resistant species against the echinocandins). These findings emphasize 
the need for regional surveillance of Candida species, as the different species prevalence seen 
in different geographical regions and their distinct susceptibility to different drug classes 
means that empirical treatment of these patients might not be working effectively in treating 
Candida infections. 
 
 
It is known that Candida species express estrogen-binding proteins, which result in a higher 
predisposition of females to Candida infection (Tarry et al, 2005 and Cheng, Yeater and 
Hoyer, 2006). High performance liquid chromatography-mass spectrometry analysis of cell 
surface fractions obtained from African Candida isolates in this study revealed the presence 
of oxireductase proteins that bind to mammalian estrogen with high affinity. These findings 
further elucidate the predisposition of females to Candida colonization. 
 
 
Drug resistance-related proteins were identified in Candida species using both SDS-PAGE 
and HPLC-MS. The use of gel electrophoresis was found to be a valuable tool in the 
proteomic study of drug resistance in clinical Candida isolates, especially in the identification 
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of low molecular weight proteins. However, its usefulness is surpassed by the more sensitive 
high performance liquid chromatography platform, which provided much more detailed 
results. 
 
The expression of Candida proteins that are related to colonization and pathogenicity 
mechanisms were found in different Candida species, in both drug-susceptible and –resistant 
isolates. The combination of different drug resistance mechanisms and binding abilities to 
salivary histatins and estrogen found in Candida species through HPLC-MS analysis seem to 
be instrumental in the ability of these organisms to colonize immunocompromised patients 
and resist the action of different chemicals and antifungal drugs. 
 
The protein band of 24kDa identified in fluconazole-resistant cell fractions analysed by SDS-
PAGE and the presence of a multidrug resistance protein known to confer resistance to azole 
drugs, which was seen only on a fluconazole-resistant C. albicans cell fraction, demonstrates 
differences in the protein expression of fluconazole-susceptible and –resistant isolates. 
 
 
The results from this study demonstrated a need for regional surveillance of Candida species 
in African countries and improved control over the sale of medications. Results also showed 
that the prevalent Candida albicans does not respond to specific antifungal drugs that might 
be dispensed empirically. Candida glabrata from Cameroon demonstrated resistance to 
micafungin while South African isolates were susceptible, which shows significant regional 
differences. The reverse of this pattern was seen in the case of 5-flucytosine, thereby re-
emphasizing the need for more epidemiological studies on the African continent. 
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Appendix 1A 
 
CONSENT FORM FOR PARTICIPATION IN RESEARCH PROJECT 
 
Title of Project:  Characterization of fluconazole-resistant Candida species from the oral 
cavity of HIV-positive patients in the Western Cape (SA)/ Bamenda (Cameroon). 
 
 Names of Researchers: Pedro Santos Abrantes, Prof P Bouic, Prof Charlene WJ Africa 
 
If you would like to participate in this study please tick the relevant boxes: 
 
1.  Have you read the attached information sheet and has the purpose of   the research project 
been explained to you?       
  
2. Do you understand the method of sample collection and any risks 
involved?   
3. Do you grant permission for information from your medical records to be 
disclosed to the research team as and when necessary?    
 
4. Do you agree that samples collected for research or diagnostic testing can be stored 
for possible use in  future research projects conducted by the above named researchers and 
/or other research collaborators?  
 
I declare that my participation in this research project is voluntary and that I am free to 
withdraw my approval for use of the sample(s) at any time without giving a reason and 
without my medical treatment or legal rights being affected. I understand that any 
information contained in my file will remain confidential and that I (or my doctor) will be 
informed if any of the results of the medical tests done (as part of the research) have 
implications for my health.  I know how to contact members of the research team should I 
change my mind about participating in this study. 
 
………………………………. …………………. ……………………………. 
Name of patient    Date    Signature 
(BLOCK CAPITALS) 
 
………………………………….  …………………… ……………………. 
Name of person taking consent  Date    Signature 
 
…………………………………  …………………… ……………………. 
Name of researcher   Date    Signature 
 
THANK YOU FOR AGREEING TO PARTICIPATE IN THIS 
RESEARCH  
 
YES NO 
YES NO 
NO YES 
NO YES 
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Appendix 1B 
INFORMATION SHEET 
 
Prospective participants are requested to read this information sheet carefully and to 
ask questions where necessary, before signing the attached consent form. This sheet 
must be detached and retained by the participant and the consent form filed for record.   
  
Candida is a yeast found as part of the normal flora of the gut and mouth of some individuals.  
Normally, it does not cause a problem but in the case of persons infected with HIV, it may 
cause infection, particularly in the oral cavity. Most patients respond to treatment with 
fluconazole, but cases showing no improvement following treatment with fluconazole have 
been reported.  This study will improve our knowledge of why this resistance happens. 
 
The clinical procedure will entail the collection of samples from the mouth using cotton 
swabs. The sample collection procedure is non-invasive and safe and will be carried out with 
the utmost care to ensure the comfort of the patient. 
 
Patients will be required to sign the attached form granting consent for the collection of swab 
samples and for the use of the samples donated and clinical parameters recorded.  The patient 
will also be required to grant permission for his/her HIV status and other medical history to 
be disclosed if necessary. Participants will not be recorded by name, but samples and 
information will be coded to protect the identity of the individual. However, the coding will 
be used by the clinic to trace the individual if relevant information (as a result of the study) 
should be passed to him/her or his/her doctor. Permission will also be sought for the use of 
additional biological material collected in the clinic, which is usually discarded but which the 
researchers may find useful for future research. 
 
Participation in this study is voluntary and refusal to participate will not prejudice the 
treatment of the patient in any way. Consent to participate will be recorded by completing the 
attached form. Should individuals agree to participate and later change their minds, they may 
withdraw by calling the following persons: 
Prof C. Africa, University of the Western Cape, Department of Medical Biosciences, Tel: 021 
9592342, or Prof  P Bouic, Synexa, University of Stellenbosch, Tel: 021 9339582. 
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Appendix 2 
 
University of the Western Cape 
 
Department of Medical Biosciences 
 
Patient Questionnaire 
 
 
Gender   M  F 
 
Partner’s gender  M  F 
 
Age: 
 
Race    Black  Coloured White  Other 
 
HIV sub-type   HIV-1  HIV-2 
 
Date diagnosed: 
 
Immune status  HIV +ve AIDS 
 
ARV    Yes (specify)  No 
 
Duration of ARV therapy: 
 
Clinical presentation: 
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Appendix 3 
Tables 1 and 2 show the colony growth patterns of all Candida species 24 hours after sample 
collection and incubation (1=scanty growth, 2=light growth, 3=moderate growth, 4=heavy 
growth). 
 
Table 1: Growth patterns of the first inoculation of all South African Candida samples. 
Patient No. Growth pattern Patient No. Growth pattern Patient No. Growth pattern 
3 2 72 2 135 1 
7 3 73 1 136 1 
10 2 77 1 138 2 
11 3 78 2 141 1 
12 3 80 1 142 2 
13 2 81 1 144 2 
14 2 82 2 145 1 
16 3 83 2 146 2 
19 2 85 2 147 2 
21 1 88 4 154 2 
23 3 89 1 155 1 
24 1 90 3 156 1 
25 3 92 2 159 1 
26 2 93 1 161 2 
27 2 94 1 163 1 
28 2 95 1 167 2 
30 2 96 1 168 1 
36 2 97 2 169 1 
37 1 99 1 174 1 
38 2 100 1 175 1 
40 3 101 1 176 1 
41 2 102 2 180 1 
42 1 103 1 181 1 
44 3 105 2 182 1 
46 2 107 2 183 1 
47 2 109 3 184 1 
48 2 110 2 185 2 
50 1 111 2 186 1 
51 1 112 2 188 2 
57 2 115 1 191 1 
58 1 116 1 192 1 
59 2 117 2 194 1 
60 2 118 1 195 1 
61 2 119 1 196 2 
62 1 120 2 197 1 
65 1 122 1 198 1 
66 2 123 1 199 2 
67 2 126 1 201 1 
68 3 127 2 203 1 
69 3 131 1 205 1 
70 3 132 2 206 2 
71 3 134 4 207 1 
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Table 2: Growth patterns of the first inoculation of all Cameroonian Candida samples. 
Patient No. Growth pattern Patient No. Growth pattern Patient No. Growth pattern 
7 2 85 4 180 1 
10 1 88 3 181 2 
11 1 90 1 182 1 
12 2 92 1 183 3 
13 2 93 1 184 1 
14 1 98 1 186 1 
15 1 99 1 196 1 
17 1 100 1 197 1 
19 1 103 2 198 2 
21 1 106 1 199 1 
24 1 108 1 200 1 
26 1 109 1 201 1 
28 1 111 1 202 1 
32 4 114 3 206 2 
33 1 115 1 207 1 
35 2 116 1 216 1 
36 2 117 1 219 1 
39 1 118 1 220 1 
40 3 119 1 221 2 
41 2 121 3 222 1 
42 2 124 1 226 1 
44 1 127 1 228 1 
48 1 132 1 229 3 
50 1 134 1 233 2 
51 1 135 1 234 1 
55 1 136 2 236 1 
56 1 137 2 237 1 
59 1 141 1 238 1 
60 1 143 1 241 1 
64 2 144 1 244 2 
69 1 146 2 245 2 
70 3 148 1 246 1 
72 1 154 1 247 1 
73 1 156 1 248 1 
74 2 158 1 249 1 
76 1 159 1 250 1 
79 1 164 1 253 3 
80 2 172 1 255 1 
81 2 174 1 256 1 
82 1 175 1 257 1 
83 2 177 1 258 1 
84 1 178 1 260 3 
 261 1 
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Appendix 4 
 
Tables 3 and 4 show the results obtained using Sabouraud’s agar, which allows for Candida 
growth, chromogenic agar which differentiates different Candida species and the tomato 
juice agar, which allows for C. albicans and C. dubliniensis differentiation. 
 
Table 3: South African results obtained from the different selective media. 
Patient no. Sabouraud's agar Chromogenic agar Tomato juice agar 
3 Candida C. albicans C. albicans 
7 Candida C. dubliniensis C. dubliniensis 
10 Candida C. albicans C. albicans 
11 Candida C. glabrata  
12 Candida C. albicans C. albicans 
13 Candida C. albicans C. albicans 
14 Candida C. albicans C. albicans 
16 Candida C. albicans C. albicans 
19 Candida C.albicans C.albicans 
21 Candida C. albicans C. albicans 
23 Candida C. albicans C. albicans 
24 Candida C. albicans C. albicans 
25 Candida C. albicans C. albicans 
26 Candida C. albicans C. albicans 
27 Candida C. albicans C. albicans 
28 Candida C. albicans C. albicans 
30 Candida C. albicans C. albicans 
36 Candida 
C. albicans and C. 
glabrata C. albicans 
37 Candida C. albicans C. albicans 
38 Candida C. albicans C. albicans 
40 Candida C. albicans C. albicans 
41 Candida C. albicans C. albicans 
42 Candida C. albicans C. albicans 
44 Candida C. albicans C. albicans 
46 Candida C. albicans C. albicans 
47 Candida C. albicans C. albicans 
48 Candida C. albicans C. albicans 
50 Candida C. albicans C. albicans 
51 Candida C. dubliniensis C. dubliniensis 
57 Candida C. albicans C. albicans 
58 Candida C. albicans C. albicans 
59 Candida C. dubliniensis C. dubliniensis 
60 Candida C. albicans C. albicans 
61 Candida C. albicans C. albicans 
62 Candida C. albicans C. albicans 
65 Candida C. albicans C. albicans 
66 Candida C. albicans C. albicans 
67 Candida C. albicans C. albicans 
68 Candida C. albicans C. albicans 
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69 Candida C. albicans C. albicans 
70 Candida C. albicans C. albicans 
71 Candida C. albicans C. albicans 
72 Candida C. glabrata  
73 Candida C. albicans C. albicans 
77 Candida C. glabrata  
78 Candida C. albicans C. albicans 
80 Candida C. albicans C. albicans 
81 Candida C. glabrata  
82 Candida C. dubliniensis C. dubliniensis 
83 Candida C. albicans C. albicans 
85 Candida C. albicans C. albicans 
88 Candida C. albicans C. albicans 
89 Candida C. albicans C. albicans 
90 Candida C. albicans C. albicans 
92 Candida C. glabrata  
93 Candida C. albicans C. albicans 
94 Candida C. albicans C. albicans 
95 Candida C. albicans C. albicans 
96 Candida C. albicans C. albicans 
97 Candida C. albicans C. albicans 
99 Candida C. albicans C. albicans 
100 Candida C. albicans C. albicans 
101 Candida C. albicans C. albicans 
102 Candida C. albicans C. albicans 
103 Candida C. albicans C. albicans 
105 Candida C. dubliniensis C. dubliniensis 
107 Candida C. glabrata  
109 Candida C. albicans C. albicans 
110 Candida C. albicans C. albicans 
111 Candida C. albicans C. albicans 
112 Candida C. albicans C. albicans 
115 Candida C. albicans C. albicans 
116 Candida C. albicans C. albicans 
117 Candida C. albicans C. albicans 
118 Candida C. glabrata  
119 Candida C. albicans C. albicans 
120 Candida C. albicans C. albicans 
122 Candida C. albicans C. albicans 
123 Candida C. albicans C. albicans 
126 Candida C. albicans C. albicans 
127 Candida C. albicans C. albicans 
131 Candida C. albicans C. albicans 
132 Candida C. albicans C. albicans 
134 Candida C. albicans C. albicans 
135 Candida C. albicans C. albicans 
136 Candida C. dubliniensis C. dubliniensis 
138 Candida C. dubliniensis C. dubliniensis 
141 Candida C. albicans C. albicans 
142 Candida C. albicans C. albicans 
144 Candida C. glabrata  
145 Candida C. albicans C. albicans 
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146 Candida C. albicans C. albicans 
147 Candida C. glabrata  
154 Candida C. dubliniensis C. dubliniensis 
155 Candida C. albicans C. albicans 
156 Candida C. albicans C. albicans 
159 Candida C. albicans C. albicans 
161 Candida C. albicans C. albicans 
163 Candida C. albicans C. albicans 
167 Candida C. albicans C. albicans 
168 Candida C. albicans C. albicans 
169 Candida C. albicans C. albicans 
174 Candida C. albicans C. albicans 
175 Candida C. albicans C. albicans 
176 Candida C. albicans C. albicans 
180 Candida C. albicans C. albicans 
181 Candida C. albicans C. albicans 
182 Candida C. albicans C. albicans 
183 Candida C. albicans C. albicans 
184 Candida C. dubliniensis C. dubliniensis 
185 Candida C. albicans C. albicans 
186 Candida C. albicans C. albicans 
188 Candida C. albicans C. albicans 
191 Candida C. albicans C. albicans 
192 Candida C. albicans C. albicans 
194 Candida C. albicans C. albicans 
195 Candida C. albicans C. albicans 
196 Candida C. glabrata  
197 Candida C. albicans C. albicans 
198 Candida C. albicans C. albicans 
199 Candida C. albicans C. albicans 
201 Candida C. albicans C. albicans 
203 Candida 
C. albicans and C. 
glabrata C. albicans 
205 Candida C. albicans C. albicans 
206 Candida C. albicans C. albicans 
207 Candida C. dubliniensis C. dubliniensis 
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Table 4: Cameroonian results obtained from the different selective media. 
Patient No. Sabouraud agar Chromogenic agar Tomato juice agar 
7 Candida Candida albicans Candida albicans 
10 Candida Candida albicans Candida albicans 
11 Candida Candida albicans Candida albicans 
12 Candida Candida albicans Candida albicans 
13 Candida Candida albicans Candida albicans 
14 Candida Candida albicans Candida albicans 
15 Candida Candida albicans Candida albicans 
17 Candida Candida 
kefyr/parapsilopsis/lusitaneae 
 
19 Candida Candida glabrata  
21 Candida Candida 
kefyr/parapsilopsis/lusitaneae 
 
24 Candida Candida albicans Candida albicans 
26 Candida Candida albicans Candida albicans 
28 Candida Candida albicans Candida albicans 
32 Candida Candida albicans Candida albicans 
33 Candida Candida albicans Candida albicans 
35 Candida Candida albicans Candida albicans 
36 Candida Candida albicans Candida albicans 
39 Candida Candida glabrata  
40 Candida Candida albicans Candida albicans 
41 Candida Candida albicans Candida albicans 
42 Candida Candida albicans Candida albicans 
44 Candida Candida glabrata  
48 Candida Candida albicans Candida albicans 
50 Candida Candida albicans Candida albicans 
51 Candida Candida albicans Candida albicans 
55 Candida Candida albicans Candida albicans 
56 Candida Candida albicans Candida albicans 
59 Candida Candida albicans Candida albicans 
60 Candida Candida albicans Candida albicans 
64 Candida Candida albicans Candida albicans 
69 Candida Candida albicans Candida albicans 
70 Candida Candida albicans Candida albicans 
72 Candida Candida albicans Candida albicans 
73 Candida Candida albicans Candida albicans 
74 Candida Candida albicans Candida albicans 
76 Candida Candida glabrata  
79 Candida Candida albicans Candida albicans 
80 Candida Candida albicans Candida albicans 
81 Candida Candida albicans Candida albicans 
82 Candida Candida albicans Candida albicans 
83 Candida Candida albicans Candida albicans 
84 Candida Candida albicans Candida albicans 
85 Candida Candida tropicalis  
88 Candida Candida albicans Candida albicans 
90 Candida Candida albicans Candida albicans 
92 Candida Candida glabrata  
93 Candida Candida glabrata  
98 Candida Candida albicans Candida albicans 
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99 Candida Candida albicans Candida albicans 
100 Candida Candida albicans Candida albicans 
103 Candida Candida albicans Candida albicans 
106 Candida Candida albicans Candida albicans 
108 Candida Candida glabrata  
109 Candida Candida glabrata  
111 Candida Candida albicans Candida albicans 
114 Candida Candida albicans Candida albicans 
115 Candida Candida albicans Candida albicans 
116 Candida Candida glabrata  
117 Candida Candida albicans Candida albicans 
118 Candida Candida albicans Candida albicans 
119 Candida Candida albicans Candida albicans 
121 Candida Candida albicans Candida albicans 
124 Candida Candida glabrata  
127 Candida Candida albicans Candida albicans 
132 Candida Candida albicans Candida albicans 
134 Candida Candida albicans Candida albicans 
135 Candida Candida albicans Candida albicans 
136 Candida Candida dubliniensis Candida dubliniensis 
137 Candida Candida albicans Candida albicans 
141 Candida Candida tropicalis  
143 Candida Candida albicans Candida albicans 
144 Candida Candida krusei  
146 Candida Candida albicans Candida albicans 
148 Candida Candida glabrata  
154 Candida Candida albicans Candida albicans 
156 Candida Candida glabrata  
158 Candida Candida albicans Candida albicans 
159 Candida Candida glabrata  
164 Candida Candida albicans Candida albicans 
172 Candida Candida krusei  
174 Candida Candida krusei  
175 Candida Candida albicans Candida albicans 
177 Candida Candida albicans Candida albicans 
178 Candida Candida glabrata  
180 Candida Candida albicans Candida albicans 
181 Candida Candida albicans Candida albicans 
182 Candida Candida albicans Candida albicans 
183 Candida Candida albicans Candida albicans 
184 Candida Candida albicans with 
pseudohyphae 
Candida albicans with 
pseudohyphae 
186 Candida Candida glabrata  
196 Candida Candida glabrata  
197 Candida Candida albicans Candida albicans 
198 Candida Candida albicans Candida albicans 
199 Candida Candida albicans Candida albicans 
200 Candida Candida glabrata  
201 Candida Candida albicans Candida albicans 
202 Candida Candida albicans Candida albicans 
206 Candida Candida albicans with 
pseudohyphae 
Candida albicans with 
pseudohyphae 
207 Candida Candida albicans Candida albicans 
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216 Candida Candida glabrata  
219 Candida Candida glabrata  
220 Candida Candida glabrata  
221 Candida Candida albicans Candida albicans 
222 Candida Candida albicans Candida albicans 
226 Candida Candida albicans with 
pseudohyphae 
Candida albicans with 
pseudohyphae 
228 Candida Candida glabrata  
229 Candida Candida albicans Candida albicans 
233 Candida Candida albicans Candida albicans 
234 Candida Candida glabrata Candida glabrata 
236 Candida Candida albicans Candida albicans 
237 Candida Candida glabrata  
238 Candida Candida albicans with 
pseudohyphae 
Candida albicans with 
pseudohyphae 
241 Candida Candida albicans Candida albicans 
244 Candida Candida albicans Candida albicans 
245 Candida Candida tropicalis  
246 Candida Candida glabrata  
247 Candida Candida albicans Candida albicans 
248 Candida Candida albicans Candida albicans 
249 Candida Candida albicans Candida albicans 
250 Candida Candida tropicalis  
253 Candida Candida albicans Candida albicans 
255 Candida Candida albicans Candida albicans 
256 Candida Candida albicans Candida albicans 
257 Candida Candida albicans Candida albicans 
258 Candida Candida krusei  
260 Candida Candida albicans Candida albicans 
261 Candida Candida albicans Candida albicans 
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Appendix 5 
 
Table 5 shows the cumulative results obtained from all South African patients. Data from the 
questionnaire and patient’s folder are included, as well as the results obtained by the different 
culturing methods. 
 
Table 5: Cumulative results from all HIV+ South African patients. 
Patient 
No. Gender 
Partner's 
gender Age Race 
Date 
diagnosed 
HIV 
status ARVs Duration 
Clinical 
presentation Other Results 
1 Male Female 29 Black Sep-05 HIV +ve 
d4T, 
EFV, 
3TC 
10 
months NAD  Negative 
2 Female Male 31 Black Aug-05 HIV +ve 
d4T, 
EFV, 
3TC 
11 
months NAD TB patient Negative 
3 Female Male 30 Black 2003 HIV +ve 
AZT, 
NVP, 
3TC 3 years NAD 
8 months 
pregnant C. albicans 
4 Female Male ? Black 2000 HIV +ve d4T, 3TC 2 months NAD NVP->rash->d4T Negative 
5 Male Female 27 Black Jan-06 HIV +ve NO  NAD  Negative 
6 Male Female 33 Black Jun-05 HIV +ve d4T, 3TC 2 weeks 
White plaque 
on mucosa 
and side of 
tongue CD4+: 97 Negative 
7 Female Male 24 Black Jun-03 HIV +ve 
d4T, 
NVP, 
3TC 7 months NAD  
C. 
dubliniensis 
8 Female Male 37 Black Sep-05 HIV +ve 
AZT, 
EFV, 
3TC 9 months NAD  Negative 
9 Female Male 42 Black 2005 HIV +ve 
AZT, 
NVP, 
3TC 1 year NAD 
Diagnosed when 
pregnant Negative 
10 Female Male 26 Black May-05 HIV +ve 
AZT, 
NVP, 
3TC 
14 
months NAD  C. albicans 
11 Male Female 49 Black Sep-04 HIV +ve 
d4T, 
EFV, 
3TC 2 years NAD  C. glabrata 
12 Female Male 31 Black Nov-02 HIV +ve NO  
White plaque 
in tongue TB patient C. albicans 
13 Female Male 19 Black Mar-05 HIV +ve NO  NAD  C. albicans 
14 Female Male 28 Black May-03 HIV +ve 
d4T, 
NVP, 
3TC 
16 
months NAD  C. albicans 
15 Male Female 38 Black 2003 HIV +ve 
d4T, 
EFV, 
3TC 2 years NAD  Negative 
16 Female Male 29 Black Nov-02 HIV +ve 
AZT, 
NVP, 
3TC 2 years NAD  C. albicans 
17 Female Male 35 Black Nov-04 HIV +ve 
d4T, 
EFV, 
3TC 
19 
months NAD  Negative 
18 Female Male 44 Black Mar-02 HIV +ve 
d4T, 
NVP, 
3TC 
14 
months NAD  Negative 
19 Male Female 53 Coloured 2006 AIDS 
d4T,NVP, 
3TC 1 month 
Candida in 
tongue  C.albicans 
20 Male Female 39 Black 2002 HIV +ve NO  NAD CD4+: 47 Negative 
21 Female Male 35 Black ? HIV +ve 
d4T, 
EFV, 
3TC 
24 
months 
White plaque 
in tongue  C. albicans 
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22 Female Male 24 Black Jul-08 HIV +ve 
AZT, 
NVP, 
3TC 2 weeks NAD 
CD4+: 144, 6 
months 
pregnant, STI Negative 
23 Female Male 24 Black 2002 AIDS 
d4T, 
EFV, 
3TC 1 month 
White plaque 
in tongue  C. albicans 
24 Female Male 29 Black Sep-08 HIV +ve NO  NAD 
CD4+: 79, 19 
weeks pregnant C. albicans 
25 Male Female 37 Black 2005 HIV +ve NO  
White plaque 
in tongue  C. albicans 
26 Female Male 25 Black Jun-08 HIV +ve NO   1 week old child C. albicans 
27 Male Female 34 Black Aug-08 AIDS NO  
Oropharyngeal 
thrush 
Patient took 
fluconazole C. albicans 
28 Female Male 28 Black 2007 AIDS 
d4T, 
EFV, 
3TC 2 weeks 
Candida in 
tongue  C. albicans 
29 Male Female 38 Black Mar-06 HIV +ve 
d4T, 
EFV, 
3TC 
29 
months 
White plaque 
in tongue  Negative 
30 Female Male 28 Black 2006 AIDS 
d4T, 
EFV, 
3TC 
22 
months 
White plaque 
in tongue TB patient C. albicans 
31 Male Female 25 Black Jul-08 HIV +ve NO  
White plaque 
in tongue  Negative 
32 Male Female 24 Black 2007 HIV +ve 
d4T, 
EFV, 
3TC 
16 
months 
White plaque 
in tongue  Negative 
33 Female Male 34 Black Dec-03 HIV +ve 
d4T, 
EFV, 
3TC 
24 
months NAD  Negative 
34 Female Male 30 Black 2002 HIV +ve 
d4T, 
NVP, 
3TC 
22 
months NAD  Negative 
35 Female Male 36 Black Aug-08 AIDS 
d4T, 
EFV, 
3TC 
Starting 
Oct-2008 NAD 
CD4+: 64, TB 
patient, Rash, 
Headaches Negative 
36 Female Male 38 Coloured Sep-08 HIV +ve NO  NAD  
C. albicans 
and C. 
glabrata 
37 Female Male 43 Black 2008 AIDS 
d4T, 
EFV, 
3TC 8 months NAD TB patient C. albicans 
38 Male Female 39 Black Sep-08 HIV +ve NO  
White plaque 
in tongue  C. albicans 
39 Female Male 22 Black May-08 HIV +ve 
AZT, 
NVP, 
3TC 2 months NAD 
31 weeks 
pregnant Negative 
40 Female Male 38 Black 2005 AIDS NO 
Starting 
Oct-2008 NAD 
CD4+: 34, TB 
patient C. albicans 
41 Male Female 36 Coloured Aug-08 AIDS NO  
White plaque 
in tongue  C. albicans 
42 Female Male 39 Black 2001 AIDS 
d4T, 
EFV, 
3TC 
24 
months 
White plaque 
in tongue  C. albicans 
43 Female Male 34 Black 2000 HIV +ve 
d4T, 
EFV, 
3TC 
26 
months 
White plaque 
in tongue  Negative 
44 Male Female 43 White Sep-08 AIDS NO  
Candida lesion 
in lower lip, Tb 
patient  C. albicans 
45 Female Male 32 Black 2004 HIV +ve 
AZT, 
NVP, 
3TC 3 months NAD 
30 weeks 
pregnant Negative 
46 Male Female 35 Black 2008 HIV +ve NO  
White plaque 
in tongue  C. albicans 
47 Female Male 22 Coloured 2006 HIV +ve 
d4T, 
EFV, 
3TC 1 month 
White plaque 
in tongue 
ARV treatment 
defaulted in 
2007 C. albicans 
48 Female Male 30 Black 2002 AIDS 
d4T, 
NVP, 
3TC 
12 
months NAD  C. albicans 
49 Female Male 30 Black 2005 AIDS 
AZT, 
DDI, KLT 
41 
months NAD 
TB patient, ARV 
regimen 2 Negative 
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50 Male Female 34 Black 2003 HIV +ve 
d4T, 
EFV, 
3TC 1 month 
White plaque 
in tongue  C. albicans 
51 Female Male 33 Black 2006 HIV +ve 
d4T, 
EFV, 
3TC 
23 
months 
White plaque 
in tongue  
C. 
dubliniensis 
52 Female Male 34 Black 2003 HIV +ve 
d4T, 
NVP, 
3TC 
20 
months 
White plaque 
in tongue  Negative 
53 Female Male 50 Black ? HIV +ve 
d4T, 
EFV, 
3TC 
15 
months 
White plaque 
in tongue  Negative 
54 Female Male 51 Black 2008 HIV +ve 
d4T, 
EFV, 
3TC 
28 
months 
White plaque 
in tongue  Negative 
55 Female Male 27 Black 2006 HIV +ve 
d4T, 
EFV, 
3TC 
22 
months 
White plaque 
in tongue  Negative 
56 Female Male 27 Coloured 2007 HIV +ve 
d4T, 
NVP, 
3TC 
12 
months 
White plaque 
in tongue  Negative 
57 Female Male 46 Black Jul-08 AIDS NO  
Oral 
candidiasis in 
tongue 
Amphotericin B 
lozenges taken 
days before 
sample 
collection C. albicans 
58 Female Male 44 Coloured 2007 HIV +ve NO  
White plaque 
in tongue  C. albicans 
59 Male Female 39 Black 2007 HIV +ve 
d4T, 
EFV, 
3TC 
13 
months NAD  
C. 
dubliniensis 
60 Male Female 43 Black Jun-08 HIV +ve 
d4T, 
EFV, 
3TC 1 month 
White plaque 
in tongue  C. albicans 
61 Male Female 36 Black May-08 HIV +ve 
d4T, 
NVP, 
3TC 2 months 
White plaque 
in tongue  C. albicans 
62 Male Female 45 Black Mar-07 AIDS 
d4T, 
EFV, 
3TC 
12 
months 
Systemic 
fungal 
infection  C. albicans 
63 Female Male 31 Black 2005 HIV +ve 
d4T, 
EFV, 
3TC 
25 
months NAD  Negative 
64 Female Male 37 Black 2005 HIV +ve 
d4T, 
NVP, 
3TC 
18 
months 
White plaque 
in tongue  Negative 
65 Male Female 40 Black 2007 HIV +ve 
d4T, 
EFV, 
3TC 
19 
months 
White plaque 
in tongue  C. albicans 
66 Female Male 33 Black 2001 HIV +ve NO  
White plaque 
in tongue  C. albicans 
67 Female Male 29 Black Sep-08 AIDS NO  
White plaque 
in tongue TB patient C. albicans 
68 Female Male 31 Black Sep-08 AIDS NO  
White plaque 
in tongue TB patient C. albicans 
69 Female Male 23 Black Jul-08 HIV +ve NO  
White plaque 
in tongue 
5 months 
pregnant C. albicans 
70 Female Male 25 Black 2006 AIDS NO 
Starting 
Oct-2008 
Oral 
candidiasis 
Fluconazole 
prescribed for 2 
weeks, TB 
patient C. albicans 
71 Female Male 30 Black Apr-08 AIDS NO  
White plaque 
in tongue CD4+: 122 C. albicans 
72 Female Male 25 Black Dec-07 AIDS 
AZT, 
NVP, 
3TC 8 months 
White plaque 
in tongue  C. glabrata 
73 Female Male 28 Black Oct-07 HIV +ve 
d4T, 
EFV, 
3TC 
12 
months 
White plaque 
in tongue  C. albicans 
74 Female Male 46 Black 2003 HIV +ve NO  
White plaque 
in tongue  Negative 
75 Female Male 34 Black 2004 HIV +ve 
d4T, 
NVP, 
3TC 
35 
months 
White plaque 
in tongue  Negative 
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76 Female Male 30 Black 2002 HIV +ve 
AZT, 
NVP, 
3TC 
47 
months 
White plaque 
in tongue  Negative 
77 Female Male 29 Black 2007 HIV +ve 
d4T, 
EFV, 
3TC 7 months 
White plaque 
in tongue  C. glabrata 
78 Male Female 44 Black Aug-08 AIDS NO 
Starting 
Oct-2008 
Oral 
candidiasis  C. albicans 
79 Male Female 38 Black 2004 HIV +ve 
d4T, 
EFV, 
3TC 
46 
months 
White plaque 
in tongue  Negative 
80 Female Male 24 Black Apr-07 HIV +ve 
d4T, 
NVP, 
3TC 
19 
months 
White plaque 
in tongue  C. albicans 
81 Female Male 35 Black May-07 HIV +ve 
d4T, 
NVP, 
3TC 5 months 
White plaque 
in tongue  C. glabrata 
82 Female Male 36 Black 2004 HIV +ve NO 
Starting 
Oct-2008 
White plaque 
in tongue  
C. 
dubliniensis 
83 Female Male 50 Coloured 2007 AIDS NO  
White plaque 
in tongue  C. albicans  
84 Female Male 40 Black May-07 HIV +ve 
d4T, 
EFV, 
3TC 
12 
months 
White plaque 
in tongue  Negative 
85 Female Male 30 Black Mar-07 HIV +ve 
d4T, 
EFV, 
3TC 
12 
months 
White plaque 
in tongue  C. albicans 
86 Female Male 33 Black 2007 HIV +ve 
d4T, 
EFV, 
3TC 7 months 
White plaque 
in tongue  Negative 
87 Male Female 48 Black Mar-08 AIDS 
d4T, 
NVP, 
3TC 6 months 
White plaque 
in tongue TB patient Negative 
88 Male Female 36 Black Sep-08 AIDS NO  
Oral 
candidiasis TB patient C. albicans 
89 Female Male 30 Black Mar-08 HIV +ve 
d4T, 
EFV, 
3TC 
18 
months 
White plaque 
in tongue  C. albicans 
90 Female Male 38 Black 2001 HIV +ve 
d4T, 
NVP, 
3TC 
48 
months 
White plaque 
in tongue  C. albicans 
91 Male Female 50 Coloured 2007 HIV +ve 
d4T, 
NVP, 
3TC 
14 
months 
White plaque 
in tongue  Negative 
92 Female Male 31 Black 2007 HIV +ve 
d4T, 
NVP, 
3TC 
18 
months 
White plaque 
in tongue  C. glabrata 
93 Female Male 40 Black 2005 HIV +ve 
d4T, 
NVP, 
3TC 9 months 
White plaque 
in tongue  C. albicans 
94 Female Male 42 Black 2007 HIV +ve 
d4T, 
EFV, 
3TC 4 months 
White plaque 
in tongue  C. albicans  
95 Female Male 38 Black 2006 HIV +ve 
AZT, 
KLT, 3TC 
34 
months 
White plaque 
in tongue  C. albicans 
96 Female Male 50 Black Oct-07 HIV +ve NO  
White plaque 
in tongue  C. albicans  
97 Male Female 49 Black 2006 AIDS NO 
Starting 
Oct-2008 
White plaque 
in tongue CD4+: 9 C. albicans 
98 Female Male 34 Black 2002 HIV +ve 
d4T, 
NVP, 
3TC 2 weeks 
White plaque 
in tongue  Negative 
99 Male Female 35 Black 2006 HIV +ve 
d4T, 
NVP, 
3TC 
12 
months 
White plaque 
in tongue  C. albicans 
100 Female Male 38 Black 2007 HIV +ve 
d4T, 
EFV, 
3TC 
10 
months 
White plaque 
in tongue  C. albicans 
101 Female Male 31 Black 2002 HIV +ve NO  
White plaque 
in tongue  C. albicans 
102 Male Female 53 Indian 1997 AIDS 
d4T, 
NVP, 
3TC 
11 
months 
Oral 
candidiasis  C. albicans  
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103 Male Female 45 Black 2002 AIDS 
d4T, 
EFV, 
3TC 
56 
months 
White plaque 
in tongue  C. albicans 
104 Male Female 42 Coloured 2005 HIV +ve 
d4T, 
NVP, 
3TC 
24 
months 
White plaque 
in tongue  Negative 
105 Female Male 25 Black 2006 HIV +ve 
AZT, 
DDI, KLT 
20 
months 
White plaque 
in tongue   
C. 
dubliniensis 
106 Female Male 32 Black Jul-07 HIV +ve 
d4T, 
NVP, 
3TC 
12 
months 
White plaque 
in tongue  Negative 
107 Female Male 33 Black 2002 HIV +ve 
d4T, 
NVP, 
3TC 4 months 
White plaque 
in tongue  C. glabrata 
108 Female Male 36 Black 2005 HIV +ve 
AZT, 
DDI, KLT 
35 
months 
White plaque 
in tongue  Negative 
109 Male Female 28 Black Apr-08 AIDS 
d4T, 
EFV, 
3TC 6 months 
Oral 
candidiasis TB patient C. albicans 
110 Female Male 36 Black 2003 HIV +ve 
AZT, 
NVP, 
3TC 
35 
months 
White plaque 
in tongue 1 week old child C. albicans 
111 Male Female 45 Black Apr-08 AIDS 
d4T, 
NVP, 
3TC 4 months 
White plaque 
in tongue TB patient C. albicans 
112 Male Female 31 Black Sep-07 AIDS 
d4T, 
EFV, 
3TC 2 months 
White plaque 
in tongue TB patient C. albicans 
113 Female Male 37 Black Jan-07 HIV +ve 
AZT, 
EFV, 
3TC 
18 
months 
White plaque 
in tongue  Negative 
114 Female Male 31 Black 2005 HIV +ve 
d4T, 
EFV, 
3TC 
33 
months 
White plaque 
in tongue  Negative 
115 Female Male 43 Black Oct-08 HIV +ve NO  
White plaque 
in tongue 
12 weeks 
pregnant C. albicans 
116 Female Male 32 Black 2005 HIV +ve 
d4T, 
EFV, 
3TC 
28 
months 
White plaque 
in tongue  C. albicans  
117 Female Male 64 Black Oct-08 AIDS NO  
White plaque 
in tongue TB patient C. albicans 
118 Female Male 31 Black 2002 HIV +ve 
AZT, 
EFV, 
3TC 
44 
months 
White plaque 
in tongue  C. glabrata 
119 Female Male 35 Black Oct-07 HIV +ve 
d4T, 
NVP, 
3TC 8 months 
White plaque 
in tongue  C. albicans 
120 Female Male 22 Black Jul-08 AIDS NO 
Starting 
Oct-2008 
Oral 
candidiasis  C. albicans  
121 Female Male 37 Black Jan-08 HIV +ve 
d4T, 
EFV, 
3TC 8 months 
White plaque 
in tongue  Negative 
122 Female Male 34 Black Jun-08 HIV +ve 
d4T, 
EFV, 
3TC 2 months 
White plaque 
in tongue  C. albicans  
123 Male Female 39 Black Apr-08 HIV +ve 
d4T, 
NVP, 
3TC 5 months 
White plaque 
in tongue  C. albicans 
124 Female Male 24 Black Jul-08 HIV +ve 
d4T, 
NVP, 
3TC 1 month 
White plaque 
in tongue  Negative 
125 Male Female 42 Black 1997 HIV +ve 
d4T, 
EFV, 
3TC 
33 
months 
White plaque 
in tongue  Negative 
126 Female Male 30 Black Sep-07 HIV +ve 
d4T, 
NVP, 
3TC 
11 
months 
White plaque 
in tongue  C. albicans  
127 Female Male 24 Black 2006 AIDS NO 
Starting 
Oct-2008 
White plaque 
in tongue  C. albicans  
128 Female Male 27 Black Aug-08 HIV +ve NO 
Starting 
Oct-2008 
White plaque 
in tongue 
19 weeks 
pregnant Negative 
129 Female Male 28 Black 2005 HIV +ve 
AZT, 
NVP, 
3TC 3 weeks 
White plaque 
in tongue  Negative 
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130 Male Female 43 Coloured 2005 HIV +ve NO 
Defaulted 
2005-
2007 
White plaque 
in tongue  Negative 
131 Female Male 35 Black 2002 HIV +ve 
d4T, 
EFV, 
3TC 6 months 
White plaque 
in tongue  C. albicans 
132 Female Male 32 Black 2003 HIV +ve NO 
Starting 
Oct-2008 
White plaque 
in tongue  C. albicans 
133 Male Female 32 Coloured Oct-04 AIDS NO 
Starting 
Oct-2008 
White plaque 
in tongue  Negative 
134 Male Female 38 Black Aug-08 AIDS NO  
Extensive oral 
candidiasis  C. albicans 
135 Male Female 41 Black Feb-08 HIV +ve NO  
White plaque 
in tongue  C. albicans  
136 Female Male 48 Black 2006 HIV +ve NO  
White plaque 
in tongue  
C. 
dubliniensis 
137 Male Female 32 Black 2006 HIV +ve 
d4T, 
EFV, 
3TC 
24 
months 
White plaque 
in tongue  Negative 
138 Male Female 51 Black Nov-07 HIV +ve 
d4T, 
EFV, 
3TC 2 weeks 
White plaque 
in tongue  
C. 
dubliniensis 
139 Female Male 47 Black 2001 HIV +ve 
d4T, 
EFV, 
3TC 
41 
months 
White plaque 
in tongue  Negative 
140 Male Female 40 Black 2006 HIV +ve 
d4T, 
EFV, 
3TC 
26 
months 
White plaque 
in tongue  Negative 
141 Male Female 33 Black 2006 AIDS 
d4T, 
EFV, 
3TC 
21 
months 
White plaque 
in tongue  C. albicans  
142 Female Male 63 Black Dec-07 HIV +ve 
d4T, 
EFV, 
3TC 2 months 
White plaque 
in sides of 
tongue  C. albicans  
143 Female Male 39 Black 2006 HIV +ve 
d4T, 
EFV, 
3TC 
21 
months 
White plaque 
in tongue  Negative 
144 Female Male 28 Black Jan-04 AIDS NO 
Starting 
Oct-2008 
Oral 
candidiasis 
(tongue)  C. glabrata 
145 Male Female 43 Black 2005 HIV +ve 
d4T, 
EFV, 
3TC 9 months 
Oral 
candidiasis 
(tongue)  C. albicans 
146 Female Male 30 Black 2005 HIV +ve NO  
White plaque 
in tongue 
17 weeks 
pregnant C. albicans 
147 Male Female 36 Black 2007 HIV +ve 
d4T, 
NVP, 
3TC 4 months 
White plaque 
in tongue  C. glabrata 
148 Female Male 33 Black Jun-08 HIV +ve 
d4T, 
NVP, 
3TC 3 months 
White plaque 
in tongue  Negative 
149 Male Female 48 Black Jul-08 HIV +ve 
d4T, 
NVP, 
3TC 2 months 
White plaque 
in tongue  Negative 
150 Male Female 45 Black 2005 HIV +ve 
d4T, 
NVP, 
3TC 
27 
months 
White plaque 
in tongue  Negative 
151 Male Female 51 Coloured May-07 HIV +ve 
d4T, 
EFV, 
3TC 
14 
months 
White plaque 
in tongue  Negative 
152 Female Male 37 Black 2006 HIV +ve 
d4T, 
NVP, 
3TC 
31 
months 
White plaque 
in tongue  Negative 
153 Female Male 41 Coloured Oct-03 HIV +ve 
d4T, 
NVP, 
3TC 
17 
months 
White plaque 
in tongue  Negative 
154 Male Female 60 Black 2006 HIV +ve 
d4T, 
NVP, 
3TC 
30 
months 
White plaque 
in tongue  
C. 
dubliniensis  
155 Female Male 23 Black Mar-08 HIV +ve 
AZT, 
NVP, 
3TC 6 months 
White plaque 
in tongue  C. albicans  
156 Female Male 38 Black Jan-07 HIV +ve 
d4T, 
NVP, 6 months 
White plaque 
in tongue  C. albicans 
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3TC 
157 Female Male 57 Coloured 2000 HIV +ve 
d4T, 
EFV, 
3TC 
32 
months 
White plaque 
in tongue  Negative 
158 Male Female 37 Black 2006 HIV +ve 
d4T, 
EFV, 
3TC 
30 
months 
White plaque 
in tongue  G+ cocci 
159 Male Female 33 Black 2007 HIV +ve 
d4T, 
EFV, 
3TC 
10 
months 
White plaque 
in tongue  C. albicans 
160 Male Female 39 Black 2002 HIV +ve 
d4T, 
EFV, 
3TC 
34 
months 
White plaque 
in tongue  Negative 
161 Male Female 51 Black Sep-08 AIDS NO  
White plaque 
in tongue TB patient C. albicans 
162 Female Male 51 Coloured 2006 HIV +ve 
d4T, 
NVP, 
3TC 7 months 
White plaque 
in tongue  Negative 
163 Male Female 27 Black Sep-08 AIDS NO  
White plaque 
in tongue TB patient C. albicans 
164 Male Female 42 Black May-07 HIV +ve 
d4T, 
EFV, 
3TC 
14 
months 
White plaque 
in tongue  Negative 
165 Male Female 36 Black 2001 HIV +ve 
d4T, 
EFV, 
3TC 
36 
months 
White plaque 
in tongue  Negative 
166 Female Male 35 Black 2003 HIV +ve 
AZT, 
EFV, 
3TC 7 months 
White plaque 
in tongue  Negative 
167 Female Male 29 Black Sep-01 HIV +ve NO  
White plaque 
in tongue  C. albicans 
168 Male Female 36 Black 2007 HIV +ve 
d4T, 
EFV, 
3TC 9 months 
White plaque 
in tongue  C. albicans 
169 Female Male 50 Black 2006 HIV +ve 
d4T, 
NVP, 
3TC 
26 
months 
White plaque 
in tongue  C. albicans  
170 Male Female 42 Black May-08 HIV +ve 
d4T, 
NVP, 
3TC 2 months 
White plaque 
in tongue  Negative 
171 Male Female 43 Black Oct-07 HIV +ve 
d4T, 
NVP, 
3TC 
10 
months 
White plaque 
in tongue  Negative 
172 Male Female 31 Black Mar-08 HIV +ve 
d4T, 
NVP, 
3TC 6 months 
White plaque 
in tongue  Negative 
173 Male Female 43 Black 2007 HIV +ve 
d4T, 
EFV, 
3TC 8 months 
White plaque 
in tongue  Negative 
174 Female Male 22 Black 2006 AIDS 
d4T, 
EFV, 
3TC 4 months 
White plaque 
in tongue  C. albicans  
175 Female Male 26 Black Oct-07 HIV +ve 
d4T, 
EFV, 
3TC 7 months 
White plaque 
in tongue  C. albicans 
176 Female Male 19 Black Jun-08 AIDS 
d4T, 
EFV, 
3TC 5 months 
White plaque 
in tongue TB patient C. albicans  
177 Female Male 38 Black Oct-06 HIV +ve 
d4T, 
NVP, 
3TC 
25 
months 
White plaque 
in tongue  Negative 
178 Female Male 46 Coloured 2005 HIV +ve 
d4T, 
EFV, 
3TC 6 months 
White plaque 
in tongue  Negative 
179 Female Male 22 Black 2006 HIV +ve NO  
White plaque 
in tongue 
ARV treatment 
defaulted Negative 
180 Female Male 40 Black 2004 HIV +ve 
d4T, 
NVP, 
3TC 
29 
months 
White plaque 
in tongue  C. albicans 
181 Female Male 52 Coloured Apr-08 HIV +ve 
d4T, 
NVP, 
3TC 4 months 
White plaque 
in tongue  C. albicans 
182 Female Male 31 Black Sep-07 HIV +ve d4T, 11 White plaque  C. albicans 
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NVP, 
3TC 
months in tongue 
183 Female Male 34 Black 2005 AIDS 
d4T, 
EFV, 
3TC 
32 
months 
White plaque 
in tongue 
TB patient, ARV 
treatment 
defaulted in 
2007 C. albicans  
184 Female Male 31 Black 1994 HIV +ve 
d4T, 
NVP, 
3TC 
12 
months 
White plaque 
in tongue  
C. 
dubliniensis  
185 Female Male 43 Black 2006 AIDS 
d4T, 
EFV, 
3TC 8 months 
White plaque 
in tongue TB patient C. albicans 
186 Female Male 31 Black 2003 HIV +ve 
d4T, 
EFV, 
3TC 
10 
months 
White plaque 
in tongue  C. albicans 
187 Female Male 32 Black 2003 HIV +ve 
d4T, 
NVP, 
3TC 1 month 
White plaque 
in tongue 
37 weeks 
pregnant Negative 
188 Female Male 28 Black 1999 AIDS 
d4T, 
NVP, 
3TC 5 months 
White plaque 
in tongue TB patient C. albicans 
189 Female Male 29 Black 2005 HIV +ve 
d4T, 
NVP, 
3TC 
24 
months 
White plaque 
in tongue  Negative 
190 Female Male 32 Black Aug-07 HIV +ve 
d4T, 
NVP, 
3TC 
12 
months 
White plaque 
in tongue 
20 weeks 
pregnant Negative 
191 Female Male 33 Black 2001 AIDS 
AZT, 
NVP, 
3TC 
36 
months 
White plaque 
in tongue 6 weeks old child C. albicans 
192 Male Female 56 Black 2002 AIDS 
TDF, 
EFV, 
3TC 1 month 
White plaque 
in tongue  C. albicans 
193 Male Female 42 Coloured Sep-08 HIV +ve 
d4T, 
NVP, 
3TC 2 weeks 
White plaque 
in tongue  Negative 
194 Female Male 32 Black Nov-07 HIV +ve 
d4T, 
NVP, 
3TC 3 months 
White plaque 
in tongue  C. albicans  
195 Female Male 35 Black 2006 HIV +ve 
d4T, 
NVP, 
3TC 7 months 
White plaque 
in tongue  C. albicans 
196 Female Male 38 Black 2007 HIV +ve 
d4T, 
NVP, 
3TC 2 weeks 
White plaque 
in tongue  C. glabrata 
197 Female Male 32 Black 2006 HIV +ve NO 
Starting 
Nov-
2008 
White plaque 
in tongue 
31 weeks 
pregnant C. albicans  
198 Female Male 25 Black 2003 HIV +ve 
d4T, 
NVP, 
3TC 3 months 
White plaque 
in tongue  C. albicans 
199 Female Male 19 Black Oct-08 HIV +ve NO  
White plaque 
in tongue 
23 weeks 
pregnant C. albicans  
200 Female Male 29 Black Jun-07 HIV +ve 
d4T, 
EFV, 
3TC 
14 
months 
White plaque 
in tongue  Negative 
201 Female Male 26 Black Jul-08 HIV +ve 
d4T, 
NVP, 
3TC 2 months NAD 
24 weeks 
pregnant C. albicans 
202 Female Male 57 Black 2004 AIDS 
d4T, 
NVP, 
3TC 8 months 
White plaque 
in tongue 
Patient 
complains of 
difficulty 
swallowing 
(oropharyngeal?) Negative 
203 Female Male 37 Black Feb-04 AIDS 
AZT, 
KLT, DDI 9 months 
White plaque 
in tongue  
C. albicans 
and C. 
glabrata 
204 Female Male 40 Black 2001 HIV +ve 
AZT, 
NVP, 
3TC 
38 
months 
White plaque 
in tongue  Negative 
205 Female Male 39 Black Jan-08 HIV +ve 
AZT, 
NVP, 
3TC 
10 
months 
White plaque 
in tongue  C. albicans  
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206 Female Male 35 Black Nov-06 HIV +ve 
d4T, 
NVP, 
3TC 
20 
months 
White plaque 
in tongue  C. albicans  
207 Female Male 42 Coloured 2006 HIV +ve 
d4T, 
NVP, 
3TC 
22 
months 
White plaque 
in tongue  
C. 
dubliniensis  
208 Female Male 23 Black 2005 HIV +ve 
d4T, 
EFV, 
3TC 
33 
months 
White plaque 
in tongue  Negative 
209 Female Male 25 Black 1999 HIV +ve 
d4T, 
EFV, 
3TC 7 months 
White plaque 
in tongue  Negative 
210 Female Male 22 Black 2003 AIDS 
d4T, 
NVP, 
3TC 
14 
months 
White plaque 
in tongue 
10 month old 
child Negative 
211 Male Female 36 Black Jan-07 HIV +ve 
d4T, 
NVP, 
3TC 3 months 
White plaque 
in sides and 
back of tongue  Negative 
212 Female Male 35 Black 2006 HIV +ve 
d4T, 
NVP, 
3TC 8 months 
White plaque 
in tongue  Negative 
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Table 6 shows the cumulative results obtained from all Cameroonian patients. Data from the 
questionnaire and patient’s folder are included, as well as the results obtained by the different 
culturing methods. 
 
Table 6: Cumulative results from all HIV+ Cameroonian patients. 
Patient 
No. Gender 
Partner's 
gender Age Race 
Date 
diagn
osed 
HIV 
status ARVs Duration 
Clinical 
presentation Other Results 
1 Male Female 35 Black ? AIDS 
d4T, 
NVP, 
3TC 5 years 
Oral 
candidiasis  Negative 
2 Male Female 49 Black 2006 HIV+ 
d4T, 
NVP, 
3TC 5 years 
White plaque 
in tongue  Negative 
3 Female Male 51 Black 2005 HIV+ 
EFV, 
3TC 6 years 
White plaque 
in tongue  Negative 
4 Female Male 20 Black 2008 AIDS 
d4T, 
EFV, 
3TC 45 months 
White lesion in 
oral mucosa Tb patient Negative 
5 Male Female 62 Black 2008 HIV+ 
AZT, 
NVP, 
3TC 3 years 
White plaque 
in tongue  
Negative 
6 Female Male 45 Black 2005 AIDS 
AZT, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
Negative 
7 Female Male 57 Black 2002 HIV+ 
AZT, 
NVP, 
3TC 9 years 
White plaque 
in tongue  
C. 
albicans 
8 Female Male 34 Black 2005 HIV+ 
d4T, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
Negative 
9 Female Male 48 Black 2007 AIDS 
AZT, 
EFV, 
3TC 4 years 
White plaque 
in tongue Tb patient 
Negative 
10 Female Male 44 Black 2007 HIV+ 
AZT, 
NVP, 
3TC 4 years 
White lesions 
in oral mucosa  
C. 
albicans 
11 Female Male 40 Black 2004 HIV+ 
AZT, 
NVP, 
3TC 7 years 
White plaque 
in tongue  
C. 
albicans 
12 Female Male 40 Black 2003 AIDS 
AZT, 
NVP, 
3TC 8 years 
White plaque 
in tongue  
C. 
albicans 
13 Female Male 38 Black 2003 HIV+ 
AZT, 
NVP, 
3TC 8 years 
White plaque 
in tongue  
C. 
albicans 
14 Female Male 38 Black ? HIV+ No n/a 
White plaque 
in tongue  
C. 
albicans 
15 Female Male 55 Black Jul-11 HIV+ 
AZT, 
NVP, 
3TC 3 months 
White plaque 
in tongue  
C. 
albicans 
16 Male Female 48 Black 2009 HIV+ 
d4T, 
NVP, 
3TC 2 years 
White plaque 
in tongue  Negative 
17 Female Male 56 Black 1996 HIV+ 
AZT, 
3TC, 
lopinavir
, 
ritonavir 6 years 
White plaque 
in tongue  
Candida 
kefyr/para
psilopsis/l
usitaneae 
18 Female Male 55 Black 2006 AIDS 
AZT, 
EFV, 
3TC 5 years 
White plaque 
in tongue Tb patient Negative 
19 Female Male 56 Black 90's HIV+ 
AZT, 
NVP, 
3TC ? NAD  
C. 
glabrata 
20 Female Male 36 Black 2003 HIV+ 
AZT, 
NVP, 
3TC 8 years 
White plaque 
in tongue  
Candida 
kefyr/para
psilopsis/l
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usitaneae 
21 Female Male 33 Black 2007 HIV+ 
d4T, 
NVP, 
3TC 4 years 
White plaque 
in tongue  Negative 
22 Male Female 51 Black 2008 HIV+ 
AZT, 
EFV, 
3TC 3 years 
White plaque 
in tongue and 
oral mucosa  Negative 
23 Male Female 62 Black 2003 HIV+ 
AZT, 
NVP, 
3TC 8 years NAD  Negative 
24 Male Female 50 Black 2006 AIDS 
AZT, 
EFV, 
3TC 5 years 
Oral 
candidiasis  
C. 
albicans 
25 Female Male 59 Black 2009 AIDS 
AZT, 
NVP, 
3TC 2 years NAD  Negative 
26 Male Female 39 Black 2007 HIV+ 
AZT, 
NVP, 
3TC 4 years 
Oral 
candidiasis  
C. 
albicans 
27 Female Male 45 Black 2007 AIDS 
d4T, 
NVP, 
3TC 4 years 
Oral 
candidiasis  Negative 
28 Female Male 46 Black 2005 AIDS 
AZT, 
NVP, 
3TC 6 years 
Oral 
candidiasis  
C. 
albicans 
29 Female Male 40 Black 
Sep-
10 AIDS 
TDF, 
EFV, 
3TC 1 year 
White plaque 
in tongue Tb patient Negative 
30 Female Male 42 Black 2005 AIDS 
d4T, 
NVP, 
3TC 2005 
Oral 
candidiasis  Negative 
31 Female Male 41 Black 
May-
09 AIDS 
AZT, 
NVP, 
3TC 30 months 
Oral 
candidiasis  Negative 
32 Male Female 53 Black 2006 AIDS 
AZT, 
EFV, 
3TC 5 years 
Oral 
candidiasis Tb patient 
C. 
albicans 
33 Female Male 40 Black Oct-10 HIV+ 
AZT, 
NVP, 
3TC 13 months 
White plaque 
in tongue  
C. 
albicans 
34 Female Male 46 Black 1997 AIDS 
AZT, 
NVP, 
3TC 4 years 
Oral 
candidiasis  Negative 
35 Female Male 40 Black 
Sep-
11 HIV+ 
AZT, 
NVP, 
3TC 1 month 
White plaque 
in tongue  
C. 
albicans 
36 Male Female 29 Black 2008 AIDS 
AZT, 
NVP, 
3TC 1 year 
Oral 
candidiasis  
C. 
albicans 
37 Female Male 49 Black 2009 HIV+ 
d4T, 
NVP, 
3TC 2 years 
White plaque 
on oral 
mucosa  Negative 
38 Female Male 36 Black 2007 HIV+ 
AZT, 
EFV, 
3TC 4 years 
White film in 
oral mucosa  Negative 
39 Male Female 51 Black 2010 AIDS 
AZT, 
EFV, 
3TC 1 year 
White film in 
tongue; oral 
candidiasis Tb patient 
C. 
glabrata 
40 Female Male 52 Black 2009 AIDS 
AZT, 
EFV, 
3TC 2 years 
Oral 
candidiasis  
C. 
albicans 
41 Male Female 43 Black 2009 HIV+ 
AZT, 
EFV, 
3TC 1 month 
White plaque 
in tongue  
C. 
albicans 
42 Female Male 30 Black Jul-11 HIV+ 
AZT, 
EFV, 
3TC 4 months 
White plaque 
in tongue 
8 months 
pregnant 
C. 
albicans 
43 Male Female 43 Black 2002 AIDS 
AZT, 
NVP, 
3TC 7 years 
White plaque 
in tongue; 
white lesion in 
oral mucosa Tb patient Negative 
44 Female Male 34 Black 2007 
HIV+ AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue  
C. 
glabrata 
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45 Female Male 30 Black 2006 
HIV+ TDF, 
NVP, 
3TC 20 months 
White plaque in tongue and 
oral mucosa Negative 
46 Female Male 60 Black 2004 
HIV+ AZT, 
NVP, 
3TC 7 years 
White plaque 
in tongue  Negative 
47 Female Male 51 Black 2001 
HIV+ AZT, 
NVP, 
3TC 10 years 
White plaque 
in tongue  Negative 
48 Female Male 50 Black 2010 
HIV+ AZT, 
NVP, 
3TC 1 year 
White plaque 
in tongue  
C. 
albicans 
49 Female Male 36 Black 2003 
HIV+ AZT, 
NVP, 
3TC 7 years 
White plaque 
in tongue and 
oral mucosa  Negative 
50 Female Male 52 Black Jan-05 
HIV+ AZT, 
NVP, 
3TC 6 years 
White plaque 
in tongue and 
oral mucosa  
C. 
albicans 
51 Female Male 40 Black 2005 
HIV+ AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue  
C. 
albicans 
52 Female Male 49 Black 2008 
HIV+ AZT, 
NVP, 
3TC 3 years 
White plaque 
in tongue  
Negative 
53 Male Female 35 Black 2010 
HIV+ AZT, 
NVP, 
3TC 4 months 
White plaque 
in tongue  
Negative 
54 Female Male 39 Black 2007 
HIV+ AZT, 
NVP, 
3TC 4 years 
White lesion in 
oral mucosa  
Negative 
55 Female Male 37 Black 2005 
HIV+ AZT, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
C. 
albicans 
56 Female Male 45 Black 2007 
HIV+ 
AZT, 
NVP, 
3TC 3 years 
White plaque 
in tongue, 
angular 
cheilitis  
C. 
albicans 
57 Female Male 37 Black 2004 
HIV+ AZT, 
EFV, 
3TC 6 months 
White plaque 
in tongue 
 
Negative 
58 Female Male 32 Black 2009 
HIV+ 
d4T, 
EFV, 
3TC 2 years 
White plaque 
in tongue, 
white lesion in 
oral mucosa  
Negative 
59 Female Male 28 Black 
Feb-
11 AIDS 
AZT, 
EFV, 
3TC 9 months 
White plaque 
in tongue Tb patient 
C. 
albicans 
60 Female Male 38 Black 2007 
HIV+ AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue  
C. 
albicans 
61 Female Male 34 Black 2009 
HIV+ AZT, 
NVP, 
3TC 1 year 
White plaque 
in tongue  
Negative 
62 Female Male 50 Black 2008 
HIV+ AZT, 
NVP, 
3TC 3 years 
White plaque 
in tongue Tb patient 
Negative 
63 Female Male 35 Black 
May-
11 
HIV+ AZT, 
EFV, 
3TC 5 months 
White plaque 
in tongue  
Negative 
64 Female Male 40 Black 2007 
HIV+ AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue  
C. 
albicans 
65 Male Female 48 Black 2004 
HIV+ AZT, 
3TC, 
lopinavir
, 
ritonavir 7 years 
White plaque 
in tongue  
Negative 
66 Female Male 34 Black 2005 AIDS 
d4T, 
3TC 6 years 
White plaque 
in tongue Tb patient 
Negative 
67 Female Male 38 Black 1998 
HIV+ 
AZT, 
NVP, 
3TC 4 years 
White lesions 
in gingivae; 
white plaque in 
tongue  Negative 
68 Female Male 29 Black 2007 HIV+ AZT, 4 years White plaque  Negative 
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NVP, 
3TC 
in tongue 
69 Female Male 52 Black 2005 AIDS 
AZT, 
3TC 6 years 
White plaque 
in tongue Tb patient 
C. 
albicans 
70 Female Male 46 Black 2005 HIV+ 
AZT, 
NVP, 
3TC 6 years 
Extensive 
plaque in 
tongue  
C. 
albicans 
71 Female Male 45 Black 2005 AIDS 
AZT, 
NVP, 
3TC 6 years 
White plaque 
in tongue Tb patient Negative 
72 Female Male 60 Black Jan-10 
HIV+ AZT, 
NVP, 
3TC 22 months 
White plaque 
in tongue  
C. 
albicans 
73 Male Female 40 Black 2010 
HIV+ AZT, 
EFV, 
3TC 1 year 
White plaque 
in tongue  
C. 
albicans 
74 Female Male 45 Black 2007 
HIV+ AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue  
C. 
albicans 
75 Female Male 48 Black 2006 
HIV+ d4T, 
NVP, 
3TC 5 years 
White plaque 
in tongue  Negative 
76 Female Male 55 Black 2004 
HIV+ AZT, 
NVP, 
3TC 7 years 
White plaque 
in tongue  
C. 
glabrata 
77 Female Male 38 Black 2006 
HIV+ AZT, 
NVP, 
3TC 5 years 
White plaque 
in tongue  Negative 
78 Female Male 30 Black 2004 
HIV+ ABC, 
LPV/r 7 years 
White plaque 
in tongue  Negative 
79 Female Male 38 Black 2006 AIDS 
AZT, 
NVP, 
3TC 5 years 
White plaque 
in tongue Tb patient 
C. 
albicans 
80 Male Female 50 Black 1996 
HIV+ AZT, 
NVP, 
3TC 9 years 
White plaque 
in tongue  
C. 
albicans 
81 Male Female 47 Black 2001 
HIV+ AZT, 
NVP, 
3TC 10 years 
White plaque 
in tongue and 
oral mucosa  
C. 
albicans 
82 Female Male 55 Black 2002 
HIV+ AZT, 
EFV, 
3TC 9 years 
White plaque 
in tongue  
C. 
albicans 
83 Female Male 29 Black 
Feb-
11 
HIV+ d4T, 
3TC 9months 
White plaque 
in tongue  
C. 
albicans 
84 Female Male 30 Black 2005 AIDS 
AZT, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
C. 
albicans 
85 Female Male 30 Black 2010 
HIV+ No 
(highCD
4+, 
starting 
ARV 
treatmen
t) n/a 
White plaque 
in tongue  
C. 
tropicalis 
86 Female Male 31 Black Jun-10 
HIV+ AZT, 
NVP, 
3TC 16 months 
White plaque 
in tongue  Negative 
87 Female Male 62 Black 2005 
HIV+ d4T, 
NVP, 
3TC 6 years 
White plaque 
in tongue  Negative 
88 Female Male 70 Black 
Sep-
10 AIDS 
TDF, 
NVP, 
3TC 14 months 
White plaque 
in tongue 
Patient 
treated 
with 
fluconazol
e in the 
past. Re-
current 
candidiasi
s. 
C. 
albicans 
89 Female Male 30 Black Jul-11 HIV+ Yes(?) 4 months 
White plaque 
in tongue, 
white lesion in 
gingiva  Negative 
90 Female Male 69 Black 2011 AIDS AZT, 5 months White plaque Tb patient C. 
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NVP, 
3TC 
in tongue and 
gingivae 
albicans 
91 Female Male 59 Black 2007 AIDS 
AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue  Negative 
92 Male Female 48 Black 2005 
HIV+ AZT, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
C. 
glabrata 
93 Male Female 56 Black 2005 
HIV+ AZT, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
C. 
glabrata 
94 Female Male 38 Black 2008 AIDS 
AZT, 
NVP, 
3TC 3 years 
White plaque 
in tongue  Negative 
95 Female Male 35 Black 2009 
HIV+ AZT, 
NVP, 
3TC 2 years 
White plaque 
in tongue  
Negative 
96 Male Female 35 Black 2005 
HIV+ AZT, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
Negative 
97 Female Male 29 Black 
Sep-
10 
HIV+ TDF, 
EFV, 
3TC 14 months 
White plaque 
in tongue and 
oral mucosa  Negative 
98 Female Male 34 Black 2007 
HIV+ AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue  
C. 
albicans 
99 Female Male 25 Black 2010 
HIV+ AZT, 
EFV, 
3TC 1 year 
White plaque 
in tongue  
C. 
albicans 
100 Female Male 38 Black 
Dec-
09 AIDS 
AZT, 
NVP, 
3TC 2 years 
White plaque 
in tongue  
C. 
albicans 
101 Male Female 42 Black 2008 
HIV+ AZT, 
EFV, 
3TC 3 years 
White plaque 
in tongue  
Negative 
102 Male Female 42 Black 2001 
HIV+ d4T, 
NVP, 
3TC 10 years 
White plaque 
in tongue  
Negative 
103 Female Male 32 Black 2006 
HIV+ AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue  
C. 
albicans 
104 Female Male 32 Black 2004 
HIV+ AZT, 
NVP, 
3TC 7 years 
White plaque 
in tongue  
Negative 
105 Female Male 39 Black 2005 
HIV+ AZT, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
Negative 
106 Female Male 39 Black 2006 
HIV+ LPV/r 
(Alluvia, 
2nd) 5 years 
White plaque 
in tongue  
C. 
albicans 
107 Male Female 40 Black 
Aug-
11 
HIV+ AZT, 
NVP, 
3TC 3 months 
White plaque 
in tongue  Negative 
108 Male Female 51 Black 2007 AIDS 
AZT, 
EFV, 
3TC 4 years 
White plaque 
in tongue  
C. 
glabrata 
109 Female Male 41 Black 2000 AIDS 
AZT, 
NVP, 
3TC 2 years 
White plaque 
in tongue Tb patient 
C. 
glabrata 
110 Female Male 53 Black 
Dec-
06 HIV+ 
AZT, 
NVP, 
3TC 5 years 
White plaque 
in tongue  Negative 
111 Male Female 39 Black Oct-11 AIDS 
AZT, 
EFV, 
3TC 1 month 
White plaque 
in tongue and 
oral mucosa  
C. 
albicans 
112 Male Female 40 Black 
Aug-
10 
HIV+ 
AZT, 
NVP, 
3TC 15 months 
White plaque 
in tongue, 
white lesion in 
oral mucosa  
Negative 
113 Female Male 45 Black 2004 
HIV+ AZT, 
NVP, 
3TC 7 years NAD 
 
Negative 
114 Male Female 36 Black 2007 
HIV+ AZT, 
NVP, 4 years 
White plaque 
in tongue  
C. 
albicans 
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3TC 
115 Female Male 52 Black 2004 
HIV+ 
Yes(?) 5 years 
White plaque 
in tongue  
C. 
albicans 
116 Female Male 
? 
(50-
60) Black 2010 
HIV+ 
Yes(?) 1 year 
White plaque 
in tongue  
C. 
glabrata 
117 Female Male 39 Black 
Aug-
10 
HIV+ TDF, 
3TC 15 months 
White plaque 
in tongue  
C. 
albicans 
118 Female Male 30 Black 
May-
11 AIDS 
AZT, 
NVP, 
3TC 6 months 
White plaque 
in tongue Tb patient 
C. 
albicans 
119 Female Male 57 Black 2002 
HIV+ 
AZT, 
NVP, 
3TC 9 years 
White plaque 
in tongue 
Patient 
took 
fluconazol
e recently 
Candida 
albicans 
120 Female Male 59 Black 2008 
HIV+ d4T, 
NVP, 
3TC 3 years 
White plaque 
in tongue  Negative 
121 Male Female 52 Black 2006 
HIV+ No 
(starting 
now) n/a 
White plaque 
in tongue  
C. 
albicans 
122 Female Male 55 Black 2008 
HIV+ AZT, 
NVP, 
3TC 3 years 
White plaque 
in tongue  
Negative 
123 Female Male 39 Black 2004 
HIV+ AZT, 
NVP, 
3TC 7 years 
White plaque 
in tongue  
Negative 
124 Female Male 41 Black 2006 
HIV+ AZT, 
NVP, 
3TC 5 years 
White plaque 
in tongue  
C. 
glabrata 
125 Male Female 50 Black 2005 AIDS 
d4T, 
NVP, 
3TC 6 years 
White plaque 
in tongue Tb patient 
Negative 
126 Female Male 36 Black 2007 
HIV+ LPV/r, 
d4T, 
3TC 4 years 
White plaque 
in tongue  
Negative 
127 Female Male 58 Black 2006 
HIV+ AZT, 
NVP, 
3TC 5 years 
White plaque 
in tongue  
C. 
albicans 
128 Female Male 37 Black 2007 
HIV+ AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue  
Negative 
129 Female Male 57 Black 2002 AIDS 
AZT, 
EFV, 
3TC 9 years 
White plaque 
in tongue Tb patient 
Negative 
130 Female Male 36 Black 2007 HIV+ 
AZT, 
NVP, 
3TC 4 years 
Extensive 
white plaque 
in tongue  Negative 
131 Female Male 30 Black 2004 AIDS 
AZT, 
NVP, 
3TC 7 years 
White plaque 
in tongue Tb patient Negative 
132 Female Male 33 Black 2006 
HIV+ AZT, 
NVP, 
3TC 5 years 
White plaque 
in tongue  
C. 
albicans 
133 Male Female 49 Black 2004 
HIV+ AZT, 
NVP, 
3TC 7 years 
White plaque 
in tongue  Negative 
134 Male Female 51 Black 2003 AIDS 
AZT, 
EFV 2 years 
White plaque 
in tongue  
C. 
albicans 
135 Female Male 34 Black 2009 
HIV+ AZT, 
EFV, 
3TC 2 years 
White plaque 
in tongue  
C. 
albicans 
136 Female Male 43 Black 1997 
HIV+ LPV/r, 
AZT, 
3TC 2 years 
White plaque 
in tongue  
C. 
dubliniensi
s 
137 Female Male 25 Black 2006 
HIV+ d4T, 
NVP, 
3TC 5 years 
White plaque 
in tongue  
C. 
albicans 
138 Female Male 31 Black 
Feb-
11 AIDS 
AZT, 
EFV, 
3TC 5 months 
White plaque 
in tongue Tb patient 
Negative 
139 Male Female 49 Black 2001 
HIV+ 
LPV/r 8 years 
White plaque 
in tongue  
Negative 
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140 Female Male 52 Black 2004 
HIV+ AZT, 
NVP, 
3TC 5 years 
White plaque 
in tongue  
Negative 
141 Female Male 57 Black ? 
HIV+ 
Yes(?) ? 
White plaque 
in tongue  
C. 
tropicalis 
142 Male Female 32 Black 2008 
HIV+ TDF, 
EFV, 
3TC 3 years 
White plaque 
in tongue  Negative 
143 Female Male 40 Black 
Dec-
10 AIDS 
AZT, 
EFV, 
3TC 1 month 
White plaque 
in tongue  
C. 
albicans 
144 Female Male 28 Black 2010 
HIV+ AZT, 
NVP, 
3TC 1 year 
White plaque 
in tongue  C. krusei 
145 Female Male 56 Black 2006 
HIV+ AZT, 
EFV, 
3TC 3 months 
White plaque 
in tongue  Negative 
146 Male Female 42 Black 2004 
HIV+ 
LPV/r, 
TDF, 
3TC 7 years 
White plaque 
in tongue and 
white lesion in 
oral mucosa  
C. 
albicans 
147 Female Male 35 Black 2009 AIDS 
AZT, 
NVP, 
3TC 2 years 
White plaque 
in tongue Tb patient Negative 
148 Male Female 45 Black 2009 
HIV+ TDF, 
EFV, 
3TC 2 years 
White plaque 
in tongue  
C. 
glabrata 
149 Female Male 60 Black 2007 
HIV+ AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue  
Negative 
150 Female Male 50 Black 2005 
HIV+ AZT, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
Negative 
151 Female Male 50 Black 2006 
HIV+ AZT, 
NVP, 
3TC 5 years 
White plaque 
in tongue  
Negative 
152 Female Male 32 Black 2004 
HIV+ AZT, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
Negative 
153 Male Female 36 Black 2010 AIDS 
AZT, 
EFV, 
3TC 1 year 
White plaque 
in tongue Tb patient 
Negative 
154 Female Male 71 Black 
Now 
(Nov 
2011) 
HIV+ No 
(starting 
now)  
Extensive 
white plaque 
in tongue  
C. 
albicans 
155 Female Male 42 Black 2007 
HIV+ AZT, 
NVP, 
3TC 2 years 
White plaque 
in tongue  Negative 
156 Female Male 72 Black 2006 
HIV+ AZT, 
NVP, 
3TC 2 years 
White plaque 
in tongue  
C. 
glabrata 
157 Female Male 53 Black 2007 
HIV+ AZT, 
EFV, 
3TC 4 years 
White plaque 
in tongue  Negative 
158 Female Male 39 Black 2006 
HIV+ AZT, 
NVP, 
3TC 5 years 
White plaque 
in tongue  
C. 
albicans 
159 Female Male 38 Black 2008 
HIV+ AZT, 
NVP, 
3TC 3 years 
White plaque 
in tongue  
C. 
glabrata 
160 Female Male 26 Black 2009 
HIV+ AZT, 
NVP, 
3TC 1 year 
White plaque 
in tongue  
Negative 
161 Female Male 40 Black 2007 
HIV+ AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue  
Negative 
162 Female Male 51 Black 2005 
HIV+ AZT, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
Negative 
163 Female Male 34 Black 2005 
HIV+ LPV/r, 
TDF, 
3TC 2 years 
White plaque 
in tongue  
Negative 
164 Female Male 35 Black 
Sep-
11 
HIV+ AZT, 
NVP, 3 months 
White plaque 
in tongue  
C. 
albicans 
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3TC 
165 Female Male 38 Black 2007 
HIV+ AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue  
Negative 
166 Female Male 61 Black 2003 
HIV+ AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue  
Negative 
167 Female Male 35 Black 2008 
HIV+ AZT, 
NVP, 
3TC 3 years 
White plaque 
in tongue  
Negative 
168 Female Male 35 Black 2007 
HIV+ AZT, 
EFV, 
3TC 4 years 
White plaque 
in tongue  
Negative 
169 Female Male 36 Black 2006 
HIV+ AZT, 
EFV, 
3TC 3 years 
White plaque 
in tongue  
Negative 
170 Female Male 30 Black 
Mar-
09 
HIV+ d4T, 
NVP, 
3TC 30 months 
White plaque 
in tongue  
Negative 
171 Female Male 33 Black 2006 AIDS 
d4T, 
NVP, 
3TC 5 years 
White plaque 
in tongue Tb patient 
Negative 
172 Female Male 35 Black 2007 
HIV+ d4T, 
NVP, 
3TC 4 years 
White plaque 
in tongue  C. krusei 
173 Female Male 43 Black 2004 
HIV+ AZT, 
NVP, 
3TC 7 years 
White plaque 
in tongue   
174 Female Male 27 Black 2007 AIDS 
AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue Tb patient C. krusei 
175 Female Male 70 Black 2005 HIV+ 
AZT, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
C. 
albicans 
176 Female Male 32 Black 2003 AIDS 
d4T, 
EFV, 
3TC 3 years 
White plaque 
in tongue  Negative 
177 Female Male 53 Black 2006 
HIV+ AZT, 
NVP, 
3TC 5 years 
White plaque 
in tongue  
C. 
albicans 
178 Female Male 38 Black 2004 
HIV+ LPV/r, 
TDF 6 years 
White plaque 
in tongue  
C. 
glabrata 
179 Female Male 29 Black 2007 AIDS 
AZT, 
3TC 4 years 
White plaque 
in tongue 
3 months 
pregnant Negative 
180 Female Male 47 Black 2005 
HIV+ AZT, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
C. 
albicans 
181 Female Male 30 Black Oct-11 
HIV+ AZT, 
NVP, 
3TC 1 week 
White plaque 
in tongue  
C. 
albicans 
182 Female Male 32 Black 2004 
HIV+ AZT, 
NVP, 
3TC 7 years 
White plaque 
in tongue  
C. 
albicans 
183 Female Male 27 Black 2009 AIDS 
AZT, 
NVP, 
3TC 2 years 
White plaque 
in tongue Tb patient 
C. 
albicans 
184 Female Male 36 Black 
Mar-
09 
HIV+ d4T, 
NVP, 
3TC 21 months 
White plaque 
in tongue  
C. 
albicans 
185 Male Female 36 Black 2005 
HIV+ d4T, 
NVP, 
3TC 6 years 
White plaque 
in tongue  Negative 
186 Male Female 39 Black 2007 
HIV+ 
d4T, 
NVP, 
3TC 4 years 
White plaque 
in tongue and 
white lesion in 
oral mucosa  
C. 
glabrata 
187 Female Male 41 Black 2006 AIDS 
LPV/r, 
TDF 5 years 
White plaque 
in tongue Tb patient 
Negative 
188 Female Male 30 Black 2005 AIDS 
d4T, 
NVP, 
3TC 6 years 
White plaque 
in tongue Tb patient 
Negative 
189 Female Male 36 Black Jul-11 
HIV+ AZT, 
NVP, 
3TC 1 month 
White plaque 
in tongue  
Negative 
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190 Male Female 46 Black 2004 
HIV+ d4T, 
NVP, 
3TC 7 years 
White plaque 
in tongue  
Negative 
191 Female Male 39 Black Oct-11 
HIV+ AZT, 
NVP, 
3TC 11 days 
White plaque 
in tongue  
Negative 
192 Female Male 42 Black 2010 
HIV+ TDF, 
EFV, 
3TC 1 year 
White plaque 
in tongue  
Negative 
193 Female Male 44 Black 2008 
HIV+ d4T, 
NVP, 
3TC 3 years 
White plaque 
in tongue  
Negative 
194 Female Male 47 Black 2006 
HIV+ AZT, 
NVP, 
3TC 5 years 
White plaque 
in tongue  
Negative 
195 Male Female 55 Black 2009 
HIV+ AZT, 
NVP, 
3TC 2 years 
White plaque 
in tongue  
Negative 
196 Female Male 50 Black 2005 
HIV+ AZT, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
Candida 
glabrata 
197 Female Male 54 Black 2003 
HIV+ AZT, 
NVP, 
3TC 8 years 
White plaque 
in tongue  
Candida 
albicans 
198 Female Male 49 Black 2002 AIDS 
AZT, 
EFV, 
3TC 9 years 
White plaque 
in tongue Tb patient 
Candida 
albicans 
199 Female Male 25 Black 2005 
HIV+ d4T, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
Candida 
albicans 
200 Female Male 37 Black Jun-10 
HIV+ AZT, 
NVP, 
3TC 1 year 
White plaque 
in tongue  
Candida 
glabrata 
201 Female Male 38 Black 2007 AIDS 
AZT, 
EFV, 
3TC 2 months 
White plaque 
in tongue and 
oral 
candidiasis Tb patient 
Candida 
albicans 
202 Male Female 37 Black 
Aug-
11 
HIV+ AZT, 
NVP, 
3TC 3 months 
White plaque 
in tongue  
Candida 
albicans 
203 Female Male 45 Black 2007 
HIV+ AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue  
Negative 
204 Female Male 42 Black 2004 AIDS 
AZT, 
NVP, 
3TC 7 years 
White plaque 
in tongue Tb patient 
Negative 
205 Female Male 33 Black 2007 HIV+ 
LPV/r, 
AZT, 
3TC 4 years 
White plaque 
in tongue  
Negative 
206 Female Male 30 Black 2010 AIDS 
AZT, 
EFV, 
3TC 1 year 
White plaque 
in tongue Tb patient 
C. 
albicans 
207 Female Male 31 Black Jul-11 
HIV+ AZT, 
NVP, 
3TC 3 months 
White plaque 
in tongue  
C. 
albicans 
208 Female Male 37 Black 2006 
HIV+ d4T, 
NVP, 
3TC 5 years 
White plaque 
in tongue  
Negative 
209 Female Male 39 Black 2010 
HIV+ AZT, 
NVP, 
3TC 2 years 
White plaque 
in tongue  
Negative 
210 Female Male 34 Black 2006 
HIV+ 
AZT, 
NVP, 
3TC 5 years 
White plaque 
in tongue and 
white lesion in 
oral mucosa  Negative 
211 Female Male 50 Black 2009 
HIV+ AZT, 
NVP, 
3TC 2 years 
White plaque 
in tongue  
Negative 
212 Female Male 42 Black 2009 AIDS 
AZT, 
EFV, 
3TC 2 years 
White plaque 
in tongue Tb patient 
Negative 
213 Female Male 41 Black 2004 AIDS 
d4T, 
NVP, 
3TC 7 years 
White plaque 
in tongue Tb patient 
Negative 
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214 Female Male 42 Black 2006 
HIV+ AZT, 
NVP, 
3TC 5 years 
White plaque 
in tongue  
Negative 
215 Female Male 55 Black 2008 
HIV+ AZT, 
NVP, 
3TC 3 years 
White plaque 
in tongue  
Negative 
216 Female Male 48 Black 2010 AIDS 
AZT, 
NVP, 
3TC 1 year 
White plaque 
in tongue Tb patient 
C. 
glabrata 
217 Female Male 50 Black 2006 HIV+ 
d4T, 
NVP, 
3TC 5 years 
White plaque 
in tongue  
Negative 
218 Female Male 38 Black 2000 AIDS 
d4T, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
Negative 
219 Female Male 33 Black 2001 HIV+ 
AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue  
C. 
glabrata 
220 Female Male 39 Black 2006 AIDS 
AZT, 
EFV, 
3TC 4 years 
White plaque 
in tongue Tb patient 
C. 
glabrata 
221 Female Male 42 Black Apr-10 
HIV+ AZT, 
NVP, 
3TC 18 months 
White plaque 
in tongue  
C. 
albicans 
222 Female Male 40 Black 2004 
HIV+ LPV/r, 
TDF 4 years 
White plaque 
in tongue  
C. 
albicans 
223 Female Male 35 Black 2008 
HIV+ AZT, 
EFV, 
3TC 3 years 
White plaque 
in tongue  
Negative 
224    Black     
White plaque 
in tongue  
Negative 
225 Male Female 38 Black 2000 AIDS 
No 
(starting 
now) n/a 
White plaque 
in tongue  
Negative 
226 Female Male 42 Black 2005 
HIV+ AZT, 
EFV, 
3TC 3 years 
White plaque 
in tongue  
C. 
albicans 
227 Female Male 47 Black 2006 
HIV+ d4T, 
NVP, 
3TC 5 years 
White plaque 
in tongue  Negative 
228 Female Male 32 Black 2005 
HIV+ d4T, 
NVP, 
3TC 6 years 
White plaque 
in tongue  
C. 
glabrata 
229 Female Male 42 Black 
Aug-
11 
HIV+ AZT, 
NVP, 
3TC 2 months 
White plaque 
in tongue  
C. 
albicans 
230 Female Male 44 Black 2008 
HIV+ d4T, 
NVP, 
3TC 3 years 
White plaque 
in tongue  
Negative 
231 Male Female 53 Black 2005 
HIV+ AZT, 
EFV, 
3TC 7 years 
White plaque 
in tongue  
Negative 
232 Female Male 42 Black 2010 
HIV+ AZT, 
NVP, 
3TC 1 year 
White plaque 
in tongue  
Negative 
233 Male Female 43 Black 2005 AIDS 
AZT, 
NVP, 
3TC 6 years 
White plaque 
in tongue Tb patient 
C. 
albicans 
234 Male Female 49 Black 2001 AIDS 
AZT, 
EFV, 
3TC 10 years 
White plaque 
in tongue Tb patient 
C. 
glabrata 
235 Male Female 62 Black 2003 
HIV+ LPV/r, 
AZT, 
3TC 8 years 
White plaque 
in tongue  Negative 
236 Female Male 43 Black 2007 
HIV+ AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue and 
oral mucosa  
C. 
albicans 
237 Female Male 60 Black Oct-10 AIDS 
AZT, 
EFV, 
3TC 1 year 
White plaque 
in tongue  
C. 
glabrata 
238 Female Male 33 Black 2002 
HIV+ 
AZT, 
NVP, 
3TC 9 years 
White plaque 
in tongue 
Patient 
has an 18 
month old 
child 
C. 
albicans 
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239 Female Male 43 Black 1997 
HIV+ d4T, 
NVP, 
3TC 4 years 
White plaque 
in tongue  
Negative 
240 Female Male 52 Black 2009 
HIV+ AZT, 
NVP, 
3TC 2 years 
White plaque 
in tongue  
Negative 
241 Female Male 26 Black 
Sep-
11 
HIV+ AZT, 
EFV, 
3TC 2 months 
White plaque 
in tongue 
22 weeks 
pregnancy 
C. 
albicans 
242 Female Male 23 Black 
Feb-
11 
HIV+ 
AZT, 
NVP, 
3TC 4 months 
White plaque 
in tongue 
Patient 
had a 
miscarriag
e in Feb 
2011 Negative 
243 Female Male 52 Black 2008 
HIV+ AZT, 
NVP, 
3TC 3 years 
White plaque 
in tongue  Negative 
244 Female Male 64 Black 2006 
HIV+ AZT, 
NVP, 
3TC 5 years 
White plaque 
in tongue  
C. 
albicans 
245 Male Female 49 Black 2005 AIDS 
AZT, 
EFV, 
3TC 2006 
White plaque 
in tongue Tb patient 
C. 
tropicalis 
246 Female Male 52 Black 2003 
HIV+ AZT, 
NVP, 
3TC 9 years 
White plaque 
in tongue  
C. 
glabrata 
247 Female Male 50 Black 2009 
HIV+ AZT, 
NVP, 
3TC 2 years 
White plaque 
in tongue  
C. 
albicans 
248 Female Male 53 Black 2009 
HIV+ LPV/r, 
AZT, 
3TC 2 years 
White plaque 
in tongue  
C. 
albicans 
249 Female Male 41 Black 
Aug-
11 
HIV+ AZT, 
NVP, 
3TC 2 months 
White plaque 
in tongue  
C. 
albicans 
250 Female Male 40 Black 2009 AIDS 
AZT, 
EFV, 
3TC 2 years 
White plaque 
in tongue Tb patient 
C. 
tropicalis 
251 Female Male 55 Black 2008 HIV+ 
AZT, 
NVP, 
3TC 3 years 
White plaque 
in tongue  
Negative 
252 Female Male 29 Black 2005 AIDS 
d4T, 
NVP, 
3TC 6 years 
White plaque 
in tongue Tb patient 
Negative 
253 Female Male ? Black 2004 
HIV+ AZT, 
NVP, 
3TC 7 years 
White plaque 
in tongue  
C. 
albicans 
254 Female Male 33 Black 2004 
HIV+ LPV/r, 
TDF, 
3TC 4 years 
White plaque 
in tongue  Negative 
255 Female Male 33 Black 
Nov-
11 
HIV+ 
No n/a 
White plaque 
in tongue  
C. 
albicans 
256 Female Male 26 Black 
Nov-
10 
HIV+ AZT, 
NVP, 
3TC 1 year 
White plaque 
in tongue  
C. 
albicans 
257 Female Male 42 Black 2009 
HIV+ AZT, 
NVP, 
3TC 2 years 
White plaque 
in tongue  
C. 
albicans 
258 Female Male 34 Black 2007 
HIV+ AZT, 
NVP, 
3TC 4 years 
White plaque 
in tongue and 
oral mucosa  C. krusei 
259 Female Male 30 Black Apr-11 AIDS 
d4T, 
EFV, 
3TC 7 months 
White plaque 
in tongue Tb patient  
260 Female Male 28 Black 
Nov-
11 AIDS 
No 
(starting 
now) n/a 
White plaque 
in tongue  
C. 
albicans 
261 Female Male 53 Black 2004 
HIV+ AZT, 
EFV, 
3TC 7 years 
White plaque 
in tongue  
C. 
albicans 
262 Female Male 37 Black 2011 
HIV+ 
No n/a 
White plaque 
in tongue  Negative 
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Appendix 6 
 
Tables 7, 8 and 9 show the results obtained from the fluconazole disk diffusion susceptibility 
testing when samples were grown in triplicate in Sabouraud (SA samples only) and YNBG 
media, respectively. Microcolony score: 0= a clear zone with no microcolonies, 1=a few 
microcolonies present, 2= moderate growth of microcolonies and 3= many microcolonies in 
the susceptibility area. 
 
Table 7.:  South African fluconazole susceptibility testing results in Sabouraud agar. 
Patient No. Inhibition area (mm) Microcolonies Interpretation Species 
3 4 0 Resistant C. albicans 
7 4 1 Resistant C. dubliniensis 
10 2 2 Resistant C. albicans 
11 4 0 Resistant C. glabrata 
12 0 Resistant Resistant C. albicans 
13 0 Resistant Resistant C. albicans 
14 2 3 Resistant C. albicans 
16 9 0 Resistant C. albicans 
19 7 0 Intermediate C. albicans 
21 1 0 Resistant C. albicans 
23 5 1 Resistant C. albicans 
24 6 1 Resistant C. albicans 
25 5 1 Resistant C. albicans 
26 0 Resistant Resistant C. albicans 
27 0 Resistant Resistant C. albicans 
28 5 0 Resistant C. albicans 
30 5 1 Resistant C. albicans 
36a 2 0 Resistant C. albicans 
36b 3 2 Resistant C. glabrata 
37 2 Resistant Resistant C. albicans 
38 0 0 Resistant C. albicans 
40 0 Resistant Resistant C. albicans 
41 0 Resistant Resistant C. albicans 
42 11 1 Intermediate C. albicans 
44 8 0 Intermediate C. albicans 
46 1 1 Resistant C. albicans 
47 5 1 Resistant C. albicans 
48 5 1 Resistant C. albicans 
50 1 Resistant Resistant C. albicans 
51 2 2 Resistant C. dubliniensis 
57 5 1 Resistant C. albicans 
58 7 2 Intermediate C. albicans 
59 5 1 Resistant C. dubliniensis 
60 17 1 Susceptible C. albicans 
61 5 1 Resistant C. albicans 
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62 5 3 Resistant C. albicans 
65 2 0 Resistant C. albicans 
66 0 Resistant Resistant C. albicans 
67 12 1 Intermediate C. albicans 
68 0 Resistant Resistant C. albicans 
69 5 Resistant Resistant C. albicans 
70 5 2 Resistant C. albicans 
71 5 Resistant Resistant C. albicans 
72 5 1 Resistant C, glabrata 
73 14 1 Susceptible C. albicans 
77 5 0 Resistant C. glabrata 
78 8 0 Resistant C. albicans 
80 6 0 Resistant C. albicans 
81 11 0 Intermediate C. glabrata 
82 6 1 Resistant C. dubliniensis 
83 5 0 Resistant C. albicans 
85 0 Resistant Resistant C. albicans 
88 1 Resistant Resistant C. albicans 
89 0 Resistant Resistant C. albicans 
90 0 Resistant Resistant C. albicans 
92 4 0 Resistant C. glabrata 
93 7 0 Intermediate C. albicans 
94 0 Resistant Resistant C. albicans 
95 0 Resistant Resistant C. albicans 
96 0 Resistant Resistant C. albicans 
97 6 2 Resistant C. albicans 
99 10 0 Intermediate C. albicans 
100 11 1 Intermediate C. albicans 
101 0 Resistant Resistant C. albicans 
102 0 Resistant Resistant C. albicans 
103 5 2 Resistant C. albicans 
105 11 0 Intermediate C. dubliniensis 
107 13 1 Susceptible C. glabrata 
109 0 Resistant Resistant C. albicans 
110 6 1 Resistant C. albicans 
111 0 Resistant Resistant C. albicans 
112 5 3 Resistant C. albicans 
115 5 3 Resistant C. albicans 
116 6 1 Resistant C. albicans 
117 10 0 Intermediate C. albicans 
118 5 0 Resistant C. glabrata 
119 0 Resistant Resistant C. albicans 
120 0 Resistant Resistant C. albicans 
122 5 1 Resistant C. albicans 
123 0 Resistant Resistant C. albicans 
126 4 3 Resistant C. albicans 
127 0 Resistant Resistant C. albicans 
131 7 0 Intermediate C. albicans 
132 0 Resistant Resistant C. albicans 
134 0 Resistant Resistant C. albicans 
135 10 0 Intermediate C. albicans 
136 14 0 Susceptible C. dubliniensis 
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138 13 0 Susceptible C. dubliniensis 
141 11 0 Intermediate C. albicans 
142 0 Resistant Resistant C. albicans 
144 0 Resistant Resistant C. glabrata 
145 0 Resistant Resistant C. albicans 
146 0 Resistant Resistant C. albicans 
147 2 1 Resistant C. glabrata 
154 15 0 Susceptible C. dubliniensis 
155 9 1 Resistant C. albicans 
156 10 0 Intermediate C. albicans 
159 0 Resistant Resistant C. albicans 
161 0 Resistant Resistant C. albicans 
163 1 1 Resistant C. albicans 
167 14 3 Resistant C. albicans 
168 10 0 Intermediate C. albicans 
169 0 Resistant Resistant C. albicans 
174 0 Resistant Resistant C. albicans 
175 0 Resistant Resistant C. albicans 
176 7 2 Intermediate C. albicans 
180 8 0 Intermediate C. albicans 
181 13 1 Resistant C. albicans 
182 0 Resistant Resistant C. albicans 
183 7 3 Resistant C. albicans 
184 5 0 Resistant C. dubliniensis 
185 10 0 Intermediate C. albicans 
186 0 Resistant Resistant C. albicans 
188 0 Resistant Resistant C. albicans 
191 0 Resistant Resistant C. albicans 
192 0 Resistant Resistant C. albicans 
194 6 3 Resistant C. albicans 
195 9 0 Intermediate C. albicans 
196 0 Resistant Resistant C. glabrata 
197 0 Resistant Resistant C. albicans 
198 8 0 Intermediate C. albicans 
199 0 Resistant Resistant C. albicans 
201 5 1 Intermediate C. albicans 
203a 0 Resistant Resistant C. albicans 
203b 3 3 Resistant C. glabrata 
205 8 0 Intermediate C. albicans 
206 6 0 Resistant C. albicans 
207 5 0 Resistant C. dubliniensis 
 
 
 
 
 
 
 
 
 
 
 
146 
 
 
Table 8.: South African fluconazole susceptibility testing results in YNBG agar. 
Patient No. Inhibition area (mm) Microcolonies Interpretation Species 
3 >20 0 Susceptible C. albicans 
7 >20 0 Susceptible C. dubliniensis 
10 0 res. Resistant C. albicans 
11 0 res. Resistant C. glabrata 
12 0 res. Resistant C. albicans 
13 0 res. Resistant C. albicans 
14 0 res. Resistant C. albicans 
16 0 res. Resistant C. albicans 
19 0 res. Resistant C. albicans 
21 0 res. Resistant C. albicans 
23 14 1 Susceptible C. albicans 
24 14 1 Susceptible C. albicans 
25 15 1 Susceptible C. albicans 
26 0 res. Resistant C. albicans 
27 18 0 Susceptible C. albicans 
28 0 res. Resistant C. albicans 
30 18 0 Susceptible C. albicans 
36a 3 0 Resistant C. albicans 
36b 9 0 Intermediate C. glabrata 
37 18 0 Susceptible C. albicans 
38 18 0 Susceptible C. albicans 
40 0 res. Resistant C. albicans 
41 18 0 Susceptible C. albicans 
42 17 0 Susceptible C. albicans 
44 0 res. Resistant C. albicans 
46 0 res. Resistant C. albicans 
47 0 res. Resistant C. albicans 
48 18 0 Susceptible C. albicans 
50 0 res. Resistant C. albicans 
51 >20 0 Susceptible C. dubliniensis 
57 >20 0 Susceptible C. albicans 
58 >20 0 Susceptible C. albicans 
59 >20 0 Susceptible C. dubliniensis 
60 0 res. Resistant C. albicans 
61 0 res. Resistant C. albicans 
62 0 res. Resistant C. albicans 
65 >20 0 Susceptible C. albicans 
66 0 res. Resistant C. albicans 
67 17 0 Susceptible C. albicans 
68 0 res. Resistant C. albicans 
69 17 0 Susceptible C. albicans 
70 17 0 Susceptible C. albicans 
71 0 res. Resistant C. albicans 
72 14 0 Susceptible C, glabrata 
73 0 res. Resistant C. albicans 
77 4 0 Resistant C. glabrata 
78 >20 0 Susceptible C. albicans 
80 0 res. Resistant C. albicans 
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81 16 0 Susceptible C. glabrata 
82 0 res. Resistant C. dubliniensis 
83 0 res. Resistant C. albicans 
85 14 1 Susceptible C. albicans 
88 0 res. Resistant C. albicans 
89 0 res. Resistant C. albicans 
90 0 res. Resistant C. albicans 
92 0 res. Resistant C. glabrata 
93 >20 0 Susceptible C. albicans 
94 0 res. Resistant C. albicans 
95 0 res. Resistant C. albicans 
96 0 res. Resistant C. albicans 
97 0 res. Resistant C. albicans 
99 >20 0 Susceptible C. albicans 
100 0 res. Resistant C. albicans 
101 0 res. Resistant C. albicans 
102 17 2 Susceptible C. albicans 
103 0 res. Resistant C. albicans 
105 >20 0 Susceptible C. dubliniensis 
107 16 0 Susceptible C. glabrata 
109 0 res. Resistant C. albicans 
110 0 res. Resistant C. albicans 
111 0 res. Resistant C. albicans 
112 0 res. Resistant C. albicans 
115 0 res. Resistant C. albicans 
116 0 res. Resistant C. albicans 
117 0 res. Resistant C. albicans 
118 0 res. Resistant C. glabrata 
119 0 res. Resistant C. albicans 
120 0 res. Resistant C. albicans 
122 19 0 Susceptible C. albicans 
123 0 res. Resistant C. albicans 
126 19 0 Susceptible C. albicans 
127 19 0 Susceptible C. albicans 
131 0 res. Resistant C. albicans 
132 0 res. Resistant C. albicans 
134 0 res. Resistant C. albicans 
135 0 res. Resistant C. albicans 
136 >20 0 Susceptible C. dubliniensis 
138 >20 0 Susceptible C. dubliniensis 
141 15 0 Susceptible C. albicans 
142 0 res. Resistant C. albicans 
144 4 0 Resistant C. glabrata 
145 0 res. Resistant C. albicans 
146 0 res. Resistant C. albicans 
147 0 res. Resistant C. glabrata 
154 >20 0 Susceptible C. dubliniensis 
155 0 res. Resistant C. albicans 
156 0 res. Resistant C. albicans 
159 0 res. Resistant C. albicans 
161 0 res. Resistant C. albicans 
163 0 res. Resistant C. albicans 
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167 >20 0 Susceptible C. albicans 
168 19 0 Susceptible C. albicans 
169 18 0 Susceptible C. albicans 
174 19 0 Susceptible C. albicans 
175 >20 1 Susceptible C. albicans 
176 17 0 Susceptible C. albicans 
180 0t res. Resistant C. albicans 
181 16 0 Susceptible C. albicans 
182 16 0 Susceptible C. albicans 
183 19 0 Susceptible C. albicans 
184 >20 0 Susceptible C. dubliniensis 
185 19 0 Susceptible C. albicans 
186 0 res. Susceptible C. albicans 
188 0 res. Resistant C. albicans 
191 17 0 Susceptible C. albicans 
192 15 0 Susceptible C. albicans 
194 18 0 Susceptible C. albicans 
195 >20 0 Susceptible C. albicans 
196 0 res. Resistant C. glabrata 
197 14 0 Susceptible C. albicans 
198 0 res. Resistant C. albicans 
199 0 res. Resistant C. albicans 
201 >20 0 Susceptible C. albicans 
203a 0 res. Resistant C. albicans 
203b 0 res. Resistant C. glabrata 
205 >20 0 Susceptible C. albicans 
206 >20 0 Susceptible C. albicans 
207 >20 0 Susceptible C. dubliniensis 
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Table 9.: Cameroonian fluconazole susceptibility testing results in YNBG agar. 
Patient 
No. 
Inhibition area 
(mm) Microcolonies Interpretation Species 
7 16 2 Susceptible Candida albicans 
10 17 3 Resistant Candida albicans 
11 17 3 Resistant Candida albicans 
12 17 2 Susceptible Candida albicans 
13 15 3 Resistant Candida albicans 
14 17 3 Resistant Candida albicans 
15 16 3 Resistant Candida albicans 
17 9 0 Intermediate 
Candida 
kefyr/parapsilopsis/lusitaneae 
19 4 0 Resistant Candida glabrata 
21 0 res. Resistant 
Candida 
kefyr/parapsilopsis/lusitaneae 
24 4 0 Resistant Candida albicans 
26 16 3 Resistant Candida albicans 
28 0 res. Resistant Candida albicans 
32 17 2 Susceptible Candida albicans 
33 17 3 Resistant Candida albicans 
35 16 3 Resistant Candida albicans 
36 0 res. Resistant Candida albicans 
39 7 2 Intermediate Candida glabrata 
40 15 2 Susceptible Candida albicans 
41 17 2 Susceptible Candida albicans 
42 17 2 Susceptible Candida albicans 
44 7 0 Intermediate Candida glabrata 
48 7 0 Intermediate Candida albicans 
50 18 2 Susceptible Candida albicans 
51 >20 2 Susceptible Candida albicans 
55 20 2 Susceptible Candida albicans 
56 21 2 Susceptible Candida albicans 
59 17 3 Resistant Candida albicans 
60 19 2 Susceptible Candida albicans 
64 17 3 Resistant Candida albicans 
69 17 2 Susceptible Candida albicans 
70 16 3 Resistant Candida albicans 
72 17 2 Susceptible Candida albicans 
73 16 2 Susceptible Candida albicans 
74 17 3 Resistant Candida albicans 
76 5 0 Resistant Candida glabrata 
79 17 3 Resistant Candida albicans 
80 0 res. Resistant Candida albicans 
81 17 3 Resistant Candida albicans 
82 19 0 Susceptible Candida albicans 
83 0 res. Resistant Candida albicans 
84 0 res. Resistant Candida albicans 
85 0 res. Resistant Candida tropicalis 
88 0 res. Resistant Candida albicans 
90 16 2 Susceptible Candida albicans 
92 4 0 Resistant Candida glabrata 
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93 5 0 Resistant Candida glabrata 
98 17 2 Susceptible Candida albicans 
99 17 2 Susceptible Candida albicans 
100 0 res. Resistant Candida albicans 
103 15 3 Resistant Candida albicans 
106 17 3 Resistant Candida albicans 
108 8 0 Intermediate Candida glabrata 
109 2 0 Resistant Candida glabrata 
111 17 2 Susceptible Candida albicans 
114 17 1 Susceptible Candida albicans 
115 15 3 Resistant Candida albicans 
116 11 0 Intermediate Candida glabrata 
117 17 0 Susceptible Candida albicans 
118 15 3 Resistant Candida albicans 
119 0 res. Resistant Candida albicans 
121 0 res. Resistant Candida albicans 
124 0 res. Resistant Candida glabrata 
127 18 1 Susceptible Candida albicans 
132 18 1 Susceptible Candida albicans 
134 17 2 Susceptible Candida albicans 
135 17 2 Susceptible Candida albicans 
136 11 0 Intermediate Candida dubliniensis 
137 17 1 Susceptible Candida albicans 
141 13 3 Resistant Candida tropicalis 
143 17 2 Susceptible Candida albicans 
144 0 res. Resistant Candida krusei 
146 18 2 Susceptible Candida albicans 
148 0 res. Resistant Candida glabrata 
154 0 res. Resistant Candida albicans 
156 0 res. Resistant Candida glabrata 
158 11 0 Intermediate Candida albicans 
159 2 0 Resistant Candida glabrata 
164 16 1 Susceptible Candida albicans 
172 0 res. Resistant Candida krusei 
174 0 res. Resistant Candida krusei 
175 17 2 Susceptible Candida albicans 
177 16 0 Susceptible Candida albicans 
178 10 0 Intermediate Candida glabrata 
180 17 2 Susceptible Candida albicans 
181 17 2 Susceptible Candida albicans 
182 0 res. Resistant Candida albicans 
183 17 2 Susceptible Candida albicans 
184 6 0 Resistant 
Candida albicans with 
pseudohyphae 
186 0 res. Resistant Candida glabrata 
196 5 0 Resistant Candida glabrata 
197 17 2 Susceptible Candida albicans 
198 17 2 Susceptible Candida albicans 
199 17 2 Susceptible Candida albicans 
200 7 0 Intermediate Candida glabrata 
201 11 0 Intermediate Candida albicans 
202 8 0 Intermediate Candida albicans 
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206 0 res. Resistant 
Candida albicans with 
pseudohyphae 
207 13 0 Susceptible Candida albicans 
216 0 res. Resistant Candida glabrata 
219 5 0 Resistant Candida glabrata 
220 0 res. Resistant Candida glabrata 
221 10 0 Intermediate Candida albicans 
222 10 0 Intermediate Candida albicans 
226 12 0 Intermediate 
Candida albicans with 
pseudohyphae 
228 >20 1 Susceptible Candida glabrata 
229 8 0 Intermediate Candida albicans 
233 5 1 Resistant Candida albicans 
234 4 1 Resistant Candida glabrata 
236 7 0 Intermediate Candida albicans 
237 4 0 Resistant Candida glabrata 
238 6 0 Resistant 
Candida albicans with 
pseudohyphae 
241 17 2 Susceptible Candida albicans 
244 0 res. Resistant Candida albicans 
245 0 res. Resistant Candida tropicalis 
246 0 res. Resistant Candida glabrata 
247 17 2 Susceptible Candida albicans 
248 0 res. Resistant Candida albicans 
249 17 2 Susceptible Candida albicans 
250 0 res. Resistant Candida tropicalis 
253 0 res. Resistant Candida albicans 
255 0 res. Resistant Candida albicans 
256 17 2 Susceptible Candida albicans 
257 17 2 Susceptible Candida albicans 
258 4 0 Resistant Candida krusei 
260 0 res. Resistant Candida albicans 
261 18 2 Susceptible Candida albicans 
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Appendix 7 
 
 
The following table shows the statistical association between Candida species and duration of 
ARV treatment seen in the Cameroonian population, using the SPSS 21.0 statistics software. 
 
CAM spp vs ART duration Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. 
(1-sided) 
Point 
Probability 
Pearson Chi-Square 33.692
a
 20 .028 .111   
Likelihood Ratio 28.897 20 .090 .016   
Fisher's Exact Test 32.315   p=0.034   
Linear-by-Linear Association 2.867
b
 1 .090 .096 .041 .009 
N of Valid Cases 126      
a. 25 cells (83.3%) have expected count less than 5. The minimum expected count is .02. 
b. The standardized statistic is 1.693. 
 
 
 
Appendix 8 
 
 
The following tables show the chi-square results and symmetric measures of the TREK 
susceptibility test done on South African and Cameroonian Candida species, using the SPSS 
21.0 statistics software. 
 
 
South African results: 
 
 
Chi-Square Tests for Amphotericin B 
  Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square 11.499
a
 2 .003 .009     
Likelihood Ratio 8.081 2 .018 .014     
Fisher's Exact Test 8.724     p=0.010     
Linear-by-Linear 
Association 2.302
b
 1 .129 .156 .107 .056 
N of Valid Cases 128           
a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is 1.17. 
b. The standardized statistic is 1.517. 
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Symmetric Measures 
  Value Approx. Sig. Exact Sig. 
Nominal by Nominal Phi .300 .003 .009 
Cramer's V .300 .003 .009 
N of Valid Cases 128     
 
 
Chi-Square Tests for Anidulafungin 
  Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square 128.317
a
 4 .000 .000     
Likelihood Ratio 70.439 4 .000 .000     
Fisher's Exact Test 63.041     p=0.000     
Linear-by-Linear 
Association 84.371
b
 1 .000 .000 .000 .000 
N of Valid Cases 128           
a. 5 cells (55.6%) have expected count less than 5. The minimum expected count is .47. 
b. The standardized statistic is 9.185. 
 
 
 
Symmetric Measures 
  Value Approx. Sig. Exact Sig. 
Nominal by Nominal Phi 1.001 .000 .000 
Cramer's V .708 .000 .000 
N of Valid Cases 128     
 
 
Chi-Square Tests for Caspofungin 
  Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square 132.214
a
 4 .000 .000     
Likelihood Ratio 73.109 4 .000 .000     
Fisher's Exact Test 65.264     p=0.000     
Linear-by-Linear 
Association 82.463
b
 1 .000 .000 .000 .000 
N of Valid Cases 128           
a. 4 cells (44.4%) have expected count less than 5. The minimum expected count is .78. 
b. The standardized statistic is 9.081. 
Symmetric Measures 
  Value Approx. Sig. Exact Sig. 
Nominal by Nominal Phi 1.016 .000 .000 
Cramer's V .719 .000 .000 
N of Valid Cases 128     
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Chi-Square Tests for Micafungin 
  Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square 128.000
a
 2 .000 .000     
Likelihood Ratio 70.186 2 .000 .000     
Fisher's Exact Test 63.098     p=0.000     
Linear-by-Linear 
Association 95.886
b
 1 .000 .000 .000 .000 
N of Valid Cases 128           
a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is .78. 
b. The standardized statistic is 9.792. 
Symmetric Measures 
  Value Approx. Sig. Exact Sig. 
Nominal by Nominal Phi 1.000 .000 .000 
Cramer's V 1.000 .000 .000 
N of Valid Cases 128     
 
 
Chi-Square Tests for 5-Flucytosine 
  Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square .849
a
 2 .654 1.000     
Likelihood Ratio 1.253 2 .534 .890     
Fisher's Exact Test .932     p=0.685     
Linear-by-Linear 
Association .126
b
 1 .722 1.000 .539 .224 
N of Valid Cases 128           
a. 3 cells (50.0%) have expected count less than 5. The minimum expected count is .47. 
b. The standardized statistic is -.355. 
Symmetric Measures 
  Value Approx. Sig. Exact Sig. 
Nominal by Nominal Phi .081 .654 1.000 
Cramer's V .081 .654 1.000 
N of Valid Cases 128     
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Chi-Square Tests for Fluconazole 
  Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square 6.667
a
 2 .036 p=0.032     
Likelihood Ratio 7.594 2 .022 .028     
Fisher's Exact Test 6.694     .028     
Linear-by-Linear 
Association 6.575
b
 1 .010 .014 .006 .004 
N of Valid Cases 128           
a. 1 cells (16.7%) have expected count less than 5. The minimum expected count is 4.53. 
b. The standardized statistic is -2.564. 
Symmetric Measures 
  Value Approx. Sig. Exact Sig. 
Nominal by Nominal Phi .228 .036 .032 
Cramer's V .228 .036 .032 
N of Valid Cases 128     
 
 
Chi-Square Tests for Itraconazole 
  Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square 9.658
a
 2 p=0.008 .006     
Likelihood Ratio 10.512 2 .005 .008     
Fisher's Exact Test 9.597     .007     
Linear-by-Linear 
Association 5.864
b
 1 .015 .021 .012 .007 
N of Valid Cases 128           
a. 1 cells (16.7%) have expected count less than 5. The minimum expected count is 4.38. 
b. The standardized statistic is -2.422. 
Symmetric Measures 
  Value Approx. Sig. Exact Sig. 
Nominal by Nominal Phi .275 .008 .006 
Cramer's V .275 .008 .006 
N of Valid Cases 128     
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Chi-Square Tests for Voriconazole 
  Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square 18.037
a
 2 p=0.000 .000     
Likelihood Ratio 23.475 2 .000 .000     
Fisher's Exact Test 19.702     .000     
Linear-by-Linear 
Association 14.219
b
 1 .000 .000 .000 .000 
N of Valid Cases 128           
a. 1 cells (16.7%) have expected count less than 5. The minimum expected count is 4.53. 
b. The standardized statistic is -3.771. 
Symmetric Measures 
  Value Approx. Sig. Exact Sig. 
Nominal by Nominal Phi .375 .000 .000 
Cramer's V .375 .000 .000 
N of Valid Cases 128     
 
 
Cameroonian results: 
 
Chi-Square Tests for Amphotericin B 
  Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square 30.865
a
 5 .000 .002     
Likelihood Ratio 16.499 5 .006 .002     
Fisher's Exact Test 20.455     p=0.001     
Linear-by-Linear 
Association 18.055
b
 1 .000 .001 .001 .000 
N of Valid Cases 126           
a. 9 cells (75.0%) have expected count less than 5. The minimum expected count is .08. 
b. The standardized statistic is 4.249. 
 
Symmetric Measures 
  Value Approx. Sig. Exact Sig. 
Nominal by Nominal Phi .495 .000 .002 
Cramer's V .495 .000 .002 
N of Valid Cases 126     
 
 
 
 
 
 
 
 
 
 
 
 
157 
 
 
Chi-Square Tests for Anidulafungin 
  Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square 153.304
a
 10 .000 .000     
Likelihood Ratio 48.224 10 .000 .000     
Fisher's Exact Test 49.353     p=0.000     
Linear-by-Linear 
Association 30.362
b
 1 .000 .000 .000 .000 
N of Valid Cases 126           
a. 15 cells (83.3%) have expected count less than 5. The minimum expected count is .02. 
b. The standardized statistic is 5.510. 
Symmetric Measures 
  Value Approx. Sig. Exact Sig. 
Nominal by Nominal Phi 1.103 .000 .000 
Cramer's V .780 .000 .000 
N of Valid Cases 126     
 
 
Chi-Square Tests for Caspofungin 
  Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square 153.304
a
 10 .000 .000     
Likelihood Ratio 48.224 10 .000 .000     
Fisher's Exact Test 49.353     p=0.000     
Linear-by-Linear 
Association 30.362
b
 1 .000 .000 .000 .000 
N of Valid Cases 126           
a. 15 cells (83.3%) have expected count less than 5. The minimum expected count is .02. 
b. The standardized statistic is 5.510. 
Symmetric Measures 
  Value Approx. Sig. Exact Sig. 
Nominal by Nominal Phi 1.103 .000 .000 
Cramer's V .780 .000 .000 
N of Valid Cases 126     
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Chi-Square Tests for Micafungin 
  Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square 225.968
a
 10 .000 .000     
Likelihood Ratio 111.921 10 .000 .000     
Fisher's Exact Test 107.397     p=0.000     
Linear-by-Linear 
Association 33.862
b
 1 .000 .000 .000 .000 
N of Valid Cases 126           
a. 15 cells (83.3%) have expected count less than 5. The minimum expected count is .02. 
b. The standardized statistic is 5.819. 
Symmetric Measures 
  Value Approx. Sig. Exact Sig. 
Nominal by Nominal Phi 1.339 .000 .000 
Cramer's V .947 .000 .000 
N of Valid Cases 126     
 
 
Chi-Square Tests for 5-Flucytosine 
  Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square 6.319
a
 5 .276 .267     
Likelihood Ratio 5.755 5 .331 .189     
Fisher's Exact Test 6.756     p=0.265     
Linear-by-Linear 
Association .074
b
 1 .786 .888 .404 .106 
N of Valid Cases 126           
a. 9 cells (75.0%) have expected count less than 5. The minimum expected count is .06. 
b. The standardized statistic is .272. 
Symmetric Measures 
  Value Approx. Sig. Exact Sig. 
Nominal by Nominal Phi .224 .276 .267 
Cramer's V .224 .276 .267 
N of Valid Cases 126     
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Chi-Square Tests for Fluconazole 
  Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square 9.899
a
 5 .078 .040     
Likelihood Ratio 12.614 5 .027 .038     
Fisher's Exact Test 9.167     p=0.041     
Linear-by-Linear 
Association 4.103
b
 1 .043 .045 .024 .009 
N of Valid Cases 126           
a. 8 cells (66.7%) have expected count less than 5. The minimum expected count is .45. 
b. The standardized statistic is -2.026. 
 
Symmetric Measures 
  Value Approx. Sig. Exact Sig. 
Nominal by Nominal Phi .280 .078 .040 
Cramer's V .280 .078 .040 
N of Valid Cases 126     
 
 
Chi-Square Tests for Itraconazole 
  Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square 9.574
a
 5 .088 .051     
Likelihood Ratio 11.034 5 .051 .075     
Fisher's Exact Test 9.170     p=0.044     
Linear-by-Linear 
Association .050
b
 1 .823 .865 .451 .067 
N of Valid Cases 126           
a. 8 cells (66.7%) have expected count less than 5. The minimum expected count is .43. 
b. The standardized statistic is .224. 
Symmetric Measures 
  Value Approx. Sig. Exact Sig. 
Nominal by Nominal Phi .276 .088 .051 
Cramer's V .276 .088 .051 
N of Valid Cases 126     
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Chi-Square Tests for Voriconazole 
  Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square 20.540
a
 5 .001 .000     
Likelihood Ratio 26.501 5 .000 .000     
Fisher's Exact Test 21.858     p=0.000     
Linear-by-Linear 
Association 9.633
b
 1 .002 .002 .000 .000 
N of Valid Cases 126           
a. 8 cells (66.7%) have expected count less than 5. The minimum expected count is .38. 
b. The standardized statistic is -3.104. 
Symmetric Measures 
  Value Approx. Sig. Exact Sig. 
Nominal by Nominal Phi .404 .001 .000 
Cramer's V .404 .001 .000 
N of Valid Cases 126     
 
 
 
Appendix 9 
 
 
The following table shows the statistical association between Candida species and duration of 
ARV treatment, azole and echinocandin susceptibility, respectively, seen in the combined 
female population, using the SPSS 21.0 statistics software. 
 
 
Chi-Square Tests for Species vs ARV duration 
 Value df Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Point 
Probability 
Pearson Chi-Square 55.070
a
 20 .000 .
b
   
Likelihood Ratio 34.609 20 .022 .007   
Fisher's Exact Test 33.674   .008   
Linear-by-Linear 
Association 
5.423
c
 1 .020 .020 .010 .002 
N of Valid Cases 195      
a. 23 cells (76.7%) have expected count less than 5. The minimum expected count is .02. 
b. Cannot be computed because there is insufficient memory. 
c. The standardized statistic is 2.329. 
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Chi-Square Tests for Species vs Azoles 
 Value df Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-sided) Point 
Probability 
Pearson Chi-Square 22.378
a
 5 .000 .000   
Likelihood Ratio 26.003 5 .000 .000   
Fisher's Exact Test 22.137   .000   
Linear-by-Linear 
Association 
9.972
b
 1 .002 .001 .000 .000 
N of Valid Cases 195      
a. 8 cells (66.7%) have expected count less than 5. The minimum expected count is .92. 
b. The standardized statistic is -3.158. 
 
 
Chi-Square Tests for Species vs Echinocandins 
 Value df Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-sided) Point 
Probability 
Pearson Chi-Square 255.767
a
 10 .000 .000   
Likelihood Ratio 116.243 10 .000 .000   
Fisher's Exact Test 108.772   .000   
Linear-by-Linear 
Association 
67.416
b
 1 .000 .000 .000 .000 
N of Valid Cases 195      
a. 13 cells (72.2%) have expected count less than 5. The minimum expected count is .10. 
b. The standardized statistic is 8.211. 
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Abstract  The treatment of invasive candidiasis and other Candida infections with the appropriate antifungal agent is 
assisted by the identification of Candida isolates to the species level. Rapid and accurate methods of differentiation are 
therefore imperat ive if t reatment is to be effective, particularly in HIV-positive patients and in pregnant mothers where 
intervention may be necessary to reduce the risk for preterm delivery. The time used for isolation, identificat ion and detection 
of mixed cultures may be reduced with the help of available chromogenic media. In this study, five commercial chromogenic 
media were evaluated for the differentiation of Candida species. Six type-strains of Candida species were streaked onto each 
of five different chromogenic media and incubated for up to 4 days at the different temperatures recommended by the 
manufacturers. This comparative evaluation demonstrated the strengths and weaknesses of each medium employed and 
found CHROMagar™ Candida and Chromogenic Candida Agar to be the most effective for distinguishing between different 
Candida species. 
Keywords  Candida, Chromogenic Agar, Rapid Species Differentiation  
 
1. Introduction 
There has been a significant increase in  the number of 
Candida resistant cases in hospital patients in the last 20 
years. Predisposing factors include particularly prolonged 
and increased use of antifungal agents[1] and patients with 
compromised immune systems, such as HIV-positive 
patients[2] and pregnant mothers with asymptomat ic 
vaginal candidiasis who run the risk of preterm delivery[3]. 
Amongst the species most frequently isolated are Candida 
albicans followed by Candida glabrata, Candida tropicalis 
and Candida krusei[4]. 
In health, Candida albicans is a harmless commensal 
fungus, while, in immunocompromised patients, it may 
cause superficial o r even life-threatening systemic 
infections[5]. It is not entirely understood how the 
mechanis ms of change from a non-pathogenic to a 
pathogenic phenotype occurs. Knowledge of the metabolic 
activity of Candida albicans remains limited even though a 
great deal of research has been done on aspects of its 
pathogenicity[5]. 
Candida dubliniensis is a fairly recent ly described  
species of Candida with similar characteristics to that of 
Candida albicans. It is clin ically important to compare the 
pathogenesis and management o f infect ion by a newly  
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discovered species, with infection caused by other members 
of the same genus[6]. Candida albicans and Candida 
dubliniensis have the same morphological and physiological 
characteristics due to the close association in their 
phylogenetics, e.g. germ-tube and chlamydospore 
formation[6]. This has caused a problem in d ifferentiating 
between the two species, with the result that Candida 
dubliniensis strains have been, and will continue to be, 
identified in the clin ical laboratory as Candida albicans[6]. 
To make a precise differentiation between the two species 
requires PCR-based tests, but due to the high quantities of 
throughput samples at diagnostic laboratories, this is not 
feasible and thus PCR-based tests are mostly used in 
research laboratories[7]. Looking at the phenotypic 
characteristics is much more inexpensive than that of the 
genotypic characteristics, and scientists have therefore 
demonstrated the use of selective and differential media for 
the presumptive identificat ion of Candida species with 
good sensitivity and specificity[8], thereby reducing the 
time used for isolation, identification and detection in 
mixed cultures[9].  
The purpose of this study was to perform a comparat ive 
evaluation of five different chromogenic media in order to 
establish which would y ield the most reliab le d ifferentiation 
of frequently isolated Candida species namely, Candida 
albicans, Candida dubliniensis, Candida tropicalis, 
Candida krusei and Candida glabrata. 
2. Materials and Methods 
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2.1. Type-strains of Candida Used 
A total of six type-strains of Candida species were used 
for the evaluation of the five chromogenic media. Of these 
type-strains, C. albicans (ATCC 90028), C. tropicalis 
(ATCC 950), C. krusei (ATCC 2159), C. glabrata (ATCC 
26512) were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA, USA.) and C. albicans 
(NCPF 3281) and C. dubliniensis (NCPF 3949a) from the 
National Collect ion of Pathogenic Fungi (NCPF, Bristol, 
United Kingdom). These type-strains were stored in frozen 
stocks in cryovials at -70℃  and cultured twice on 
Sabouraud’s dextrose agar (Oxoid , CM 0041) for 24 hours 
prior to the inoculation of the chromogenic media.  
2.2. Inoculation of Chromogenic Media 
Chromogenic media used, included commercially  
prepared CandiSelect™4 Agar (Bio-Rad, 63746) while, 
Chromogenic Candida Agar (Oxoid, CM1002A), Bismuth 
Sulphite Glucose Glycine Yeast agar (BiGGY Agar) (Oxoid, 
CM0589B) also known as Nickerson’s medium[10], 
modified Candida Ident Agar, (Fluka, 94382) and 
CHROMagar™ Candida (CHROMagar, CA220) were 
purchased in a dehydrated form and prepared  according to 
the manufacturers’ instructions. All plates were left  to reach 
room temperature prior to inoculation if previously stored at 
-4℃ . Type-strains of Candida species were inoculated onto 
the different chromogenic media and each incubated for up 
to 4 days at the different temperatures recommended by the 
manufacturers. Th is was done in triplicate. CandiSelect™4 
Agar and CHROMagar™ Candida were incubated at 37℃, 
modified Candida Ident Agar, and Chromogenic Candida 
Agar were incubated at 30℃ , and BiGGY Agar was 
incubated at 28-30℃ . The plates were checked after 24, 48, 
72 and 96 hrs for growth to determine when (according to the 
manufacturers’ claims) the expected colour, morphology or 
texture of the colonies appeared, and whether prolonged 
incubation would affect the results. 
2.3. Statistical Analysis 
Because of the small sample size no meaningfu l statistical 
analyses could be performed. 
3. Results 
All the type-strains grew on the five different 
chromogenic media. Some type-strains were more 
distinguishable than others. The appropriate colour, textu re 
and morphology of the colonies were observed after each 
24-hour period for a total of 96 hours and compared with the 
recommended time period of the manufacturers. Some 
chromogenic media characterized the different type-strains 
by colour only while others characterized them by colour, 
texture and morphology.  
Both C. albicans type-strains (ATCC 90028 and NCPF 
3281) appeared as predicted on CHROMagar™ Candida, 
modified Candida Ident, and Chromogenic Candida Agar 
(Table 1). They appeared as pink colonies after 24 hours, 
which darkened to purple after incubation for 48 hours on 
CandiSelect™4 Agar. On BiGGY Agar, the predicted colour 
reactions for C. albicans were expressed, while the expected 
mycelial fringe was not observed even after prolonged 
incubation of 96 hours. (Table 1) 
Table 1.  Ability of Chromogenic Media to Accurately Differentiate Candida albicans From Other Candida Species 
Agar Incubation Predicted Observed 
 
CHROMagar™ Candida agar @ 
37 ℃ 
 
 
48hrs 
 
green 
 
green-turquoise 
Candida Ident Agar, (modified) @ 
30 ℃ 
 
18-24hrs light green light green 
Chromogenic Candida Agar @ 
30 ℃ 
 
24hrs green green 
CandiSelect™4 Agar @ 37 ℃ 
 
 
 
24hrs pink-purple  pink 
48hrs purple purple 
BiGGY Agar @ 28-30 ℃ 
 48-96hrs 
smooth, circular brown-black with 
slight mycelial fringe 
 
smooth, circular brown 
colonies. No mycelial fringe 
even after 96hrs 
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Colonial morphology of C.dubliniensis differed from the 
predicted patterns for all 5 of the chromogenic media used 
(Table 2). A lthough the guidelines for CHROMagar™ 
Candida, modified Candida Ident Agar and BIGGY Agars 
predicted that C.dubliniensis could not be distinguished, 
results on the CHROMagar™ Candida revealed that C. 
albicans and C. dubliniensis could clearly be d istinguished 
with C. albicans colonies yielding a green-turquoise colour 
while C. dubliniensis appeared plain green after 48 hours 
incubation (Table 2). After a longer incubation period (96 
hours), no change was observed in C. albicans while 
colonies of C. dubliniensis formed a darker centre, a 
characteristic clearly distinguishing it from C. albicans (Fig. 
1a,b). 
Chromogenic Candida Agar guidelines predicted a green 
colour, but we observed translucent light-blue colonies after 
24 hours which intensified to dark blue on prolonged 
incubation of 96 hours (Fig.1c,d). Prolonged incubation was 
also required for CandiSelect™4 Agar since the pink-purp le 
colonies predicted after 24 hours only appeared after 72 
hours of incubation (Table 2). 
 
Figure 1.  Differentiation of C.albicans and C.dubliniensis Using Different Chromogenic Media 
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Table 2.  Ability of Chromogenic Media to Accurately Differentiate Candida dubliniensis From Other Candida Species 
Agar Incubation Predicted Observed 
 
CHROMagar™ Candida agar @ 37°C 
 
 
48hrs 
 
96hrs 
 
not distinguishable from C.albicans 
 
plain green, 
 
green with a dark centre 
 
Candida Ident Agar, (modified) @ 
30°C 
 
18-24hrs ND* white colonies 
48hrs  metallic green 
 
Chromogenic Candida Agar @ 30°C 
 
 
24hrs 
 
green 
 
translucent light blue 
 
25-48hrs  blue  
96hrs  dark-blue  
CandiSelect™4 Agar @ 37°C 
 
 
 
24-48hrs Pink to purple Light pink  
72hrs  pink-purple 
BiGGY Agar @ 28-30°C 
 
48hrs ND* 
 
smooth irregular shaped, light 
brown 
 
96hrs  smooth irregular shaped brown 
*Not distinguishable from other Candida species 
Table 3.  Ability of Chromogenic Media to Accurately Differentiate Candida glabrata From Other Candida Species 
Agar Incubation Predicted Observed 
 
CHROMagar™ Candida agar @ 
37°C 
 
 
48hrs 
 
not distinguishable (but other species 
white to mauve) 
 
 
mauve-colour 
Candida Ident Agar, (modified) @ 
30°C 
 
18-24hrs cream white cream-white to slight pink 
Chromogenic Candida Agar @ 
30°C 
 
24hrs 
 variable, natural pigment 
 
beige-cream to light brown 
 
24-48hrs 
(max 72hrs) variable, natural pigment 
brown with slight signs of pink 
 
CandiSelect™4 Agar @ 37°C 
 
 
 
 
24hrs ND* 
 
pale turquoise, flat, shiny, 
smooth, turquoise center and 
small white periphery 
 
48hrs pale turquoise, flat, shiny, smooth, turquoise center and white periphery 
dark turquoise, flat, shiny, 
smooth, dark turquoise center 
and white periphery 
 
BiGGY Agar @ 28-30°C 48hrs not distinguishable small, cream, opaque 
 
CHROMagar™ Candida, modified Candida Ident Agar, 
and BIGGY Agar were not able to d istinguish C. glabrata 
from other Candida species (Table 3), while Candiselect™4 
Agar yielded the predicted pale turquoise colonies after 24 
hours, which darkened to deep turquoise centred colonies 
with white peripheries after 48 hours. Chromogenic Candida 
Agar produced beige-cream to light brown colonies. 
However, this did not distinguish them from other Candida 
species but when incubated for longer than 72 hours, the 
colonies started to turn pink. 
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All of the 5 chromogenic media y ielded the predicted 
results for C. krusei (Table 4). Although the guidelines 
mention silver b rown-black, we concede that the reflection 
of the light in the dark brown colonies could have been 
interpreted by us as gold rather than silver. 
The CHROMagar™ Candida and modified Candida Ident 
Agar, guidelines predict a metallic blue colony for 
C.tropicalis, but we observed dark-purple blue colonies on 
the CHROMagar™ Candida (Table 5) and light lilac 
colonies on modified Candida Ident Agar after 24 hours, 
which intensified to blue after 48 hours. Neither of the agars 
grew colonies with a metallic sheen. Growth on 
CandiSelect™4 Agar appeared to match the overall 
morphology as described in the guidelines, but the colonies 
appeared blue and not turquoise in colour. Likewise, the 
colonies appeared to be similar to the BiGGY Agar 
guidelines, but no mycelial fringe was evident, nor did the 
media blacken after 72 hours. 
Following the pilot study using only the type-strains, 
clin ical strains from our laboratory collection, prev iously 
identified as C. albicans, C. dubliniensis, C. krusei, C. 
glabrata and C. tropicalis were also compared for 
consistency in the evaluation of the chromogenic media. 
Colony colour and morphology observations from the 
different clin ical strains showed the same results as the type- 
strains for all chromogenic agars. 
Table 4.  Ability of Chromogenic Media to Accurately Differentiate Candida krusei From Other Candida Species 
Agar Incubation Predicted Observed 
 
CHROMagar™ Candida agar @ 
37°C 
 
 
48hrs 
 
pink, fuzzy 
 
rough, pink, dry, fuzzy 
 
Candida Ident Agar, (modified) @ 
30°C 
 
18-24hrs purple, fuzzy light purple, fuzzy 
Chromogenic Candida Agar @ 
30°C 
 
24-72hrs 
 brown or pink, dry, irregular 
pink with beige to brown 
periphery, irregular 
 
CandiSelect™4 Agar @ 37°C 
 
 
24-48hrs 
turquoise-blue, rough, dry 
appearance, irregular 
 
turquoise-blue, rough, 
dry ,irregular 
 
BiGGY Agar @ 28-30°C 
 48hrs 
large, flat, wrinkled silvery 
brown-black with brown peripheries; 
yellow halo diffused into medium 
flat, wrinkled, gold glittery 
dark brown,  brown 
periphery; no halo diffused 
into medium 
Table 5.  Ability of Chromogenic Media to Accurately Differentiate Candida tropicalis From Other Candida Species 
Agar Incubation Predicted Observed 
 
CHROMagar™ Candida agar 
@ 37°C 
 
 
48hrs 
 
metallic blue 
 
dark purple-blue no 
metallic appearance 
 
Candida Ident Agar, (modified) 
@ 30°C 
 
18-24hrs blue-metallic blue light lilac  
48hrs  blue  
Chromogenic Candida Agar @ 
30°C 
 
24-72hrs 
 blue blue 
CandiSelect™4 Agar @ 37°C 
 
 
 
 
24hrs ND* 
white to light turquoise, 
mat, uniformly coloured, 
convex, smooth 
 
48hrs 
intense turquoise, mat, 
uniformly coloured, convex, 
smooth 
 
blue, mat, uniformly 
coloured, convex, 
smooth 
BiGGY Agar @ 28-30°C 
 
48hrs 
smooth, dark brown with 
black centre with mycelial 
fringe 
smooth, dark brown with 
slightly darker centre, no 
mycelial fringe 
 
72hrs diffuse blackening of media after 72hrs 
no diffuse blackening of 
media, no mycelial fringe 
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4. Discussion 
This study evaluated CHROMagar™ Candida, Candida 
Ident Agar (modified), Chromogenic Candida Agar, 
CandiSelect™4 Agar and BiGGY Agar for their efficacy in 
the presumptive identificat ion and differentiat ion of Candida 
species. An appropriate primary cu lture medium that assists 
in the recovery and differentiation of colonies which are 
phenotypically similar is a vital requirement for the 
laboratory detection of mixed fungal clinical specimens. 
Traditional methods for identification of yeast pathogens 
involves several days and specific mycology media while 
chromogenic media contains chromogenic substrates which 
react with enzymes secreted by the organisms to give colour 
reactions for d ifferent species[9] thus complementing 
traditional methods of identification[11]. CHROMagar™ 
Candida is the most well-known and widely used 
chromogenic medium for the identificat ion of different 
Candida species and is the most expensive of the five 
chromogenic media. Results from mixed cultures are 
reported to provide results 24 to 48 hours sooner than 
standard isolation and identification methods. It contains a 
variety of substrates which interact with the enzymes 
secreted by the yeast species and has been reported to 
selectively isolate and identify Candida species with a high 
degree of accuracy[12] sensitivity and specificity[13].  
As in our study, previous studies reported green colonies 
for C. albicans[12],[14] dark b lue colonies for C. tropicalis 
and pink co lonies with a downy appearance for C.krusei[8]. 
Although not clearly distinguishable after 48 hours, 
prolonged incubation (96 hours) proved useful for 
differentiating C.albicans from C.dubliniensis. Modified 
Candida Ident Agar, is a new chromogenic medium on 
which, we assume, not much research has been done. In this 
study, modified Candida Ident Agar and CHROMagarTM 
differentiated between the different Candida species by 
colour only. C. krusei however, could be differentiated by 
both colour and texture on both media. With the exception of 
C. glabrata, a more accurate colour expression of the other 
three species occurred after 48 hours of incubation, which 
suggested that the colours and texture description of the 
specific species of Candida presented by Candida Ident 
Agar would  have been more accurate following an 
incubation of 48 hours rather than 24 hours. These results 
confirm that this medium does not reflect the appropriate 
results suggested by the manufacturer and therefore is not as 
effective in the differentiation of Candida species.  
Chromogenic Candida Agar (Oxoid) has been re-named 
“Oxoid Brilliance Candida Agar” but in this study, we refer 
to it as “Chromogenic Candida Agar”. It is a new 
commercial ready-to-use chromogenic medium, contains 
chromogenic substrates which react with the different 
enzymes of species of Candida, such as hexosaminidase and 
alkaline phosphatase resulting in the expression of a specific 
colour in the colony. The different colours appear as a result 
of different enzymes produced by the different species[15]. 
C. albicans, C. dubliniensis and C. tropicalis produce the 
enzyme hexosaminidase which results in the colonies being 
green, but C. tropicalis yields dark blue colonies due to other 
metabolic reactions causing a drop in pH[15]. C. krusei 
yielded brown or pink colonies because it produces alkaline 
phosphatase and due to a combination of natural 
pigmentation and some alkaline phosphatase activity, C. 
glabrata yielded a variety of natural colour, such as beige, 
brown and yellow.  
CandiSelect™4 Agar (Bio-Rad) contains two 
chromogenic substrates which interact with hexosamin idase 
and phosphatase produced by the different Candida 
species[4], while a combination of antibiot ics such as 
chloramphenicol and gentamicin may suppress bacterial 
growth. In this study, C. albicans, C. krusei and C. glabrata 
yielded results described by the manufacturer while the other 
type-strains did not, thus questioning the reliability of this 
medium. Each of the different species of Candida requires 
different incubation periods on this medium. Similar results 
have been reported[4] for C. krusei, while identification o f C. 
tropicalis and C. glabrata were regarded as presumptive 
only. 
In this study, BiGGY Agar was not able to distinguish the 
different Candida species due to the fact that all the 
type-strains were in  the same colour range and that the 
distinctive characteristics such as the mycelial fringe 
scarcely occurred and when it did occur, it was never at the 
recommended incubation period.  
We have just touched on the differentiat ion between 
Candida albicans and Candida dubliniensis, since, in 
addition to looking at the other commonly isolated Candida 
species, we were also interested in establishing whether adj
usting incubation times of chromogenic media could 
adequately differentiate between Candida albicans and 
Candida dubliniensis. We believe that we have achieved 
this.  
5. Conclusions 
The expression of antifungal susceptibility among 
different Candida species and the misidentificat ion of C. 
dubliniensis as C. albicans highlights the potential clinical 
importance of accurate species differentiation. The use of 
chromogenic med ia for the rap id and effective identification 
of Candida species has gained popularity within the clinical 
laboratory but presents with limitations in that inaccuracies 
often occur between the reactions described by the 
manufacturer and the actual results obtained in the laboratory. 
Differences in colonial morphology may occur as a result of 
differences in the laboratory conditions under-which the 
experiments are conducted e.g. the water used for media 
preparation may be of a different purity, thus affecting the 
substrate in the medium and thereby producing a different 
colour expression for specific species. Differences in co lour 
and reflection perceptions by different examiners should also 
be taken into account. By employing several chromogenic 
media and optimising the incubation periods for each species, 
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sometimes deviating from the recommendations of the 
manufacturers, we were ab le to establish which media 
produced the most reliab le and consistent results and thus 
accurately differentiate the Candida species commonly 
infecting HIV-positive indiv iduals and pregnant 
Candida-infected mothers.  
This comparative evaluation proved that CHROMagar™ 
Candida and Chromogenic Candida Agar were the most 
effective of the chromogenic media evaluated and both 
yielded the expected colour colonies at the expected time 
period of incubation as suggested by the manufacturer. 
Candida Ident Agar (modified) and CandiSelect™4 Agar 
only yielded results typical of three of the type-strains as 
suggested by the manufacturer, while BiGGY Agar y ielded 
all of the type-strains in one colour range and none of the 
differentiating morphological characteristics predicted were 
ever observed. In order to eliminate inaccuracies in the 
presumptive identificat ion of C. dubliniensis, we strongly 
support the use of CHROMagar™ Candida since this 
medium most clearly demonstrated the difference between 
Candida albicans and Candida dubliniensis thus reducing 
error in the identification of the two species. 
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ABSTRACT 
 
Candida species are a common cause of infection in immune-compromised HIV-positive 
individuals, who are usually treated with the antifungal drug, fluconazole in public hospitals 
in Africa. However, information about the prevalence of drug resistance to fluconazole and 
other antifungal agents on Candida species is very limited. This study examined 128 Candida 
isolates from South Africa and 126 Cameroonian Candida isolates for determination of 
species prevalence and antifungal drug susceptibility. The isolates were characterized by 
growth on chromogenic and selective media and by their susceptibility to nine antifungal 
drugs tested using the TREK™ YeastOne9 drug panel (Thermo Scientific).  Eighty three 
percent (82.8%) of South African isolates were C. albicans (106 isolates), 9.4% were C. 
glabrata (12 isolates) and 7.8% were C. dubliniensis (10 isolates). Of the Cameroonian 
isolates, 73.02% were C. albicans (92 isolates); 19.05% C. glabrata (24 isolates); 3.2% C. 
tropicalis (4 isolates); 2.4% C. krusei (3 isolates); 1.59% either C. kefyr, C. parapsilopsis or 
C. lusitaneae (2 isolates); and 0.79% C. dubliniensis (1 isolate).  Widespread C. albicans 
resistance to azoles was detected phenotypically in both populations. Differences in drug 
resistance were seen within C. glabrata found in both populations. Echinocandin drugs were 
more effective on isolates obtained from the Cameroon than in South Africa. A multiple drug 
resistant (MDR) C. dubliniensis strain isolated from the South African samples was inhibited   
only by 5-flucytosine  in vitro on the YO9 panel.  Drug resistance among oral Candida 
species is common among African HIV patients in these two countries. Regional surveillance 
of Candida species drug susceptibility should be undertaken to ensure effective treatment for 
HIV-positive patients.  
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1. Introduction 
 
The chronic nature of HIV infection and the increased incidence of mucosal and disseminated 
forms of Candida infections have necessitated the systemic use of antifungal agents, notably, 
the azole drugs, fluconazole and itraconazole. Fluconazole is routinely administered for 
candidiasis in healthcare facilities on the African continent and is also used to treat cases 
unresponsive to topical antifungal treatment (Powderly et al., 1999). 
 
Widespread and repeated use of azole drugs (Jia et al., 2008) has led to resistance to 
antifungal therapies; a problem that is apparently spreading widely (Manzano-Gayosso et al., 
2008; Luque et al., 2009). Thus, there is an urgent need to determine the extent of this 
problem on the African continent. High HIV infection rates, the lack of surveillance and the 
uncontrolled distribution of medications have all contributed to drug resistance that has 
emerged unchecked. This is especially important in resource-poor countries, where little 
information and limited resources by which to obtain it, seriously complicates the issue. 
 
Various methods are available for the determination of antifungal drug susceptibility, 
employing either broth dilution or disk diffusion. These include the use of Yeast Nitrogen 
Base agar (May et al., 1997) and the methylene-blue and glucose-enriched Mueller-Hinton 
agar diffusion test, the antifungal disk diffusion medium recommended by the Clinical and 
Laboratory Standards Institute (2009).  However, these time- and resource-consuming 
methods are being replaced by more modern techniques such as the TREK Vision diagnostic 
system. The TREK Sensititre YeastOne 9 (YO9) system (Thermo Scientific, USA) is a broth 
micro-dilution method that provides antifungal drug susceptibility testing for multiple drugs 
simultaneously and relatively inexpensively. This method has the advantage of being 
standardized to CLSI standards (Eraso et al., 2008; Pfaller et al., 2012) and consists of 
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microtiter plates coated with nine different drugs in ascending concentrations which provide 
for the determination of a minimal inhibitory concentration (MIC). The drugs are as follows: 
the echinocandins (anidulafungin, micafungin and caspofungin), which inhibit β1-3 glucan 
synthesis in the fungal cell wall; the fluorinated pyrimidine analogue (5-flucytosine), that 
inhibits protein and DNA synthesis; triazole drugs (posaconazole, voriconazole, itraconazole 
and fluconazole), which block ergosterol synthesis thereby affecting the fungal cytoplasmic 
membrane, and  a polyene (amphotericin B), which interferes with ergosterol synthesis, 
leading to cell membrane leakage. The wells are also coated with a colorimetric agent with 
the advantage that the MIC of each drug can be easily detected with the naked eye and with 
the supplied Vizion computer-assisted plate reading system (Thermo Scientific, USA). In 
resource-limited environments the plates can also be read manually with the aid of a simple 
inexpensive light box. 
 
The objective of this study was to determine the species prevalence and phenotypic drug 
susceptibility profiles of Candida species isolated from HIV-infected African populations in 
South Africa and Cameroon, using chromogenic and selective media and the TREK Sensititre 
diagnostic system. This study was prompted by an increasing number of patients being lost to 
follow-up or failing conventional therapy. 
 
2. Materials and Methods 
Approval from the Ministry of Health Regional Hospital Institutional Review Board (IRB) in 
Cameroon and from the Ethics Committee at the University of the Western Cape in Cape 
Town, South Africa, was obtained.  A total of 212 HIV-positive patients attending clinics in 
Khayelitsha (n=18)  and Delft (n=204) in the Western Cape, South Africa, and 262 HIV-
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
positive patients receiving routine care from the HIV clinic at the Bamenda Hospital in 
Cameroon, participated in the study.  Samples were collected over a period of 6 months.  
 
Prior to sample collection, the reasons for, and nature of the study were explained to the 
patients who willingly consented to participate.  Only HIV-positive patients presenting with 
white pseudomembranous plaque on the tongue or other visible oral candidiasis were 
selected.  Included in the study were two South African patients (male and female) who 
reported that they had started fluconazole therapy at the time of sample collection. Another 
South African patient had started taking Amphotericin B lozenges at the time of sample 
collection and two females from Cameroon reported recent fluconazole therapy.    The 
application of adequate exclusion criteria was limited by the fact that we were unable to 
collect accurate patient history of previous Candida infection or antifungal treatment due to 
incomplete patient records and patients’ lack of knowledge of drug names and usage.   
 
Oral swabs were used to collect  samples from the affected areas and swabs were plated onto 
Sabouraud’s agar and incubated for 24 hours at 37 ˚C followed by 24-72 hours of growth at 
30 ˚C on Fluka chromogenic Candida identification agar, (Cat. no. 94382, Sigma-Aldrich, 
USA) and Oxoid chromogenic Candida agar (Cat. no. CM1002A, Oxoid, UK). Confirmation 
of Candida species was achieved using microscopy, Gram staining and the germ tube test. 
 
Presumptive C. albicans and C. dubliniensis cultures were incubated at 37 ˚C for 2-3 hours in 
fetal bovine serum to stimulate germ tube production, and the two species further 
differentiated by growth at 37 ˚C for 48 hours in Tomato (V8) agar (Alves, Linares et al. 
2006) at 28 ˚C for 48-72 hours in Tobacco agar (Khan, Ahmad et al. 2004) and at 45 ˚C for 
24-48 hours in Sabouraud dextrose agar (Pinjon, Sullivan et al. 1998). Differences in growth, 
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colony morphology and pseudohyphae/chlamydospore expression, allowed for species 
identification (Messeir et al., 2012). 
 
Type strains of C. albicans (ATCC 90028 and NCPF 3281) and C. dubliniensis (NCPF 
3949a) served as positive controls for the germ tube test, while C. tropicalis (ATCC 950) 
served as a negative control. Type strains of C. albicans (ATCC 90028 and NCPF 3281), C. 
tropicalis (ATCC 950), C. dubliniensis (NCPF 3949a), C. glabrata (ATCC 26512) and C. 
krusei (ATCC 2159) served as quality control organisms for the chromogenic species 
differentiation and drug susceptibility testing. 
 
Second-generation Candida strains were diluted with sterile phosphate buffered saline to 
concentrations of 1x10
6 
to 5x10
6 
cells per ml, corresponding to a 0.5 McFarland standard, 
measured using the supplied TREK nephelometer. This was followed by vortexing of the 
suspension and the addition of 100µl of the vortexed solution to YeastOne broth (Product 
code Y3462, Thermo Scientific). The diluted broth was dispensed into the YO9 plate using 
an automated 25-1250µl multichannel pipette and incubated for 24 hours at 37 °C. 
The plates were then read using the Vizion plate reader and analyzed using the TREK SWIN 
software (Thermo Scientific, USA). 
 
Recently developed species-specific clinical breakpoints were used (Pfaller et al., 2012) to 
categorise C. albicans and C. tropicalis as  susceptible, intermediate or resistant to  
echinocandin drugs (anidulafungin, caspofungin and micafungin).  CLSI breakpoint 
categories were used for 5-flucytosine, itraconazole, fluconazole and amphotericin B (Eraso, 
et al., 2008) and the breakpoints proposed by Pfaller et al. (2006) were used for voriconazole. 
In the case of posaconazole, for which no clinical breakpoints have been established, wild-
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type MIC values were used as previously proposed (Pfaller et al., 2011).  MICs were defined 
as the lowest concentrations that inhibited growth at 100%. The MIC breakpoints of the 
different drugs for different Candida species are listed in Table 1.  
 
Statistical analysis to demonstrate the association between Candida species  and drug 
susceptibility was calculated by means of Chi-square tests using the SPSS 21.0 statistics 
software (p<0.05). 
 
 
3. Results 
 
3.1 Frequency of species 
Of the 212 South African samples, 128 (60%) were positive for Candida of which 82.8% 
were identified as C. albicans (106 isolates), 9.4% as C. glabrata (12 isolates) and 7.8% as C. 
dubliniensis (10 isolates).   Candida albicans was the most frequently isolated species from 
both regions.  A greater diversity of species was observed among the Cameroonian isolates. 
One hundred and twenty-six of the 262 Cameroonian samples (48%)  were positive for 
Candida, of which  73.02% were C. albicans (92 isolates); 19.05% were C. glabrata (24 
isolates); 3.2% were C. tropicalis (4 isolates); 2.4% were C. krusei (3 isolates); 1.59% were 
either C. kefyr, C. parapsilopsis or C. lusitaneae (2 isolates); and 0.79% were C. dubliniensis 
(1 isolate). 
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3.2. Susceptibility profiles of isolates 
All C. albicans and C. glabrata species isolated from South Africa were susceptible to 
micafungin and exhibited intermediate resistance to caspofungin and complete resistance to 
anidulafungin. While more than 50% of the South African C. albicans strains were found to 
demonstrate resistance to all azoles tested (Table 2), C. glabrata and C. dubliniensis strains 
demonstrated good overall susceptibility to azoles. A C. dubliniensis strain was remarkable in 
that it was resistant to all the antifungal drugs on the panel except 5-flucytosine in 
concentrations above 2µg/ml (Table 2). 
 
The results from Cameroonian strains showed that with the exception of C. glabrata, other 
Candida species, namely, C. albicans, C. tropicalis and C. krusei strains were susceptible to 
echinocandin drugs (Table 3). In the case of the azole drugs, the reverse of this pattern was 
observed: C. albicans strains were resistant to azoles (greater than or equal to 50% resistance 
to all azoles tested).    C. glabrata was better inhibited by this class of drugs. Candida 
dubliniensis and two species identified as C. parapsilopsis/lusitaneae/kefyr were susceptible 
to all azole drugs tested, while C. tropicalis strains were susceptible to both fluconazole and 
voriconazole.  
 
Six South African isolates, 5(4.7%)  C. albicans and 1(8.3%) C. glabrata were resistant to 5-
flucytosine, while most of the species isolated in Cameroon were sensitive to 5-flucytosine. 
The exceptions among the Cameroonian samples were C. krusei, where only one isolate 
(33.3% of total) showed intermediate non-susceptibility and 6 (6.52%) C. albicans were 
totally resistant.  
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Notably, although isolates were frequently susceptible to amphotericin B, Candida species 
from both populations contained isolates that were resistant (Tables 2 and 3). 
 
Wild-type MIC determinations with respect to both South African and Cameroonian isolates 
tested,  demonstrated resistance  / non-susceptibility to posaconazole (84% for C. albicans 
and 41.7% for C. glabrata in South Africa and 80.4%, 62.5%, 100% and 66.7% for C. 
albicans, C. glabrata, C. tropicalis and C. krusei, in Cameroon respectively).  C. krusei is 
intrinsically resistant to fluconazole and there is a general lack of certainty about the 
interpretive categories with regard to other azoles. We therefore elected to use the term “non-
susceptible” rather than “resistant” to the azoles when referring to C. krusei in our results. 
.  
Of the 106 C. albicans isolated from the South African population, 13 (12.3%) were resistant 
to 2 classes of antifungals, while 6/92 (6.5%)  C. albicans isolates from Cameroon were 
resistant to 2 classes of antifungals.  In Cameroon, the C. albicans resistance was either to 
Amphotericin B and the azoles or to 5-flucytocine and the azoles, while in South Africa, C. 
albicans demonstrated resistance to Amphotericin B, 5-Flucytosine, anidulafungin and the 
azoles in different combinations. 
 
C. glabrata demonstrated resistance to 2 or more antifungals in 3/12 (25%) of the South 
African isolates and 10/24 (41.7%) isolates from Cameroon.  In Cameroon, the antifungal 
combinations were anidulafungin, micafungin and azoles, while in South Africa, the 
antifungal combinations were either Amphotericin B and the azoles or anidulafungin and the 
azoles.  
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Statistical analysis showed significant associations between Candida species and antifungal 
drug resistance.   
 
4. Discussion 
Oropharyngeal candidiasis (OPC) continues to be a common opportunistic infection in 
patients infected by HIV.    It occurs in up to 90% of HIV/AIDS patients during the 
prolonged course of HIV disease and greatly reduces their quality of life.  They are 
predisposed to recurrent episodes of OPC that can increase in frequency and severity,    
resulting in increased morbidity and mortality.  This is especially true in Africa, where  
 high incidences of mucosal and deep seated forms of candidiasis have resulted in the use of 
systemic antifungal agents, especially fluconazole and itraconazole. As in other African 
countries, the present guidelines for South Africa and Cameroon for the management of HIV-
positive patients include fluconazole as a first choice drug for systemic infection (Guidelines, 
2009).   The widespread use of these antifungal agents have been followed by an increase in 
antifungal resistance and by a shift from C. albicans to  non-albicans species prevalence such 
as those described in this study.    
  
As reported in previous studies from Africa (Blignaut et al., 2002; Hamza et al., 2008), C. 
albicans, C. glabrata and C. krusei were the most frequently isolated species from these 
South African and Cameroonian patients. Candida dubliniensis was isolated more frequently 
from South African patients. 
 
Two  South African patients (one male and one female ) and two Cameroonian patients (both 
females) who had recently started  fluconazole therapy had visible oropharyngeal thrush at 
the time of sample collection and their samples yielded the  growth of C. albicans highly 
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susceptible to all the drugs tested.  Another South African patient who had started taking 
Amphotericin B lozenges at the time of sample collection, also yielded an isolate of  C. 
albicans highly susceptible to all the drugs tested except posaconazole,    
 
However, this study reports that over 50% of C. albicans isolated from South Africa and 
Cameroon have developed resistance to fluconazole. A previous report of baseline data from 
South Africa demonstrated 100% susceptibility of C. albicans to fluconazole indicating a 
marked change in susceptibility. However, and of importance, is that the study was done 
before the introduction of fluconazole to patients attending HIV-AIDS clinics (Blignaut et al., 
2002) and that the patient population was from another province. High resistance levels were 
observed to other azole drugs tested. Although lower resistance levels have been previously 
reported from South Africa (Molepo et al., 2006), compared with the current data, other 
African studies have reported frequent resistance of C. albicans and non-albicans species to 
azoles (Njunda et al., 2012; Mulu et al., 2013).  Cross-resistance to fluconazole has been 
observed in patients receiving itraconazole prophylaxis (Goldman et al., 2000) and other 
previously administered azole therapies such as ketoconazole and miconazole (Pelletier et al., 
2000; Rautemaa et al., 2008).  These observations are a cause for concern as fluconazole is 
the most widely used antifungal available to treat Candida infections in HIV patients in South 
Africa.  The same applies in Cameroon and the rest of the African continent.  Second choice 
is itraconazole.  Ketoconazole is also used, but has been superseded by fluconazole and 
itraconazole.   
   
Resistance to amphotericin B was seen with respect to all Candida species, with non-albicans 
species demonstrating especially high resistance levels, particularly C. glabrata isolated from 
the South African population. The South African C. dubliniensis isolate which showed 
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resistance to all eight of the nine drugs on the YO9 panel may indicate a serious public health 
problem, since it suggests the emergence of multiple-drug resistant Candida species in the 
HIV population.  
 
Another finding presenting a clinical challenge was the demonstration of C. albicans and C. 
glabrata resistance to 2 or more classes of antifungals in this study, with C. albicans being 
the predominant resistant species in the South African population and C. glabrata in the 
Cameroonian population.  The dispensing of these antifungal drugs should therefore be 
carefully monitored and should be based upon established epidemiological data (Blignaut, 
Pujol et al. 2002). In this way, in vitro resistance may be related to treatment failure (Rogers 
2006) and aid in the assessment prevalence of multiple drug resistance in the population. 
 
The rate of relapse and clinical response to therapy varies in different populations. Some 
HIV-positive patients experience recurrent Candida infections with shorter disease-free 
episodes.  They are therefore subjected to numerous courses of antifungals which may 
ultimately result in antifungal resistance. There is a possibility that the repeated exposure of 
Candida species to antifungal drugs, particularly in the Cameroon, might have led to 
increased variability in the distribution of Candida species with more non-albicans species 
reported. Species-specific azole resistance has been documented in Brazil (Colombo, Da 
Matta et al. 2002) and resistance to a specific antifungal drug has been shown to result in 
cross-resistance to other drugs of the same class (Muller, Weig et al. 2000). This was clearly 
evident in the present study.  
 
As in many other African countries, street access to antifungals and other drugs without 
prescription is common in Cameroon.  This factor, along with a lack of patient knowledge of 
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
antifungal drugs, made it difficult to ascertain whether patients were exposed to these drugs 
for a long period of time. The possibility exists that specific Candida consortia play a role in 
the acquisition of resistance and with most patients not having access to adequate medical 
treatment, combined with limited health care resources and the inability of health care 
workers to monitor the acquisition of antifungals on the street, this problem will escalate 
leading to an increase in HIV-positive patient morbidity and mortality. 
 
This study demonstrates a need for regional surveillance of Candida species on the African 
continent and improved control over the sale of medications. This study has shown that the 
prevalent C. albicans does not respond to specific antifungal drugs that might be dispensed 
empirically. C. glabrata from Cameroon was resistant to micafungin while South African 
isolates were susceptible, demonstrating significant regional differences. The reverse of this 
pattern was seen in the case of 5-flucytosine, thereby re-emphasizing the need for more 
epidemiological studies. 
 
Limitations of this study include the paucity of patient information (whether early or late 
presenters of HIV-AIDS), and the lack of patient history of previous episodes of Candida 
infection and treatment. Inconsistencies occur with species differentiation and drug 
susceptibility techniques due to lack of resources in many African countries, thus 
complicating a direct comparison of our results with other studies done in Africa. 
 
Finally, the use of the TREK Sensititre platform in this study for drug susceptibility testing 
proved a rapid and reliable method requiring minimal training and utilizing available 
reagents. We suggest this approach may be a promising method for use in resource-limited 
laboratories in Africa. The TREK system avoids the limitations of current drug susceptibility 
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testing protocols for fungi, as multiple drugs can be tested simultaneously on a single plate 
using a simple protocol. Furthermore, an inexpensive light box can be used to screen the 
plates manually. 
 
Standardized methods available from the Clinical and Laboratory Standards Institute (CLSI) 
are useful for the calculation of clinical breakpoints and epidemiologic cutoff values for 
reliable in vitro antifungal susceptibility testing.  These results indicate that not only does 
resistance differ from country to country, but also in different regions of the same country. 
Programmes on species prevalence and antifungal use and resistance pattern surveillance 
have been successfully developed and introduced in Europe, Asia-Pacific, Latin America and 
North America (Cuenca-Estrella et al., 2008; Adriaenssens et al., 2010; Pfaller et al., 2011). 
The high HIV prevalence and accompanying immunodeficiency in sub-Saharan Africa are 
strong driving factors emphasizing the need for regional Candida surveillance programmes. 
Changes in drug susceptibility over time serve as a reminder for the need to test clinical 
Candida isolates for sensitivity to antifungal drugs in the effort to improve patient care and 
reduce patient morbidity and mortality. 
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Table 1  
Drug susceptibility clinical breakpoints used in this study 
 
  C. albicans C. glabrata 
  Susceptible Intermediate Resistant Susceptible Intermediate Resistant 
Anidulafungin ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL ≤0.12 μg/mL  0.25 μg/mL ≥0.5 μg/mL 
Caspofungin ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL ≤0.12 μg/mL  0.25 μg/mL ≥0.5 μg/mL 
Micafungin ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL ≤0.06 μg/mL 0.12 μg/mL ≥0.25 μg/mL 
5-Flucytosine ≤4 µg/mL 8-16 μg/mL ≥32 µg/mL ≤4 µg/mL 8-16 μg/mL ≥32 µg/mL 
Itraconazole ≤0.12 µg/mL 0.25-0.5 µg/mL ≥1 µg/mL ≤0.12 µg/mL 0.25-0.5 µg/mL ≥1 µg/mL 
Fluconazole ≤8 µg/mL 16-32 μg/mL ≥64 µg/mL ≤8 µg/mL 16-32 μg/mL ≥64 µg/mL 
Amphotericin B <1 µg/mL _ ≥1 μg/mL <1 µg/mL _ ≥1 μg/mL 
Posaconazole <0.016µg/mL _ ≥0.016µg/mL <0.5µg/mL _ ≥0.5µg/mL 
Voriconazole ≤1 µg/mL 2µg/mL ≥4 μg/mL ≤1 µg/mL 2µg/mL ≥4 μg/mL 
 
  C. tropicalis C. krusei 
  Susceptible Intermediate Resistant Susceptible Intermediate Non-
susceptible 
Anidulafungin ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL 
Caspofungin ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL 
Micafungin ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL ≤0.25 μg/mL 0.5 μg/mL ≥1 μg/mL 
5-Flucytosine ≤4 µg/mL 8-16 μg/mL ≥32 µg/mL ≤4 µg/mL 8-16 μg/mL ≥32 µg/mL 
Itraconazole ≤0.12 µg/mL 0.25-0.5 µg/mL ≥1 µg/mL ≤0.12 µg/mL 0.25-0.5 µg/mL ≥1 µg/mL 
Fluconazole ≤8 µg/mL 16-32 μg/mL ≥64 µg/mL ≤8 µg/mL 16-32 μg/mL ≥64 µg/mL 
Amphotericin B <1 µg/mL _ ≥1 μg/mL <1 µg/mL _ ≥1 μg/mL 
Posaconazole <0.03µg/mL _ ≥0.03µg/mL <0.25µg/mL _ ≥0.25µg/mL 
Voriconazole ≤1 µg/mL 2µg/mL ≥4 μg/mL ≤1 µg/mL 2µg/mL ≥4 μg/mL 
 
  C. dubliniensis C. kefyr/para/lusi 
  Susceptible Intermediate Resistant Susceptible Intermediate Resistant 
Anidulafungin _ _ _ _ _ _ 
Caspofungin _ _ _ _ _ _ 
Micafungin _ _ _ _ _ _ 
5-Flucytosine ≤4 µg/mL 8-16 μg/mL ≥32 µg/mL ≤4 µg/mL 8-16 μg/mL ≥32 µg/mL 
Itraconazole ≤0.12 µg/mL 0.25-0.5 µg/mL ≥1 µg/mL ≤0.12 µg/mL 0.25-0.5 µg/mL ≥1 µg/mL 
Fluconazole ≤8 µg/mL 16-32 μg/mL ≥64 µg/mL ≤8 µg/mL 16-32 μg/mL ≥64 µg/mL 
Amphotericin B <1 µg/mL _ ≥1 μg/mL <1 µg/mL _ ≥1 μg/mL 
Posaconazole _ _ _ _ _ _ 
Voriconazole ≤1 µg/mL 2µg/mL ≥4 μg/mL ≤1 µg/mL 2µg/mL ≥4 μg/mL 
“-“  No clinical breakpoint available for this drug. 
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Table 2 
Antifungal susceptibility for South African Candida isolates 
 
 
C. albicans 
n=106 
C. glabrata 
n=12 
C. dubliniensis 
n=10 
Spp/resistance 
associations 
Amphotericin B 
 
Susceptible 97 7 9 
 
p=0.01 
Intermediate 0 0 0 
Resistant 9 5 1 
5-Flucytosine 
 
Susceptible 101 11 10 
 
 
Intermediate 0 0 0 
Resistant 5 1 0 
Anidulafungin 
 
Susceptible 101 11 _ 
 
p=0.000 
Intermediate 3 0 _ 
Resistant 2 1 _ 
Caspofungin 
 
Susceptible 98 9 _ 
 
p=0.000 
Intermediate 8 3 _ 
Resistant 0 0 _ 
Micafungin 
 
Susceptible 106 12 _ 
 
p=0.000 
Intermediate 0 0 _ 
Resistant 0 0 _ 
Fluconazole 
 
Susceptible 53 8 9 
 
p=0.032 
Intermediate 1 4 0 
Resistant 52 0 1 
Itraconazole 
 
Susceptible 43 4 9 
 
p=0.008 
Intermediate 1 6 0 
Resistant 62 2 1 
Voriconazole 
 
Susceptible 49 12 9 
 
p=0.000 
Intermediate 0 0 0 
Resistant 57 0 1 
“-“  No clinical breakpoint available for the organism/drug. 
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Table 3 
Antifungal susceptibility for Cameroonian Candida isolates 
 
 
C. albicans 
n=92 
C. glabrata 
n=24 
C. tropicalis 
n=4 
C. krusei 
n=3 
C. para/lusi/kefyr 
n=2 
C. dubliniensis 
n=1 
Spp/resistance 
associations 
Amphotericin B 
 
Susceptible 88 23 2 1 1 0 
p=0.001 
 
Intermediate 0 0 0 0 0 0 
Resistant/non-
susceptible 4 1 2 2 1 1 
5-Flucytosine 
 
Susceptible 86 24 4 2 1 1 
 
Intermediate 0 0 0 1 0 0 
Resistant/non-
susceptible 6 0 0 0 0 0 
Anidulafungin 
 
Susceptible 92 16 4 3 - - 
p=0.000 
 
Intermediate 0 5 0 0 - - 
Resistant/non-
susceptible 0 3 0 0 - - 
Caspofungin 
 
Susceptible 92 16 4 3 - - 
p=0.000 
 
Intermediate 0 7 0 0 - - 
Resistant/non-
susceptible 0 1 0 0 - - 
Micafungin 
 
Susceptible 92 3 4 3 - - 
p=0.000 
 
Intermediate 0 5 0 0 - - 
Resistant/non-
susceptible 0 16 0 0 - - 
Fluconazole 
 
Susceptible 45 16 4 1 2 1 
p=0.041 
 
Intermediate 1 7 0 0 0 0 
Resistant/non-
susceptible 46 1 0 2 0 0 
Itraconazole 
 
Susceptible 44 5 1 1 2 1 
p=0.044 
 
Intermediate 1 15 3 2 0 0 
Resistant/non-
susceptible 47 4 0 0 0 0 
Voriconazole 
 
Susceptible 46 23 4 2 2 1 
p=0.000 
 
Intermediate 0 0 0 0 0 0 
Resistant/non-
susceptible 46 1 0 1 0 0 
“-“  No clinical breakpoint available for the organism/drug. 
 
 
 
 
 
 
